UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
31584,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2763109/0/en/Harvia-Plc-distributes-a-dividend-of-EUR-0-32-per-share.html,Harvia Plc distributes a dividend of EUR 0.32 per share,Harvia Plc  Stock Exchange Release  October 19  2023 at 3.00 PM EEST                        The Board of Directors of Harvia Plc has decided today on...,Harvia Plc  Stock Exchange Release  October 19  2023 at 3.00 PM EESTThe Board of Directors of Harvia Plc has decided today on the record date and payment date of the second dividend instalment for the financial year 2022  EUR 0.32 per share  based on the decision by the Annual General Meeting held 20.4.2023.Harvia Plc‚Äôs Annual General Meeting  held on 20 April 2023  decided that EUR 0.64 per share will be paid as dividend in two instalments for the financial year 2022. The first dividend instalment  EUR 0.32 per share  was paid 2 May 2023. The second dividend instalment  EUR 0.32 per share  was decided to be paid in October 2023.According to decision of the Board of Directors today  the dividend  EUR 0.32 per share  will be paid to a shareholder registered in the company‚Äôs shareholder register maintained by Euroclear Finland Ltd on the record date for the dividend 23 October 2023. The dividend will be paid on 30 October 2023.Further information:Matias J√§rnefelt  CEOtel: +358 40 505 6080matias.jarnefelt@harvia.comAri Vesterinen  CFOtel: +358 40 505 0440ari.vesterinen@harvia.comHarvia is one of the leading companies operating in the sauna and spa market globally  as measured by revenue. Harvia‚Äôs brands and product portfolio are well known in the market  and the company‚Äôs comprehensive product portfolio strives to meet the needs of the international sauna and spa market of both private and professional customers.Harvia‚Äôs revenue totaled EUR 172.4 million in 2022. Harvia Group employs more than 600 professionals in Finland  China and Hong Kong  Romania  Austria  United States  Germany and Estonia. The company is headquartered in Muurame  Finland  adjacent to its largest sauna and sauna component manufacturing facility.,neutral,0.02,0.98,0.01,neutral,0.02,0.97,0.01,True,English,"['Harvia Plc', 'EUR', 'share', 'sauna component manufacturing facility', 'Stock Exchange Release', 'second dividend instalment', 'Annual General Meeting', 'first dividend instalment', 'Matias J√§rnefelt', 'comprehensive product portfolio', 'Euroclear Finland Ltd', 'international sauna', 'largest sauna', 'record date', 'payment date', 'financial year', 'two instalments', 'Further information', 'leading companies', 'professional customers', 'Hong Kong', 'United States', 'spa market', 'shareholder register', 'Ari Vesterinen', 'Harvia Plc', 'Harvia Group', 'October', 'Board', 'Directors', 'decision', '20 April', 'company', 'CEO', 'jarnefelt', 'CFO', 'revenue', 'brands', 'needs', 'private', '600 professionals', 'China', 'Romania', 'Austria', 'Germany', 'Estonia', 'Muurame', '3.00']",2023-10-19,2023-10-20,globenewswire.com
31585,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/ARTMARKET-COM-5174/news/Artmarket-com-Artprice-by-Artmarket-com-congratulates-the-artist-Tarik-Kiswanson-winner-of-th-45106546/,Artmarket.com : Artprice by Artmarket.com congratulates the artist Tarik Kiswanson  winner of the 2023 Marcel Duchamp Prize  sponsored by ADIAF -October 19  2023 at 01:20 pm EDT,(marketscreener.com)  Dedicated to the international promotion of the French contemporary art scene  the Marcel Duchamp Prize shortlisted four finalists at the beginning of this year: Bertille Back   Bouchra Khalili   Massinissa Selmani and finally Tarik Ki‚Ä¶,"Dedicated to the international promotion of the French contemporary art scene  the Marcel Duchamp Prize shortlisted four finalists at the beginning of this year: Bertille Back (represented by the Xippas gallery and The Gallery Apart)  Bouchra Khalili (represented by the Mor Charpentier gallery and ADN Galeria)  Massinissa Selmani (represented by the Anne-Sarah Benichou gallery  Selma Feriani and Jane Lombard) and finally Tarik Kiswanson (represented by the carlier | gebauer and Sfeir-Semler galleries) who has won the prize for this 23rd edition.For thierry Ehrmann  Artprice Founder and CEO of Artmarket  ‚ÄúOnce again this year  the four finalists whose works are currently being shown at the Pompidou Center illustrate the diversity and excellence of the French artistic scene. We extend our warm congratulations to them and  in particular  to Tarik Kiswanson  this year's Marcel Duchamp Prize winner. Artprice.com by Artmarket is proud to support ADIAF and the Prix Marcel Duchamp as a patron.‚ÄùImage: [ https://imgpublic.artprice.com/img/wp/sites/11/2023/10/HD-9473-TAE_Tarik_%C2%A9-julie-ansiau-1024px.jpg ]Tarik Kiswanson ¬© Julie AnsiauTarik KiswansonAs Matthieu Jacquet points out in an article for the Pompidou Center in Paris  Tarik Kiswanson was ‚Äúborn in the small town of Halmstad  in Sweden  to Palestinian parents exiled in the 1970s. He has always kept one foot in his native country and the other in the Middle East  where he has gone every year since his birth. Like many second-generation immigrants  the artist was exposed to the imperatives of conformism and integration in the country adopted by his parents but was constantly reminded of his roots by the predominantly white society in which he evolved. He moved from Sweden to Paris 14 years ago.‚ÄùThrough diverse and transversal practices such as sculpture  writing  performance  drawing  sound and video works  the thirty-year-old addresses the theses of uprooting  belonging  memory but also those of transformation and regeneration in his personal journey as well as in the history of the contemporary world.‚ÄúI am a second-generation immigrant and my work is largely inspired by notions of displacement and uprooting.‚Äù Tarik KiswansonObtaining the Marcel Duchamp Prize is the high point of a year 2023 marked by three solo exhibitions around the world: one at the Museo Tamayo in Mexico  one at the Bonniers Konsthall in Stockholm and another at the Salzburger Kunstverein in Salzburg. In 2022  Tarik Kiswanson's works were shown at the Lyon Biennale  at the Museum of Contemporary Art in Antwerp (Belgium) and at the Hallands Konstmuseum (Sweden). In 2021 he had an exhibition at the Carr√© d'Art - Museum of Contemporary Art in N√Æmes in 2021  and in 2019 he participated in New York's Performa 19 Biennale.Tarik Kiswanson graduated from Central Saint Martins  London (2010) and the √âcole Nationale Sup√©rieure des Beaux-arts in Paris (2014). The most recent winners of the Marcel Duchamp Prize were Mimosa Echard (2022)  Lili Reynaud Dewar (2021) and Kapwani Kiwanga (2020).The ADIAF and the Marcel Duchamp PrizeFounded by Gilles Fuchs and chaired since 2021 by Claude Bonnin  the ADIAF (Association for the International Diffusion of French Art) brings together 300 collectors of Contemporary French art. Supported by patrons  including Artprice  the ADIAF highlights the French scene and contributes to its international influence.The Marcel Duchamp Prize hands out a total of 90 000 euros  including 35 000 euros to the winner who also benefits from a residency in the United States at the Villa Albertine. Organized in collaboration with the Pompidou Center  the ADIAF offers an exhibition of the four finalists at the Pompidou Center as part of the Marcel Duchamp Prize. The exhibition currently dedicated to Bertille Bak  Bouchra Khalili  Massinissa Selmani and Tarik Kiswanson can be discovered on the fourth floor of the Parisian museum until 8 January 2024.According to Xavier Rey  Director of the National Museum of Modern Art  this ‚Äúexhibition represents  thanks to the excellence of the four finalists  the best of the French artistic scene. With Tarik Kiswanson we honor an extremely accomplished multidisciplinary work  both in its formal dimension and in its relationship to history. Based on the energetic relationships between various elements  his works aim  with great sensitivity  to convey a universal message.For this 23rd edition of the Marcel Duchamp Prize  the jury consisted of seven key figures from the art world: Xavier Rey  Director of the National Museum of Modern Art - Pompidou Center  Claude Bonnin  Collector and President of Adiaf  Akemi Shiraha  Representative of the Marcel Duchamp Association  Dr. Jimena Blazquez Abascal  Collector and Director of the Montenmedio Contemporary Foundation (Spain)  Jos√©e Gensollen  Collector  Collection Gensollen La Fabrique (Marseille)  B√©atrice Salmon  Director of the National Center for Plastic Arts (CNAP) and Adam D. Weinberg  Director of the Whitney Museum of American Art  in New York.Past winners of the Marcel Duchamp PrizeThomas Hirschhorn (2000-2001)Dominique Gonzalez-Foerster (2002)Matthew Mercier (2003)Carole Benzaken (2004)Claude Closky (2005)Philippe Mayaux (2006)Tatiana Trouv√© (2007)Laurent Grasso (2008)Sa√¢dane Afif (2009)Cyprien Gaillard (2010)Mircea Cantor (2011)Daniel Dewar and Gr√©gory Gicquel (2012)Latifa Echakhch (2013)Julien Pr√©vieux (2014)Melik Ohanian (2015)Kader Attia (2016)Joana Hadjithomas and Khalil Joreige (2017)Cl√©ment Cogitore (2018)Eric Baudelaire (2019)Kapwani Kiwanga (2020)Lili Reynaud Dewar (2021)Mimosa Echard (2022)Tarik Kiswanson (2023)Image: [ https://imgpublic.artprice.com/img/wp/sites/11/2023/10/HD-9473-TAE_Tarik_%C2%A9-julie-ansiau-1024px.jpg ]Copyright 1987-2023 thierry Ehrmann www.artprice.com - www.artmarket.comDon't hesitate to c ontact our E conometrics Department for your requirements regarding statistics and personalized studies: econometrics@artprice.comTry our services (free demo): https://www.artprice.com/demoSubscribe to our services: https://www.artprice.com/subscriptionAbout Artmarket:Artmarket.com is listed on Eurolist by Euronext Paris  SRD long only and Euroclear: 7478 - Bloomberg: PRC - Reuters: ARTF.Discover Artmarket and its Artprice department on video: www.artprice.com/videoArtmarket and its Artprice department was founded in 1997 by its CEO  thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur  created in 1987.See certified biography in Who's who ¬©:https://imgpublic.artprice.com/img/wp/sites/11/2023/04/2023_2_Biographie-thierry-Ehrmann_WhosWhoInFrance.pdfArtmarket is a global player in the Art Market with  among other structures  its Artprice department  world leader in the accumulation  management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results  covering more than 824 000 artists.Artprice by Artmarket  the world leader in information on the art market  has set itself the ambition through its Global Standardized Marketplace to be the world's leading Fine Art NFT platform.Artprice Images¬Æ allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day  commented by our art historians.Artmarket with its Artprice department accumulates data on a permanent basis from 7200 Auction Houses and produces key Art Market information for the main press and media agencies (7 200 publications). Its 7.2 million (‚Äòmembers log in'+social media) users have access to ads posted by other members  a network that today represents the leading Global Standardized Marketplace¬Æ to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France's Commercial Code).Artmarket  with its Artprice department  has twice been awarded the State label ""Innovative Company"" by the Public Investment Bank (BPI)  which has supported the company in its project to consolidate its position as a global player in the art market.Artprice by Artmarket publishes its 2023 Contemporary Art Market Report:https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2023Artprice by Artmarket's Global Art Market Report  ‚ÄúThe Art Market in 2022‚Äù  published in March 2023:https://www.artprice.com/artprice-reports/the-art-market-in-2022Artprice releases its 2022 Ultra-Contemporary Art Market Report:https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2022Index of press releases posted by Artmarket with its Artprice department:https://serveur.serveur.com/artmarket/press-release/en/Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:www.facebook.com/artpricedotcom/ (over 6.4 million followers)twitter.com/artmarketdotcomtwitter.com/artpricedotcomDiscover the alchemy and universe of Artmarket and its artprice department https://www.artprice.com/video headquartered at the famous Organe Contemporary Art Museum ‚ÄúThe Abode of Chaos‚Äù (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013La Demeure du Chaos / Abode of ChaosGESAMTKUNSTWERK & SINGULAR ACRHITECTUREConfidential bilingual work now public:https://ftp1.serveur.com/abodeofchaos_singular_architecture.pdfL'Obs - The Museum of the Future: https://youtu.be/29LXBPJrs-owww.facebook.com/la.demeure.du.chaos.theabodeofchaos999 (over 4 million followers)https://vimeo.com/124643720Contact Artmarket.com and its Artprice department - Contact: ir@artmarket.comThis publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: nW1xlclul2bJmJ+fZ8trb2iUl2ZlmZHKaGPGk2RtlMeWcJxpm21qb8qaZnFjmWln- Check this key: https://www.security-master-key.com .Unregulated information:Full and original press release in PDF: https://www.actusnews.com/news/82441-artprice-by-artmarket-com-congratulates-artist-tarik-kiswanson-winner-of-the-2023-marcel-duchamp-prize-sponsored-by-adiaf.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2023 ActusNews",neutral,0.34,0.65,0.01,positive,0.73,0.26,0.01,True,English,"['2023 Marcel Duchamp Prize', 'Artmarket.com', 'Tarik Kiswanson', 'Artprice', 'artist', 'winner', 'ADIAF', 'October', '01:20', 'Nationale Sup√©rieure des', 'Dr. Jimena Blazquez Abascal', 'Collection Gensollen La Fabrique', 'The Marcel Duchamp Prize', 'Marcel Duchamp Prize winner', 'French contemporary art scene', 'Jos√©e Gensollen', 'Prix Marcel Duchamp', 'three solo exhibitions', 'Central Saint Martins', 'Lili Reynaud Dewar', 'seven key figures', 'B√©atrice Salmon', 'Adam D. Weinberg', 'French artistic scene', 'The Gallery Apart', 'Mor Charpentier gallery', 'Anne-Sarah Benichou gallery', 'Montenmedio Contemporary Foundation', 'many second-generation immigrants', 'Marcel Duchamp Association', 'Contemporary French art', 'French scene', 'Xippas gallery', 'contemporary world', 'Modern Art', 'American Art', 'The ADIAF', 'international promotion', 'four finalists', 'Bertille Back', 'Bouchra Khalili', 'ADN Galeria', 'Massinissa Selmani', 'Selma Feriani', 'Jane Lombard', 'Tarik Kiswanson', 'Sfeir-Semler galleries', '23rd edition', 'thierry Ehrmann', 'Pompidou Center', 'warm congratulations', 'Julie Ansiau', 'Matthieu Jacquet', 'small town', 'one foot', 'Middle East', 'white society', 'transversal practices', 'personal journey', 'high point', 'Museo Tamayo', 'Bonniers Konsthall', 'Salzburger Kunstverein', 'Lyon Biennale', 'Hallands Konstmuseum', 'N√Æmes', 'New York', 'Performa 19 Biennale', 'recent winners', 'Mimosa Echard', 'Kapwani Kiwanga', 'Gilles Fuchs', 'Claude Bonnin', 'International Diffusion', 'international influence', 'United States', 'Villa Albertine', 'Bertille Bak', 'fourth floor', 'Xavier Rey', 'formal dimension', 'energetic relationships', 'various elements', 'great sensitivity', 'universal message', 'Akemi Shiraha', 'National Center', 'Plastic Arts', 'Past winners', 'art world', 'Parisian museum', 'National Museum', 'Whitney Museum', 'Palestinian parents', 'native country', 'multidisciplinary work', 'Artprice Founder', 'video works', 'beginning', 'year', 'carlier', 'gebauer', 'CEO', 'Artmarket', 'diversity', 'excellence', 'com', 'patron', 'Image', 'sites', 'article', 'Halmstad', 'Sweden', '1970s', 'birth', 'imperatives', 'conformism', 'integration', 'roots', 'diverse', 'sculpture', 'writing', 'performance', 'drawing', 'sound', 'old', 'theses', 'uprooting', 'belonging', 'memory', 'transformation', 'regeneration', 'history', 'notions', 'displacement', 'Mexico', 'Stockholm', 'Antwerp', 'Belgium', 'London', 'Beaux-arts', '300 collectors', 'total', '90,000 euros', '35,000 euros', 'residency', 'collaboration', '8 January', 'Director', 'jury', 'President', 'Representative', 'Spain', 'Marseille', 'CNAP', 'Thom']",2023-10-19,2023-10-20,marketscreener.com
31586,Euroclear,NewsApi.org,https://www.marketscreener.com/quote/stock/ROCKPOOL-ACQUISITIONS-PLC-36862094/news/Rockpool-Acquisitions-Notice-of-Annual-General-Meeting-45106531/,Rockpool Acquisitions : Notice of Annual General Meeting -October 19  2023 at 01:15 pm EDT,(marketscreener.com)   Rockpool Acquisitions Plc   Notice of Annual General Meeting   Company Number: NI644683   Notice is hereby given that the Annual General Meeting of Rockpool Acquisitions Plc will be held at The Merchant Room  Eagle Star House‚Ä¶,Rockpool Acquisitions Plc Notice of Annual General Meeting Company Number: NI644683 Notice is hereby given that the Annual General Meeting (Meeting) of Rockpool Acquisitions Plc (Company) will be held at The Merchant Room  Eagle Star House  5-7 Upper Queen Street  Belfast  BT1 6FB on Friday 17 November 2023 at 10:00am. You will be asked to consider and vote on resolutions 1 to 9  below  all of which will be proposed as ordinary resolutions. 1. Receipt of annual accounts To receive the Company's annual accounts for the financial year ended 31 March 2023 together with the strategic report  the directors' report and the auditor's report on those accounts. 2. Re-appointment of Richard Beresford as director To re-appoint Richard Beresford who is retiring by rotation in accordance with the Company's articles of association  being recommended by the board and eligible for re-appointment  as a director of the Company. 3. Re-appointment of Michael Irvine as director To re-appoint Michael Irvine who is retiring by rotation in accordance with the Company's articles of association  being recommended by the board and eligible for re-appointment  as a director of the Company. 4. Re-appointment of Neil Adair as director To re-appoint Neil Adair who is retiring by rotation in accordance with the Company's articles of association  being recommended by the board and eligible for re-appointment  as a director of the Company. 5. Remuneration Report To approve the Directors' Remuneration Report (other than the Directors' Remuneration Policy) set out on pages 13 to 16 of the annual report for the financial year ended 31 March 2023. 6. Re-appointment of auditor To re-appoint Grant Thornton (NI) LLP as the Company's auditor to hold office from the 1conclusions of this meeting until the conclusion of the next annual general meeting at which account are laid before the Company. 7. Authority to determine auditor's remuneration To authorise the directors of the Company to determine the auditor's remuneration. 8. Relaxation of the operation of Article 111 of the Company's Articles of Association To continue relaxing the operation of Article 111 of the Company's Articles of Association so that the directors may  notwithstanding any interest they may have  vote and form part of the quorum in relation to any issue of shares or rights to acquire shares or any other transaction or arrangement that is put before the directors for their approval for the purposes of or in connection with the acquisition of Amcomri Group Limited or the readmission of the Company's shares to the market immediately following that acquisition or as may otherwise be contemplated by the Company's letter of intent in relation to Amcomri Group Limited dated 11 November 2022 including without limitation the grant of options to the Directors. 9. Share Issuance authority To authorise the directors generally and unconditionally for the purposes of section 551 of the Companies Act 2006 to exercise any power of the Company to (i) offer or allot; (ii) grant rights to subscribe for or to convert any security into; and (iii) otherwise deal in or dispose of  any shares (or any options  warrants  conversion rights and all other rights to acquire or subscribe for shares) to any person  at any time and subject to any terms and conditions as the directors think proper. The authority referred to in this resolution shall be limited to shares having a maximum nominal amount of ¬£40 million and shall only apply insofar as the Company has not  subject to the Company's articles of association  renewed  waived or revoked it by ordinary resolution and shall expire  if not renewed prior to such time  on the date occurring 24 months from the date of the passing of this resolution save that the expiry of this authority shall not affect the offer  allotment  grant or dealing after the expiry of this authority where such offer  allotment  grant or dealing was approved pursuant to this authority. You will also be asked to consider and vote on resolution 10 below which will be proposed as special resolution .10. Disapplication of statutory pre-emption rights THAT  in accordance with section 570(1) of the Companies Act 2006 (the Act)  the directors be granted the power to allot equity securities (as defined in section 560(1) of the Act) pursuant to the authorisation granted by resolution 9 as if section 561 (existing shareholders' right of pre-emption) did not apply to the allotment or applied to the allotment with such modifications as the directors may determine. In accordance with section 570(4) of the Act  the directors may  prior to the expiry of the power conferred by this resolution  make an offer 2or agreement which would  or might  require any equity securities to be allotted after the expiry of such power (and the directors may allot equity securities in pursuance of such an offer or agreement as if such power had not expired). By order of the Board ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶. Richard Beresford  Director Rockpool Acquisitions Plc c/o Cordovan Capital Management Limited Suite 102 Urban Hq  Upper Queen Street  Belfast  Northern Ireland  BT1 6FB Dated: 19 October 2023 3Notes Entitlement to attend  participate and vote Only those members registered on the Company's register of members at 6:00pm onWednesday 15 November 2023 (or in the event of an adjournment  6pm on the date which is two working days prior to the adjourned meeting) shall be entitled to attend  ask questions and vote at the meeting. Changes to the register of members after this time will be disregarded in determining the rights of any person to attend  ask questions and vote at the meeting. In the case of joint holders  the vote of the senior joint holder who tenders a vote  whether during the meeting or in proxy  shall be accepted to the exclusion of the votes of the other joint holders. For this purpose  seniority will be determined by the order in which the names of the holders appear in the Company's register of holders (the first- named being the most senior). Appointment of proxies If you are a shareholder who is entitled to attend and vote at the meeting  you are entitled to appoint one or more proxies to exercise all or any of your rights to attend  speak and vote at the meeting and you should have received a proxy form with this notice of meeting. A proxy does not need to be a shareholder of the Company but must attend the meeting in person to represent you. You can only appoint a proxy using the procedures set out in these notes and the notes to the proxy form. You may appoint more than one proxy provided each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. To appoint more than one proxy  please photocopy the proxy form and list the details for each proxy on a separate photocopied form (each form requires signing). You will need to state clearly on each proxy form the number of shares in relation to which the proxy is appointed. If you wish your proxy to speak on your behalf at the meeting you will need to appoint your own choice of proxy (not the chairman) and give your instructions directly to them. Shareholders can: Appoint a proxy or proxies and give proxy instructions by returning the enclosed proxy form by post (see note 7).7). Register their proxy appointment electronically (see note 8).8). Appoint a proxy via CREST (see notes 10 - 14) If no voting indication is given  your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting. Appointment of proxy by post 7. The notes to the proxy form explain how to direct your proxy how to vote on each resolution. 4To appoint a proxy using the proxy form  the form must be: completed and signed;sent or delivered to the Company c/o McCarthy Denning Ltd  70 Mark Lane  London  EC3R 7NQ (FAO Carina Loibl); andreceived by the Company no later than 48 hours (excluding non-working days) before the time of the meeting. In the case of a shareholder which is a company  the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form. If you have not received a proxy form and believe that you should have one  or if you require additional proxy forms  please contact Carina Loibl by email cloibl@mccarthydenning.com(with a copy to mike@cordovancapital.com). Appointment of proxies electronically 8. As an alternative to completing a hard-copy proxy form  you can appoint a proxy electronically by emailing the proxy form to Carina Loibl by email cloibl@mccarthydenning.com(with a copy to mike@cordovancapital.com). For an electronic proxy appointment to be valid  your appointment must be received by the Company no later than 48 hours (excluding non-working days) before the time of the meeting. Appointment of proxy by joint members 9. In the case of joint holders  where more than one of the joint holders completes a proxy appointment  only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first- named being the most senior). Appointment of proxy through CREST CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy instruction service may do so for the meeting to be held on 17 November 2023 and any adjournment(s) of it by using the procedures described in the CREST Manual (available at www.euroclear.com). CREST personal members or other CREST sponsored members  and those CREST members who have appointed voting service providers  should refer to their CREST sponsors or voting service providers  who will be able to take the appropriate action on their behalf. In order for a proxy appointment made by means of CREST to be valid  the appropriate CREST message (a CREST Proxy Instruction) must be properly authenticated in accordance with Euroclear UK & International Limited's (EUI) specifications and must contain the information required for such instructions  as described in the CREST Manual. The 5message must be transmitted so as to be received by the issuer's agent Neville Registrars  (ID 7RA11) by no later than 48 hours (excluding non-working days) prior to the meeting. For this purpose  the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed byCREST. CREST members and  where applicable  their CREST sponsors or voting service providers should note that EUI does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is therefore the responsibility of the CREST member concerned to take (or  if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s)  to procure that his/her CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection  CREST members and  where applicable  their CREST sponsors or voting service providers are referred  in particular  to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5) (a) of the Uncertificated Securities Regulations 2001  as amended. Changing proxy instructions 15. Shareholders may change proxy instructions by submitting a new proxy appointment using the methods set out above. Note that the cut-off time for receipt of proxy appointments also apply in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded. Where you have appointed a proxy using the hard-copy proxy form and would like to change the instructions using another hard-copy proxy form  please contact Carina Loibl by email cloibl@mccarthydenning.com(with a copy to mike@cordovancapital.com). If you submit more than one valid proxy appointment  the appointment received last before the latest time for the receipt of proxies will take precedence. Termination of proxy appointment 16. A shareholder may change a proxy instruction but to do so you will need to inform the Company in writing by either: Sending a signed hard-copy notice clearly stating your intention to revoke your proxy appointment to the Company Secretary. In the case of a shareholder which is a company  the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice.hard-copy notice clearly stating your intention to revoke your proxy appointment to the Company Secretary. In the case of a shareholder which is a company  the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice. Attaching a written notice clearly stating your intention to revoke your proxy 6appointment to the Company  executed as above  to an email and sending it to Carina Loibl by email cloibl@mccarthydenning.com(with a copy to mike@cordovancapital.com). In either case  the revocation notice must be received by the Company no later than 24 hours before the time of the meeting. If you attempt to revoke your proxy appointment but the revocation is received after the time specified  your original proxy appointment will remain valid unless you attend the meeting electronically and vote in person. Appointment of a proxy does not preclude you from attending the meeting and voting in person. If you have appointed a proxy and attend the meeting in person your proxy appointment will automatically be terminated. Corporate representatives A corporation which is a shareholder can appoint one or more corporate representatives who may exercise  on its behalf  all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same share. Nominated persons Any persons whose shares are held on their behalf by another person and who have been nominated to receive communications from the Company in accordance with section 146 of the Companies Act 2006 (Nominated Persons) may have a right under an agreement with the registered shareholder who holds shares on their behalf to be appointed (or to have someone else appointed) as a proxy. Alternatively  if Nominated Persons do not have such a right  or do not wish to exercise it  they may have a right under such an agreement to give instructions to the registered holder of the shares as to the exercise of voting rights. The statement of the rights of shareholders in relation to the appointment of proxies set out above does not apply to Nominated Persons. The rights described in these Notes can only be exercised by shareholders of the Company. Voting by way of a poll 17. Voting on each resolution will be conducted by way of a poll. The Company believes that a poll is more representative of the shareholders' voting intentions because shareholder votes are counted according to the number of votes held and all votes tendered are taken into account. The results of the poll will be announced to the London Stock Exchange and will be made available on the Company's website at www.rockpoolacquisitions.plc.uk as soon as practicable following the conclusion of the meeting. Issued shares and total voting rights 18. As at 6:00pm on 17 October 2023  which is the latest practicable date before publication of this notice  the Company's issued share capital comprised 12 725 003 ordinary shares of ¬£0.05 each. Each ordinary share carries the right to one vote at a general meeting of the Company and  therefore  the total number of voting rights in the Company as at 6:00pm on 17 October 2023  is 12 725 003. 7Shareholder requisition rights and rights to require publication of certain statements 19. Under section 527 of the Companies Act 2006  members meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to: the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the meeting; or any circumstances connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual accounts and reports were laid in accordance with section 437 of the Companies Act 2006. The Company may not require the shareholder requesting any such website publication to pay its expenses in complying with sections 527 or 528 of the Companies Act 2006. Where the Company is required to place a statement on a website under section 527 of the Companies Act 2006  it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the meeting includes any statement that the Company has been required under section 527 of the Companies Act 2006 to publish on a website. 20. Under sections 338 and 338A of the Companies Act 2006  a member or members meeting the qualification criteria in those sections have the right to require the Company: To give to members of the Company entitled to receive notice of the meeting  notice of a resolution which may properly be moved and is intended to be moved at the meeting; and/or To include in the business to be dealt with at the meeting any matter (other than a proposed resolution) which may be properly included in the business. A resolution may properly be moved or a matter may properly be included in the business unless:a. (in the case of a resolution only) it would  if passed  be ineffective (whether by reason of inconsistency with any enactment of the Company's constitution or otherwise); or it is defamatory of any person; or c. it is frivolous or vexatious. The Company will give notice of such a resolution or of such other business if sufficient requests have been received in accordance with section 338(3) and 338A(3) of the Companies Act 2006. Communication 21. Except as provided above  shareholders who have general queries about the meeting should contact Carina Loibl by email cloibl@mccarthydenning.com. 8,neutral,0.02,0.97,0.01,neutral,0.04,0.9,0.06,True,English,"['Annual General Meeting', 'Rockpool Acquisitions', 'Notice', 'October', '01:15', 'Cordovan Capital Management Limited Suite', 'Annual General Meeting Company Number', '5-7 Upper Queen Street', 'next annual general meeting', 'Rockpool Acquisitions Plc Notice', 'Director Rockpool Acquisitions Plc', 'Amcomri Group Limited', 'The Merchant Room', 'Eagle Star House', 'maximum nominal amount', ""existing shareholders' right"", 'Share Issuance authority', 'statutory pre-emption rights', ""Directors' Remuneration Policy"", ""Directors' Remuneration Report"", 'annual report', 'annual accounts', 'Friday 17 November', 'financial year', 'strategic report', 'Richard Beresford', 'Michael Irvine', 'Neil Adair', '5. Remuneration Report', 'other transaction', 'equity securities', 'Urban Hq', 'conversion rights', 'other rights', 'ordinary resolutions', 'Companies Act', ""directors' report"", 'special resolution', 'Grant Thornton', 'Belfast', 'BT1', '10:00am', 'Receipt', 'auditor', 'appointment', 'rotation', 'accordance', 'articles', 'association', 'board', 'pages', 'office', 'conclusions', 'Relaxation', 'operation', 'interest', 'part', 'quorum', 'relation', 'issue', 'shares', 'arrangement', 'approval', 'purposes', 'connection', 'readmission', 'market', 'letter', 'intent', 'limitation', 'options', 'section', 'power', 'security', 'warrants', 'person', 'time', 'terms', 'conditions', 'date', 'passing', 'expiry', 'offer', 'allotment', 'dealing', 'Disapplication', 'authorisation', 'modifications', 'agreement', 'pursuance', 'order']",2023-10-19,2023-10-20,marketscreener.com
31587,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-Gets-a-Buy-rating-from-Deutsche-Bank-45103060/,DEUTSCHE B√ñRSE AG : Gets a Buy rating from Deutsche Bank -October 19  2023 at 08:15 am EDT,(marketscreener.com) Analyst Benjamin Goy from Deutsche Bank research considers the stock attractive and recommends it with a Buy rating. The target price remains set at EUR 206.https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE‚Ä¶,Deutsche B√∂rse AG is one of the leading European stock exchanges. Net sales break down by activity as follows: - trading services (44%): execution and management of operations on derivatives and in cash (shares  bonds  warrants  etc.; Xetra); - compensation  payment-delivery  and conservation services and securities (41.2%); - distribution of indexes and market data (14.8%). The group is also involved in development and implementation of IT solutions. Net sales are distributed geographically as follows: European Union (53.1%)  Europe (27.5%)  America (13.4%) and Asia/Pacific (6%).,neutral,0.02,0.97,0.01,neutral,0.02,0.93,0.05,True,English,"['DEUTSCHE B√ñRSE AG', 'Deutsche Bank', 'Buy rating', 'October', 'EDT', 'Deutsche B√∂rse AG', 'leading European stock exchanges', 'European Union', 'Net sales', 'trading services', 'conservation services', 'market data', 'IT solutions', 'activity', 'execution', 'management', 'operations', 'derivatives', 'cash', 'shares', 'bonds', 'warrants', 'Xetra', 'compensation', 'payment-delivery', 'securities', 'distribution', 'indexes', 'group', 'development', 'implementation', 'America', 'Asia/Pacific']",2023-10-19,2023-10-20,marketscreener.com
31588,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-JP-Morgan-remains-Neutral-45104986/,DEUTSCHE B√ñRSE AG : JP Morgan remains Neutral -October 19  2023 at 10:34 am EDT,(marketscreener.com) In a research note published by Enrico Bolzoni  JP Morgan gives a Neutral rating to the stock. The target price continues to be set at EUR 183.https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-JP-M‚Ä¶,Deutsche B√∂rse AG is one of the leading European stock exchanges. Net sales break down by activity as follows: - trading services (44%): execution and management of operations on derivatives and in cash (shares  bonds  warrants  etc.; Xetra); - compensation  payment-delivery  and conservation services and securities (41.2%); - distribution of indexes and market data (14.8%). The group is also involved in development and implementation of IT solutions. Net sales are distributed geographically as follows: European Union (53.1%)  Europe (27.5%)  America (13.4%) and Asia/Pacific (6%).,neutral,0.01,0.98,0.01,neutral,0.02,0.93,0.05,True,English,"['DEUTSCHE B√ñRSE AG', 'JP Morgan', 'October', 'EDT', 'Deutsche B√∂rse AG', 'leading European stock exchanges', 'European Union', 'Net sales', 'trading services', 'conservation services', 'market data', 'IT solutions', 'activity', 'execution', 'management', 'operations', 'derivatives', 'cash', 'shares', 'bonds', 'warrants', 'Xetra', 'compensation', 'payment-delivery', 'securities', 'distribution', 'indexes', 'group', 'development', 'implementation', 'America', 'Asia/Pacific']",2023-10-19,2023-10-20,marketscreener.com
31589,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/Deutsche-Boerse-Good-Q3-23-figures-burdened-by-one-offs-45100683/,Deutsche Boerse : Good Q3 23 figures burdened by one-offs -October 19  2023 at 04:54 am EDT,(marketscreener.com) EARNINGS/SALES RELEASES¬ï Net revenues increased by 9% to ¬Ä1.19bn for Q3 23 compared to Q3 22¬ï EBITDA rose by 7% to ¬Ä685m for Q3 23 compared to Q3 22¬ï Net profit attributable to shareholders increased by 7% to ¬Ä400m for Q3 23¬ï Deutsche ‚Ä¶,Deutsche B√∂rse AG is one of the leading European stock exchanges. Net sales break down by activity as follows: - trading services (44%): execution and management of operations on derivatives and in cash (shares  bonds  warrants  etc.; Xetra); - compensation  payment-delivery  and conservation services and securities (41.2%); - distribution of indexes and market data (14.8%). The group is also involved in development and implementation of IT solutions. Net sales are distributed geographically as follows: European Union (53.1%)  Europe (27.5%)  America (13.4%) and Asia/Pacific (6%).,neutral,0.27,0.69,0.04,neutral,0.02,0.93,0.05,True,English,"['Good Q3 23 figures', 'Deutsche Boerse', 'one-offs', 'October', '04', 'Deutsche B√∂rse AG', 'leading European stock exchanges', 'European Union', 'Net sales', 'trading services', 'conservation services', 'market data', 'IT solutions', 'activity', 'execution', 'management', 'operations', 'derivatives', 'cash', 'shares', 'bonds', 'warrants', 'Xetra', 'compensation', 'payment-delivery', 'securities', 'distribution', 'indexes', 'group', 'development', 'implementation', 'America', 'Asia/Pacific']",2023-10-19,2023-10-20,marketscreener.com
31590,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-DZ-Bank-remains-its-Buy-rating-45104995/,DEUTSCHE B√ñRSE AG : DZ Bank remains its Buy rating -October 19  2023 at 10:35 am EDT,(marketscreener.com) Thorsten Wenzel from DZ Bank retains his positive opinion on the stock with a Buy rating.https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-DZ-Bank-remains-its-Buy-rating-45104995/?utm_medium=RSS&ut‚Ä¶,Deutsche B√∂rse AG is one of the leading European stock exchanges. Net sales break down by activity as follows: - trading services (44%): execution and management of operations on derivatives and in cash (shares  bonds  warrants  etc.; Xetra); - compensation  payment-delivery  and conservation services and securities (41.2%); - distribution of indexes and market data (14.8%). The group is also involved in development and implementation of IT solutions. Net sales are distributed geographically as follows: European Union (53.1%)  Europe (27.5%)  America (13.4%) and Asia/Pacific (6%).,neutral,0.01,0.98,0.01,neutral,0.02,0.93,0.05,True,English,"['DEUTSCHE B√ñRSE AG', 'DZ Bank', 'Buy rating', 'October', '10', 'Deutsche B√∂rse AG', 'leading European stock exchanges', 'European Union', 'Net sales', 'trading services', 'conservation services', 'market data', 'IT solutions', 'activity', 'execution', 'management', 'operations', 'derivatives', 'cash', 'shares', 'bonds', 'warrants', 'Xetra', 'compensation', 'payment-delivery', 'securities', 'distribution', 'indexes', 'group', 'development', 'implementation', 'America', 'Asia/Pacific']",2023-10-19,2023-10-20,marketscreener.com
31591,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-Warburg-Research-maintains-a-Buy-rating-45104683/,DEUTSCHE B√ñRSE AG : Warburg Research maintains a Buy rating -October 19  2023 at 10:07 am EDT,(marketscreener.com) Analyst Andreas Pl√§sier from Warburg Research research considers the stock attractive and recommends it with a Buy rating. The target price is unchanged and still at EUR 204.https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449‚Ä¶,Deutsche B√∂rse AG is one of the leading European stock exchanges. Net sales break down by activity as follows: - trading services (44%): execution and management of operations on derivatives and in cash (shares  bonds  warrants  etc.; Xetra); - compensation  payment-delivery  and conservation services and securities (41.2%); - distribution of indexes and market data (14.8%). The group is also involved in development and implementation of IT solutions. Net sales are distributed geographically as follows: European Union (53.1%)  Europe (27.5%)  America (13.4%) and Asia/Pacific (6%).,neutral,0.02,0.98,0.01,neutral,0.02,0.93,0.05,True,English,"['DEUTSCHE B√ñRSE AG', 'Warburg Research', 'Buy rating', 'October', '10', 'Deutsche B√∂rse AG', 'leading European stock exchanges', 'European Union', 'Net sales', 'trading services', 'conservation services', 'market data', 'IT solutions', 'activity', 'execution', 'management', 'operations', 'derivatives', 'cash', 'shares', 'bonds', 'warrants', 'Xetra', 'compensation', 'payment-delivery', 'securities', 'distribution', 'indexes', 'group', 'development', 'implementation', 'America', 'Asia/Pacific']",2023-10-19,2023-10-20,marketscreener.com
31592,Deutsche Boerse,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-Berenberg-gives-a-Neutral-rating-45105037/,DEUTSCHE B√ñRSE AG : Berenberg gives a Neutral rating -October 19  2023 at 10:37 am EDT,(marketscreener.com) Peter Richardson from Berenberg retains his Neutral opinion on the stock. The target price remains set at EUR 175.https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/DEUTSCHE-BORSE-AG-Berenberg-gives-a-Neutral-rating-‚Ä¶,Deutsche B√∂rse AG is one of the leading European stock exchanges. Net sales break down by activity as follows: - trading services (44%): execution and management of operations on derivatives and in cash (shares  bonds  warrants  etc.; Xetra); - compensation  payment-delivery  and conservation services and securities (41.2%); - distribution of indexes and market data (14.8%). The group is also involved in development and implementation of IT solutions. Net sales are distributed geographically as follows: European Union (53.1%)  Europe (27.5%)  America (13.4%) and Asia/Pacific (6%).,neutral,0.01,0.98,0.01,neutral,0.02,0.93,0.05,True,English,"['DEUTSCHE B√ñRSE AG', 'Neutral rating', 'Berenberg', 'October', '10', 'Deutsche B√∂rse AG', 'leading European stock exchanges', 'European Union', 'Net sales', 'trading services', 'conservation services', 'market data', 'IT solutions', 'activity', 'execution', 'management', 'operations', 'derivatives', 'cash', 'shares', 'bonds', 'warrants', 'Xetra', 'compensation', 'payment-delivery', 'securities', 'distribution', 'indexes', 'group', 'development', 'implementation', 'America', 'Asia/Pacific']",2023-10-19,2023-10-20,marketscreener.com
31593,Deutsche Boerse,Bing API,https://finance.yahoo.com/news/roundhill-exit-europe-closing-metaverse-172728031.html,Roundhill to Exit Europe After Closing Metaverse ETF,The Round Ball Metaverse UCITS ETF (METV) will delist from the Deutsche Boerse on Nov. 30 after gathering just $1.8 million in assets under management since its inception. It is the U.S.-based firm‚Äôs only ETF listed in Europe despite also having a sports ...,"Roundhill Investments is set to exit the European ETF market after announcing the closure of its metaverse exchange-traded fund just 18 months after launching.The Round Ball Metaverse UCITS ETF (METV) will delist from the Deutsche Boerse on Nov. 30 after gathering just $1.8 million in assets under management since its inception.It is the U.S.-based firm‚Äôs only ETF listed in Europe despite also having a sports betting and gaming exchange-traded fund registered with the Central Bank of Ireland.""After careful consideration  we decided to refocus our distribution efforts back to our home market in the U.S.  where we believe there are currently numerous opportunities for innovation ‚Äù Tim Maloney  chief investment officer of Roundhill Investments  told ETF Stream.""This fund closure is in no way an indication of a wavering belief in the metaverse  a theme we remain deeply committed to and where our U.S.-listed Fund remains the largest in the world.""Establishing a business presence in a new market is always a challenging proposition  and in this case  we were unable to identify a model for growth that was sustainable despite the strong support from all of our partners on the initiative.""Metaverse ETF in the U.S.The firm launched the world‚Äôs first metaverse ETF in the U.S.  tracking the same index as METV  which at one point had $710 million in assets under management.Assets have since fallen to $413 million  even though the fund has returned 34.5% this year as of Oct. 18.METV was the second metaverse ETF to list in Europe following the launch of the $7.9 millon ETC Group Global Metaverse UCITS ETF (METR) just five days earlier.The metaverse theme has struggled to take off since a flurry of launches last year which saw Franklin Templeton  Fidelity Investments  Legal & General Investment Management and BlackRock all enter the market.The iShares Metaverse UCITS ETF (MTAV) is the largest ETF tracking the metaverse. It launched in December  but has amassed only $19.1 million in assets.Permalink | ¬© Copyright 2023 etf.com. All rights reserved",neutral,0.06,0.92,0.01,negative,0.01,0.32,0.67,True,English,"['Metaverse ETF', 'Roundhill', 'Europe', '$7.9 millon ETC Group Global Metaverse UCITS ETF', 'The Round Ball Metaverse UCITS ETF', 'iShares Metaverse UCITS ETF', 'U.S.-listed Fund', 'U.S.-based firm', 'first metaverse ETF', 'second metaverse ETF', 'chief investment officer', 'metaverse exchange-traded fund', 'gaming exchange-traded fund', 'European ETF market', 'General Investment Management', 'ETF Stream', 'largest ETF', 'metaverse theme', 'fund closure', 'Roundhill Investments', 'Deutsche Boerse', 'sports betting', 'Central Bank', 'careful consideration', 'distribution efforts', 'home market', 'numerous opportunities', 'Tim Maloney', 'wavering belief', 'business presence', 'new market', 'challenging proposition', 'strong support', 'same index', 'one point', 'Franklin Templeton', 'Fidelity Investments', 'METV', 'Nov.', 'assets', 'inception', 'Ireland', 'innovation', 'way', 'indication', 'world', 'case', 'model', 'growth', 'partners', 'initiative', 'Oct.', 'launch', 'METR', 'flurry', 'Legal', 'BlackRock', 'MTAV', 'December', 'Permalink', 'Copyright', 'rights']",2023-10-20,2023-10-20,finance.yahoo.com
31594,Deutsche Boerse,Bing API,https://finance.yahoo.com/news/blackrock-launches-mining-etf-europe-171702856.html,BlackRock Launches Mining ETF in Europe,The fund will invest in companies that are involved in the mining and manufacturing of metals deemed necessary to create more renewable energy.,"BlackRock has launched an ETF capturing companies that are focused on mining and manufacturing the metals facilitating the transition to renewable energy.The iShares Essential Metals UCITS ETF (METL) is listed on Deutsche Boerse and Euronext Amsterdam with a total expense ratio of 0.55%.METL tracks the S&P Global Essential Metals Producers index  which offers exposure to companies mining or manufacturing alumina  aluminum  bauxite  cobalt  copper  lithium  manganese  molybdenum  nickel  palladium  platinum  silver  rare earth elements and zinc  which S&P Global Commodity Insights deems essential for energy transition technologies.BlackRock said increased interest in the sector has been driven by the shift to a low-carbon economy  supply-chain challenges and strategic and geopolitical priorities.‚ÄúClients are becoming more intentional in their climate transition investment ambitions and building precision exposure to potential beneficiaries ‚Äù Manuela Sperandeo  global head of sustainable indexing at BlackRock  said.Low-Carbon Economy‚ÄúWe see structurally rising demand for minerals and metals like copper  lithium and nickel that are critical for renewable energy infrastructure and will help power the transition to a low-carbon economy "" Sperandeo added.‚ÄúIn our view  investing in assets such as those that provide key inputs necessary for decarbonization could offer some of the most attractive investment opportunities in the transition to a low-carbon economy.‚ÄùThe arrival of METL marks the expansion of BlackRock‚Äôs transition metal miners offering  after ETF Stream reported on the launch of the iShares Copper Miners UCITS ETF (COPM) in June.Permalink | ¬© Copyright 2023 etf.com. All rights reserved",neutral,0.03,0.96,0.01,neutral,0.1,0.88,0.02,True,English,"['Mining ETF', 'BlackRock', 'Europe', 'S&P Global Essential Metals Producers index', 'S&P Global Commodity Insights', 'iShares Essential Metals UCITS ETF', 'iShares Copper Miners UCITS ETF', 'climate transition investment ambitions', 'attractive investment opportunities', 'transition metal miners', 'total expense ratio', 'rare earth elements', 'renewable energy infrastructure', 'energy transition technologies', 'global head', 'ETF Stream', 'Deutsche Boerse', 'Euronext Amsterdam', 'low-carbon economy', 'supply-chain challenges', 'geopolitical priorities', 'potential beneficiaries', 'sustainable indexing', 'rising demand', 'key inputs', 'precision exposure', 'Manuela Sperandeo', 'BlackRock', 'companies', 'mining', 'The', 'METL', 'alumina', 'aluminum', 'bauxite', 'cobalt', 'lithium', 'manganese', 'molybdenum', 'nickel', 'palladium', 'platinum', 'silver', 'zinc', 'interest', 'sector', 'shift', 'strategic', 'Clients', 'minerals', 'view', 'assets', 'decarbonization', 'arrival', 'expansion', 'launch', 'COPM', 'June', 'Permalink', 'Copyright', 'rights']",2023-10-20,2023-10-20,finance.yahoo.com
31595,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762918/0/en/Share-Buyback-Transaction-Details-October-12-October-18-2023.html,Share Buyback Transaction Details October 12 ‚Äì October 18  2023,Share Buyback Transaction Details October 12 ‚Äì October 18  2023           October 19  2023 - Wolters Kluwer (Euronext: WKL)  a¬†global leading provider...,Share Buyback Transaction Details October 12 ‚Äì October 18  2023October 19  2023 - Wolters Kluwer (Euronext: WKL)  a global leading provider of expert solutions  insights and services for professionals  today reports that it has repurchased 198 760 of its own ordinary shares in the period from October 12  2023  up to and including October 18  2023  for ‚Ç¨24.2 million and at an average share price of ‚Ç¨121.51.These repurchases are part of the share buyback program announced on February 22  2023  under which we intend to repurchase shares for up to ‚Ç¨1 billion during 2023.The cumulative amounts repurchased to date under this year‚Äôs buyback program are as follows:Share Buyback 2023Period Cumulative shares repurchased in period Total consideration(‚Ç¨ million) Average share price(‚Ç¨) 2023 to date 6 849 974 764.4 111.59For the period starting August 3  2023  up to and including October 30  2023  we have mandated third parties to execute ‚Ç¨300 million in share buybacks on our behalf  within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company‚Äôs Articles of Association.Repurchased shares are added to and held as treasury shares and will be used for capital reduction purposes or to meet obligations arising from share-based incentive plans.Further information is available on our website:About Wolters KluwerWolters Kluwer (EURONEXT: WKL) is a global leader in information  software  and services for professionals in healthcare  tax and accounting  financial and corporate compliance  legal and regulatory  and corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.Wolters Kluwer reported 2022 annual revenues of ‚Ç¨5.5 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 20 900 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).For more information  visit www.wolterskluwer.com   follow us on LinkedIn   Twitter   Facebook   and YouTube .Media Investors/Analysts Paul Lyon Meg Geldens External Communications Investor Relations t + 44 20 3197 6586 t + 31 172 641 407 press@wolterskluwer.com ir@wolterskluwer.comForward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as ‚Äúexpect‚Äù  ‚Äúshould‚Äù  ‚Äúcould‚Äù  ‚Äúshall‚Äù and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include  without limitation  general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers  suppliers  and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal  tax  and regulatory rules affecting Wolters Kluwer‚Äôs businesses  as well as risks related to mergers  acquisitions  and divestments. In addition  financial risks such as currency movements  interest rate fluctuations  liquidity  and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events or otherwise.This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.Attachment,neutral,0.01,0.99,0.0,negative,0.02,0.37,0.62,True,English,"['Share Buyback Transaction Details', 'October', 'Analysts Paul Lyon Meg Geldens External Communications Investor Relations', 'Alphen aan den Rijn', 'Level 1 American Depositary Receipt', 'Share Buyback Transaction Details', 'Other Important Legal Information', 'capital reduction purposes', 'share-based incentive plans', 'deep domain knowledge', 'interest rate fluctuations', 'average share price', 'global leading provider', 'new ICT systems', 'general economic conditions', 'share buyback program', 'Wolters Kluwer shares', 'Period Cumulative shares', 'share buybacks', 'cumulative amounts', 'global leader', 'ADR) program', 'new information', 'ordinary shares', 'Repurchased shares', 'treasury shares', 'expert solutions', 'Total consideration', 'third parties', 'relevant laws', 'corporate compliance', 'corporate performance', 'critical decisions', 'specialized technology', '2022 annual revenues', 'counter market', 'U.S.', 'Media Investors', 'similar expressions', 'actual results', 'technological developments', 'currency movements', 'future results', 'foregoing list', 'press release', 'Forward-looking Statements', 'Further information', 'Euronext Amsterdam', 'Euronext 100 indices', 'regulatory rules', 'credit risks', 'future events', 'financial risks', 'October', 'WKL', 'insights', 'services', 'professionals', 'repurchases', 'February', 'date', 'year', 'August', 'behalf', 'limits', 'regulations', 'company', 'Articles', 'Association', 'obligations', 'website', 'software', 'healthcare', 'tax', 'accounting', 'ESG', 'customers', 'group', '180 countries', 'operations', '40 countries', '20,900 people', 'Netherlands', 'AEX', 'ADRs', 'WTKWY', 'LinkedIn', 'Twitter', 'Facebook', 'YouTube', 'report', 'words', 'uncertainties', 'Factors', 'limitation', 'markets', 'behavior', 'suppliers', 'competitors', 'implementation', 'execution', 'outsourcing', 'businesses', 'mergers', 'acquisitions', 'divestments', 'addition', 'liquidity', 'intention', 'Attachment', '31']",2023-10-19,2023-10-20,globenewswire.com
31596,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762869/0/en/Cabka-realizes-144-million-in-sales-up-to-third-quarter.html,Cabka realizes ‚Ç¨144 million in sales up to third quarter,Amsterdam October 19  2023. Cabka N.V. (together with its subsidiaries ‚ÄúCabka‚Äù  or the ‚ÄúCompany‚Äù)  a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP)  listed at Euronext Amsterdam  published ‚Ä¶,Amsterdam October 19  2023. Cabka N.V. (together with its subsidiaries ‚ÄúCabka‚Äù  or the ‚ÄúCompany‚Äù)  a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP)  listed at Euronext Amsterdam  published its trading update for the third quarter of 2023  today.Total sales over the first three quarters of 2023 came at ‚Ç¨ 144 million  6% behind last year (22Q3: ‚Ç¨ 152 million)  driven by a ‚Ç¨ 8 million decline in non-strategic segments sales. Sales figures reflect challenging economic circumstances with clients continue to destock  driven by increased interest rates and inflation  and postpone larger orders over the quarter  resulting in quarterly sales of ‚Ç¨ 40 million.Strategic business segments showed comparable sales as last year. Based on decreasing raw material and energy price trends  we implemented a partial reversal of certain indexed prices  supporting margins.Cabka consolidated its strong European position in RTP Portfolio  up 2%. Customized Solutions grew with 22% with especially strong results in the US. The ECO business performed well with an 11% sales growth. These positive developments were offset by soft sales in Contract Manufacturing (-15%) and a 24% decline in RTP US reflecting a very slow sales pickup post-flooding.For the fourth quarter Cabka expects a strong recovery of sales based on the announced major co-development launches  such as CHEP  Continental and BMW  coming up to speed.A new two-year framework agreement with Tesla was recently signed  coming into effect in 2024.Based on its strong fundamentals Cabka confirms it mid-term guidance1 as well as full year 2023 outlook2  be it towards the lower end of the indicated spectrum for 2023.Financial Reporting Calendar 2024March 20: Preliminary Results 2023April 18: Publication Annual Report 2023 and Trading Update 2024Q1May 30: Annual General Meeting of ShareholdersAugust 13: Half-Year Results and Half-Year Report 2024October 21: Trading Update 2024Q3For more information  please contact:David Brilleslijper  Investor & Press contactIR@cabka.com   or D.Brilleslijper@cabka.com  +316 109 42514www.investors.cabka.comCommercial contact:info@cabka.comwww.cabka.comAbout CabkaCabka is in the business of recycling plastics from post-consumer and post-industrial waste into innovative reusable transport packaging (RTP)  like pallets- and large container solutions enhancing logistics chain sustainability. ECO products are mainly construction and road safety products produced exclusively out of post-consumer waste.Cabka is leading the industry in its integrated approach closing the loop from waste  to recycling  to manufacturing. Backed by its own innovation center it has the rare industry knowledge  capability  and capacity of making maximum use bringing recycled plastics back in the production loop at attractive returns. Cabka is fully equipped to exploit the full value chain from waste to end-products.Cabka is listed at Euronext Amsterdam as of 1 March 2022 under the CABKA ticker with international securities identification number NL00150000S7.DisclaimerThe content of this press release may include statements that are  or may be deemed to be  ‚Äò‚Äôforward-looking statements‚Äô‚Äô. These forward-looking statements may be identified by the use of forward-looking terminology  including the terms ‚Äò‚Äôbelieves‚Äô‚Äô  ‚Äò‚Äôestimates‚Äô‚Äô  ‚Äò‚Äôplans‚Äô‚Äô  ‚Äò‚Äôprojects‚Äô‚Äô  ‚Äò‚Äôanticipates‚Äô‚Äô  ‚Äò‚Äôexpects‚Äô‚Äô  ‚Äò‚Äôintends‚Äô‚Äô  ‚Äò‚Äômay‚Äô‚Äô  ‚Äò‚Äôwill‚Äô‚Äô or ‚Äò‚Äôshould‚Äô‚Äô or  in each case  their negative or other variations or comparable terminology  or by discussions of strategy  plans  objectives  goals  future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company‚Äôs current view with respect to future events and are subject to risks relating to future events and other risks  uncertainties and assumptions relating to the Company‚Äôs business  results of operations  financial position  liquidity  prospects  growth  or strategies.Readers are cautioned that any forward-looking statements are not guarantees of future performance. Given these uncertainties  the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. The Company undertakes no obligation to publicly update or revise the information in this press release  including any forward-looking statements  except as may be required by law.This document contains information that qualifies as inside information within the meaning of Article 7(1) of Regulation (EU) No 596/2014 on market abuse.1 Mid-term guidance: High single digit revenue growth; >20% EBITDA margin; ~4% maintenance and replacement CAPEX and ~20% NWC as percentage of revenues; ~30-35% pay-out ratio of net profit (‚Ç¨ 0.15 for 2022FY)2 Based on current challenging market conditions  we expect 2023 revenues of ‚Ç¨ 200 - 210 million with a recovery of EBITDA margin towards 13-15%Attachment,neutral,0.04,0.95,0.01,mixed,0.25,0.29,0.45,True,English,"['third quarter', 'Cabka', 'sales', 'to', 'High single digit revenue growth', 'innovative Reusable Transport Packaging', 'new two-year framework agreement', 'international securities identification number', 'current challenging market conditions', 'challenging economic circumstances', 'first three quarters', 'energy price trends', 'Annual General Meeting', 'logistics chain sustainability', 'full value chain', '~30-35% pay-out ratio', 'Financial Reporting Calendar', 'large container solutions', 'road safety products', 'full year 2023 outlook', 'strategic segments sales', 'slow sales pickup', 'Strategic business segments', 'rare industry knowledge', 'strong European position', 'Publication Annual Report', 'Cabka N.V.', 'The ECO business', 'ECO products', 'current view', 'financial position', 'market abuse', '11% sales growth', 'Customized Solutions', 'Half-Year Report', 'last year', 'strong fundamentals', 'Total sales', 'Sales figures', 'quarterly sales', 'comparable sales', 'soft sales', 'strong results', 'trading update', 'interest rates', 'larger orders', 'raw material', 'partial reversal', 'positive developments', 'development launches', 'mid-term guidance1', 'lower end', 'David Brilleslijper', 'Press contact', 'D.Brilleslijper', 'Commercial contact', 'integrated approach', 'innovation center', 'attractive returns', 'press release', 'forward-looking terminology', 'other variations', 'comparable terminology', 'future events', 'future performance', 'undue reliance', 'EU) No', '1 Mid-term guidance', '>20% EBITDA margin', 'replacement CAPEX', 'net profit', 'looking statements', 'Preliminary Results', 'Half-Year Results', 'actual results', 'strong recovery', 'The Company', 'Euronext Amsterdam', 'third quarter', 'fourth quarter', 'plastic waste', 'post-industrial waste', '‚Ç¨ 8 million decline', 'RTP Portfolio', 'Contract Manufacturing', 'maximum use', 'recycled plastics', 'production loop', 'other risks', 'inside information', 'CABKA ticker', 'post-consumer waste', 'RTP US', '24% decline', 'subsidiaries', 'clients', 'inflation', 'prices', 'margins', 'CHEP', 'Continental', 'BMW', 'speed', 'Tesla', 'effect', 'spectrum', 'March', 'April', 'May', 'Shareholders', 'October', 'Investor', 'construction', 'recycling', 'capability', 'capacity', 'end-products', 'Disclaimer', 'content', 'terms', 'plans', 'projects', 'case', 'negative', 'discussions', 'strategy', 'objectives', 'goals', 'intentions', 'respect', 'uncertainties', 'assumptions', 'operations', 'liquidity', 'prospects', 'strategies', 'Readers', 'guarantees', 'obligation', 'law', 'document', 'meaning', 'Article', 'Regulation', '~4% maintenance', '~20% NWC', 'percentage', 'revenues', '2022FY']",2023-10-19,2023-10-20,globenewswire.com
31597,EuroNext,NewsApi.org,https://wealthofgeeks.com/gut-feeling-bowel-disease-drugmaker-abivax-uplists-from-paris-to-nasdaq/,Gut Feeling: Bowel Disease Drugmaker Abivax Uplists from Paris to Nasdaq,Investors with an appetite for bowel disease biotech have a new European deal to digest.¬† French biotech firm Abivax S.A. is commencing a transatlantic uplisting ... Read More,Investors with an appetite for bowel disease biotech have a new European deal to digest.French biotech firm Abivax S.A. is commencing a transatlantic uplisting from Euronext Paris to the Nasdaq.On Monday  October 15  the firm kicked off its roadshow for its planned debut. It will float under the ticker ‚ÄúABVX ‚Äù while staging a concurrent private offering elsewhere in Europe.On Wednesday  October 18  the company  which develops therapeutics for chronic inflammatory bowel diseases  topped up its offering to 20.33 million American Depositary Share (ADS) shares with an F-1/A filing. The offering's estimated proceeds remain at $250.06 million. The proposed price range will be $11.60 to $13.00 per share.Abivax's lead drug candidate  obefazimod  treats severe cases of ulcerative colitis (‚ÄúUC‚Äù). Obefazimod is currently in Phase 3 clinical trials. The firm is planning a Phase 2a clinical trial to test how obefazimod may be used to treat patients with Crohn's disease (‚ÄúCD‚Äù)  too.The company says last year  almost 3 million patients across the United States  EU4 (France  Germany  Italy  and Spain  the United Kingdom  and Japan suffered from the kinds of bowel diseases it treats.Feeling for a PulseNew offerings have recovered somewhat this year after 2022's historic collapse. Yet  if the broader IPO market is still a bit under the weather  biotech deals have been chronically ill.In the first half of 2023  only nine biotech companies have gone public  making it the slowest IPO year for the industry in at least six years  per BioPharma Dive data. In a sign of the cautious times  David Diamond of business consulting firm CBIZ MHM recently told industry publication BioSpace that investors are now looking for data from Phase II or later-stage studies to ensure they invest only in firms with effective assets.Sick Man of Europe?More broadly  European IPOs this year have been at their lowest since 2008.The Planisware  which was billed to be France's largest IPO in two years  at ‚Ç¨300 million  was abruptly canceled on fears ‚Äúextremely cautious‚Äù investors would let the float flop. Germany's military hardware maker Renk Group has also postponed a ‚Ç¨350 million deal. Meanwhile  German toll payments provider DKV Mobility is also reported to be delaying its launch.Financial Times columnist Craig Cohen likens Europe's IPO market to a sad  stiff cadaver that requires ever-greater shocks of electro-stimulation: ‚ÄúA lifeless IPO market is periodically revived  only for the unsettling realization that ‚Äî except for world-class companies with scale and profile ‚Äî it's still largely kaput.‚ÄùWith bourses across the continent starved of new sizable deals  it's no wonder Abivex is heading ‚Äòacross the pond' to dive into the deep capital pools only found in the U.S.A.,neutral,0.03,0.79,0.18,negative,0.03,0.25,0.72,True,English,"['Bowel Disease Drugmaker Abivax', 'Gut Feeling', 'Paris', 'Nasdaq', 'German toll payments provider', 'Phase 2a clinical trial', 'chronic inflammatory bowel diseases', '20.33 million American Depositary Share', 'Phase 3 clinical trials', 'lead drug candidate', 'military hardware maker', 'sad, stiff cadaver', 'deep capital pools', 'U.S.A.', 'Financial Times columnist', 'nine biotech companies', 'new sizable deals', 'broader IPO market', 'lifeless IPO market', 'Abivax S.A.', 'BioPharma Dive data', 'business consulting firm', 'industry publication BioSpace', 'bowel disease biotech', 'French biotech firm', 'concurrent private offering', 'new European deal', 'biotech deals', '‚Ç¨350 million deal', 'Phase II', 'New offerings', 'cautious times', 'European IPOs', 'world-class companies', 'IPO year', 'largest IPO', '3 million patients', 'transatlantic uplisting', 'Euronext Paris', 'ADS) shares', 'F-1/A filing', 'price range', 'severe cases', 'ulcerative colitis', 'United States', 'United Kingdom', 'historic collapse', 'first half', 'six years', 'David Diamond', 'CBIZ MHM', 'later-stage studies', 'effective assets', 'Sick Man', 'The Planisware', 'two years', 'Renk Group', 'DKV Mobility', 'Craig Cohen', 'greater shocks', 'unsettling realization', 'cautious‚Äù investors', 'appetite', 'Nasdaq', 'Monday', 'October', 'roadshow', 'debut', 'ticker', 'ABVX', 'Wednesday', 'company', 'therapeutics', 'proceeds', 'obefazimod', 'UC', 'Crohn', 'CD', 'France', 'Germany', 'Italy', 'Spain', 'Japan', 'kinds', 'Pulse', 'weather', 'sign', 'firms', 'fears', 'float', 'launch', 'electro-stimulation', 'scale', 'profile', 'bourses', 'continent', 'Abivex', 'pond']",2023-10-19,2023-10-20,wealthofgeeks.com
31598,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/CABKA-N-V-115395161/news/Cabka-realizes-144-million-in-sales-up-to-third-quarter-45097755/,Cabka realizes ¬Ä144 million in sales up to third quarter,(marketscreener.com) Amsterdam October 19  2023. Cabka N.V.   a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging   listed at Euronext Amsterdam  published its trading update for the third quarter o‚Ä¶,Amsterdam October 19  2023. Cabka N.V. (together with its subsidiaries ‚ÄúCabka‚Äù  or the ‚ÄúCompany‚Äù)  a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP)  listed at Euronext Amsterdam  published its trading update for the third quarter of 2023  today.Total sales over the first three quarters of 2023 came at ‚Ç¨ 144 million  6% behind last year (22Q3: ‚Ç¨ 152 million)  driven by a ‚Ç¨ 8 million decline in non-strategic segments sales. Sales figures reflect challenging economic circumstances with clients continue to destock  driven by increased interest rates and inflation  and postpone larger orders over the quarter  resulting in quarterly sales of ‚Ç¨ 40 million.Strategic business segments showed comparable sales as last year. Based on decreasing raw material and energy price trends  we implemented a partial reversal of certain indexed prices  supporting margins.Cabka consolidated its strong European position in RTP Portfolio  up 2%. Customized Solutions grew with 22% with especially strong results in the US. The ECO business performed well with an 11% sales growth. These positive developments were offset by soft sales in Contract Manufacturing (-15%) and a 24% decline in RTP US reflecting a very slow sales pickup post-flooding.For the fourth quarter Cabka expects a strong recovery of sales based on the announced major co-development launches  such as CHEP  Continental and BMW  coming up to speed.A new two-year framework agreement with Tesla was recently signed  coming into effect in 2024.Based on its strong fundamentals Cabka confirms it mid-term guidance1 as well as full year 2023 outlook2  be it towards the lower end of the indicated spectrum for 2023.Financial Reporting Calendar 2024March 20: Preliminary Results 2023April 18: Publication Annual Report 2023 and Trading Update 2024Q1May 30: Annual General Meeting of ShareholdersAugust 13: Half-Year Results and Half-Year Report 2024October 21: Trading Update 2024Q3For more information  please contact:David Brilleslijper  Investor & Press contactIR@cabka.com   or D.Brilleslijper@cabka.com  +316 109 42514www.investors.cabka.comCommercial contact:info@cabka.comwww.cabka.comAbout CabkaCabka is in the business of recycling plastics from post-consumer and post-industrial waste into innovative reusable transport packaging (RTP)  like pallets- and large container solutions enhancing logistics chain sustainability. ECO products are mainly construction and road safety products produced exclusively out of post-consumer waste.Cabka is leading the industry in its integrated approach closing the loop from waste  to recycling  to manufacturing. Backed by its own innovation center it has the rare industry knowledge  capability  and capacity of making maximum use bringing recycled plastics back in the production loop at attractive returns. Cabka is fully equipped to exploit the full value chain from waste to end-products.Cabka is listed at Euronext Amsterdam as of 1 March 2022 under the CABKA ticker with international securities identification number NL00150000S7.DisclaimerThe content of this press release may include statements that are  or may be deemed to be  ‚Äò‚Äôforward-looking statements‚Äô‚Äô. These forward-looking statements may be identified by the use of forward-looking terminology  including the terms ‚Äò‚Äôbelieves‚Äô‚Äô  ‚Äò‚Äôestimates‚Äô‚Äô  ‚Äò‚Äôplans‚Äô‚Äô  ‚Äò‚Äôprojects‚Äô‚Äô  ‚Äò‚Äôanticipates‚Äô‚Äô  ‚Äò‚Äôexpects‚Äô‚Äô  ‚Äò‚Äôintends‚Äô‚Äô  ‚Äò‚Äômay‚Äô‚Äô  ‚Äò‚Äôwill‚Äô‚Äô or ‚Äò‚Äôshould‚Äô‚Äô or  in each case  their negative or other variations or comparable terminology  or by discussions of strategy  plans  objectives  goals  future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company‚Äôs current view with respect to future events and are subject to risks relating to future events and other risks  uncertainties and assumptions relating to the Company‚Äôs business  results of operations  financial position  liquidity  prospects  growth  or strategies.Readers are cautioned that any forward-looking statements are not guarantees of future performance. Given these uncertainties  the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. The Company undertakes no obligation to publicly update or revise the information in this press release  including any forward-looking statements  except as may be required by law.This document contains information that qualifies as inside information within the meaning of Article 7(1) of Regulation (EU) No 596/2014 on market abuse.1 Mid-term guidance: High single digit revenue growth; >20% EBITDA margin; ~4% maintenance and replacement CAPEX and ~20% NWC as percentage of revenues; ~30-35% pay-out ratio of net profit (‚Ç¨ 0.15 for 2022FY)2 Based on current challenging market conditions  we expect 2023 revenues of ‚Ç¨ 200 - 210 million with a recovery of EBITDA margin towards 13-15%Attachment,neutral,0.04,0.95,0.01,mixed,0.25,0.29,0.45,True,English,"['third quarter', 'Cabka', 'sales', 'High single digit revenue growth', 'innovative Reusable Transport Packaging', 'new two-year framework agreement', 'international securities identification number', 'current challenging market conditions', 'challenging economic circumstances', 'first three quarters', 'energy price trends', 'Annual General Meeting', 'logistics chain sustainability', 'full value chain', '~30-35% pay-out ratio', 'Financial Reporting Calendar', 'large container solutions', 'road safety products', 'full year 2023 outlook', 'strategic segments sales', 'slow sales pickup', 'Strategic business segments', 'rare industry knowledge', 'strong European position', 'Publication Annual Report', 'Cabka N.V.', 'The ECO business', 'ECO products', 'current view', 'financial position', 'market abuse', '11% sales growth', 'Customized Solutions', 'Half-Year Report', 'last year', 'strong fundamentals', 'Total sales', 'Sales figures', 'quarterly sales', 'comparable sales', 'soft sales', 'strong results', 'trading update', 'interest rates', 'larger orders', 'raw material', 'partial reversal', 'positive developments', 'development launches', 'mid-term guidance1', 'lower end', 'David Brilleslijper', 'Press contact', 'D.Brilleslijper', 'Commercial contact', 'integrated approach', 'innovation center', 'attractive returns', 'press release', 'forward-looking terminology', 'other variations', 'comparable terminology', 'future events', 'future performance', 'undue reliance', 'EU) No', '1 Mid-term guidance', '>20% EBITDA margin', 'replacement CAPEX', 'net profit', 'looking statements', 'Preliminary Results', 'Half-Year Results', 'actual results', 'strong recovery', 'The Company', 'Euronext Amsterdam', 'third quarter', 'fourth quarter', 'plastic waste', 'post-industrial waste', '‚Ç¨ 8 million decline', 'RTP Portfolio', 'Contract Manufacturing', 'maximum use', 'recycled plastics', 'production loop', 'other risks', 'inside information', 'CABKA ticker', 'post-consumer waste', 'RTP US', '24% decline', 'subsidiaries', 'clients', 'inflation', 'prices', 'margins', 'CHEP', 'Continental', 'BMW', 'speed', 'Tesla', 'effect', 'spectrum', 'March', 'April', 'May', 'Shareholders', 'October', 'Investor', 'construction', 'recycling', 'capability', 'capacity', 'end-products', 'Disclaimer', 'content', 'terms', 'plans', 'projects', 'case', 'negative', 'discussions', 'strategy', 'objectives', 'goals', 'intentions', 'respect', 'uncertainties', 'assumptions', 'operations', 'liquidity', 'prospects', 'strategies', 'Readers', 'guarantees', 'obligation', 'law', 'document', 'meaning', 'Article', 'Regulation', '~4% maintenance', '~20% NWC', 'percentage', 'revenues', '2022FY']",2023-10-19,2023-10-20,marketscreener.com
31599,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/JCDECAUX-SE-4664/news/JCDecaux-renews-and-extends-its-advertising-concession-with-Madrid-Metro-for-10-years-with-new-icon-45105652/,JCDecaux renews and extends its advertising concession with Madrid Metro for 10 years  with new iconic and innovative digital screens,(marketscreener.com) JCDecaux renews and extends its advertising concession with Madrid Metro for 10 years  with new iconic and innovative digital screens Paris  October 19th  2023 ‚Äì JCDecaux SE   the number one outdoor advertising company worldwide  announce‚Ä¶,"JCDecaux renews and extends its advertising concession with Madrid Metro for 10 years  with new iconic and innovative digital screensParis  October 19th  2023 ‚Äì JCDecaux SE (Euronext Paris: DEC)  the number one outdoor advertising company worldwide  announces that following a competitive tender it has renewed and extended its advertising concession with Madrid Metro (5 million daily passengers on average)  making it the most digitised JCDecaux-marketed metro in Europe and the first 100% data-driven advertising space in Spain. The digital transformation of the oldest Spanish metro network has started in August and will be completed by the end of the year.The 10-year contract covers 3 100 traditional displays as well as more than 460 new  larger  sharper and more energy-efficient digital screens  extending their life cycle and making metro stations more efficient and sustainable. The new contract aims to deliver a high-quality media space and to modernise Spain‚Äôs capital metro with up to 2 000 sq m of screens. It includes innovative and high-impact displays such as large-format screens and columns with an anamorphic effect  twin curved screens as well as ‚Äúcinema formats‚Äù  a new type of large-format screen created exclusively for platforms  142 of which will be installed in 39 key stations. A brand-new network of digital screens will also be created with nearly 300 high-definition screens across 100 strategic locations  mostly within the M30 perimeter  ensuring maximum coverage and visibility.Technological innovation and a data-driven approach also play an important role in shaping new  more digital and intelligent advertising in metro stations. It will include measurement tools  an unprecedented milestone that will make it possible to fine-tune the calculation of impressions in close to real time and offer much more precise performance metrics. This new contract will also enable JCDecaux to introduce programmatic buying opportunities into the metro environment for the first time  following its launch in street furniture and shopping centres.By the end of the year  JCDecaux will operate a total of 2 750 digital faces in Spain.Jean-Charles Decaux  Co-Chief Executive Officer of JCDecaux  said: ""We are delighted to have been awarded this strategic contract to digitise Madrid Metro  continuing our long-term partnership which started in 2007. JCDecaux has rolled-out an in-depth media transformation plan  including the introduction of large and iconic digital media opportunities to create memorable brand experience while offering one of the major communications-platform for brands. It will participate to enhance the Madrid Metro environment  further raising engagement and ultimately generating revenue to invest in delivering an even better commuter experience. It is one of our most ambitious projects to date in Europe and we want it to become a benchmark in terms of digitisation and sustainability. Metro advertising (OOH and DOOH) is an ideal canvas to create impactful and memorable campaigns  leaving a lasting impression on commuters long after their journey has ended. As the number one outdoor advertising company worldwide  our vision is to deliver innovative and sustainable media assets that enhance communication  benefiting partners  people  advertisers and their brands.‚ÄùKey Figures for JCDecaux2022 revenue: ‚Ç¨3 317m (a) ‚Äì H1 2023 revenue: ‚Ç¨1 585m (a)‚Äì H1 2023 revenue: ‚Ç¨1 585m N¬∞1 Out-of-Home Media company worldwideA daily audience of more than 850 million people in more than 80 countries1 040 132 advertising panels worldwidePresent in 3 573 cities with more than 10 000 inhabitants11 200 employeesJCDecaux is listed on the Eurolist of Euronext Paris and is part of the Euronext 100 and Euronext Family Business indexesJCDecaux is recognised for its extra-financial performance in the FTSE4Good (3.4/5)  CDP (A-)  MSCI (AA) and has achieved Platinum Medal status from EcoVadis1st Out-of-Home Media company to join the RE100Leader in self-service bike rental scheme: pioneer in eco-friendly mobilityN¬∞1 worldwide in street furniture (604 536 advertising panels)N¬∞1 worldwide in transport advertising with 153 airports and 205 contracts in metros  buses  trains and tramways (333 620 advertising panels)N¬∞1 in Europe for billboards (101 976 advertising panels worldwide)N¬∞1 in outdoor advertising in Europe (654 957 advertising panels)N¬∞1 in outdoor advertising in Asia-Pacific (170 973 advertising panels)N¬∞1 in outdoor advertising in Latin America (129 305 advertising panelsN¬∞1 in outdoor advertising in Africa (24 198 advertising panels)N¬∞1 in outdoor advertising in the Middle East (19 371 advertising panels)(a) Adjusted revenueFor more information about JCDecaux  please visit jcdecaux.com .Join us on Twitter   LinkedIn   Facebook   Instagram and YouTube .Communications Department: Albert Ass√©raf+33 (0) 1 30 79 79 10 ‚Äì albert.asseraf@jcdecaux.comInvestor Relations: R√©mi Grisard+33 (0) 1 30 79 79 93 ‚Äì remi.grisard@jcdecaux.comAttachment",neutral,0.15,0.84,0.01,positive,0.63,0.35,0.02,True,English,"['innovative digital screens', 'advertising concession', 'Madrid Metro', 'new iconic', 'JCDecaux', '10 years', 'up to 2,000 sq m', 'self-service bike rental scheme', 'depth media transformation plan', 'Euronext Family Business indexes', 'oldest Spanish metro network', 'one outdoor advertising company', 'iconic digital media opportunities', 'first 100% data-driven advertising space', 'high-quality media space', 'Home Media company', 'programmatic buying opportunities', 'sustainable media assets', 'Co-Chief Executive Officer', 'Platinum Medal status', 'precise performance metrics', 'twin curved screens', '460 new, larger, sharper', 'memorable brand experience', 'Albert Ass√©raf', 'R√©mi Grisard', 'energy-efficient digital screens', 'Madrid Metro environment', 'innovative digital screens', 'digital transformation', 'new iconic', 'brand-new network', 'data-driven approach', 'first time', 'commuter experience', 'memorable campaigns', 'extra-financial performance', 'Metro advertising', '2,750 digital faces', 'advertising concession', 'intelligent advertising', '1,040,132 advertising panels', '604,536 advertising panels', 'transport advertising', '101,976 advertising panels', '654,957 advertising panels', '70,973 advertising panels', '29,305 advertising panels', '371 advertising panels', 'large-format screens', '300 high-definition screens', 'new contract', 'new type', 'JCDecaux-marketed metro', 'metro stations', 'capital metro', 'competitive tender', '10-year contract', '3,100 traditional displays', 'life cycle', 'high-impact displays', 'anamorphic effect', 'cinema formats', '39 key stations', '100 strategic locations', 'M30 perimeter', 'maximum coverage', 'Technological innovation', 'important role', 'measurement tools', 'unprecedented milestone', 'real time', 'street furniture', 'shopping centres', 'Jean-Charles Decaux', 'strategic contract', 'long-term partnership', 'major communications-platform', 'ambitious projects', 'ideal canvas', 'lasting impression', 'Key Figures', 'daily audience', 'eco-friendly mobility', 'Latin America', 'Middle East', 'Communications Department', 'Investor Relations', 'Euronext Paris', '850 million people', 'H1 2023 revenue', 'JCDecaux SE', 'Euronext 100', '2022 revenue', '10 years', 'number', 'Europe', 'Spain', 'August', 'columns', 'platforms', 'visibility', 'calculation', 'impressions', 'close', 'launch', 'total', 'introduction', 'brands', 'engagement', 'benchmark', 'terms', 'digitisation', 'sustainability', 'OOH', 'impactful', 'commuters', 'journey', 'vision', 'advertisers', '80 countries', '3,573 cities', '10,000 inhabitants', '11,200 employees', 'Eurolist', 'FTSE4Good', 'CDP', 'MSCI', 'AA', 'EcoVadis', '1st', 'RE100', 'Leader', 'pioneer', '153 airports', '205 contracts', 'metros', 'buses', 'trains', 'tramways', 'billboards', 'N¬∞', 'Asia-Pacific', 'Africa', 'information', 'Twitter', 'LinkedIn', 'Facebook', 'Instagram', 'YouTube', 'asseraf', 'remi', 'Attachment']",2023-10-19,2023-10-20,marketscreener.com
31600,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/RACING-FORCE-S-P-A-129457864/news/Racing-Force-S-p-a-Racing-Force-Group-consolidates-growth-in-the-third-quarter-of-2023-45097703/,Racing Force S.p.a. : Racing Force Group consolidates growth in the third quarter of 2023 -October 19  2023 at 01:20 am EDT,(marketscreener.com)  IN THE FIRST 9 MONTHS OF 2023 REVENUES AT¬†‚Ç¨49.8 MLN Ronco Scrivia   October 19th  2023 - Racing Force S.p.A.  the parent company of Racing Force Group  which is specialized in the development  production  and marketing of safety comp‚Ä¶,"IN THE FIRST 9 MONTHS OF 2023 REVENUES AT ‚Ç¨49.8 MLN (+9.6% y/y)Ronco Scrivia (GE  Italy)  October 19th  2023 - Racing Force S.p.A.  the parent company of Racing Force Group  which is specialized in the development  production  and marketing of safety components for motorsports worldwide  listed on the Euronext Growth segment in Milan (RFG) and Paris (ALRFG)  announces consolidated sales figures for the first nine months of 2023 equal to ‚Ç¨49.8 million  up 9.6% compared to ‚Ç¨45.5 in 2022 (+10.0% at constant exchange rates). The incidence of consolidated revenues for the third quarter of 2023 is equal to ‚Ç¨12.6 million  up 6.1% compared to ‚Ç¨11.9 million in the third quarter of 2022 (+8.0% at constant exchange rates).In terms of geographical areas  countries in the EMEA and APAC macro-regions continue to record a significant growth  exceeding +14% compared to the first nine months of 2022; Americas show a slight decline (-3.1%)  mainly due to a one-off supply made in the previous fiscal year and to the weakening of dollar against euro compared to the last year's highs. Net of these effects  even growth in the Americas would have been double digits (+12.5%).With regards to product categories  Driver's Equipment represents the main segment (72% of total sales)  up 8.8% compared to the first nine months of 2022  thanks to the increase registered in all the main racewear products offered by the Group  while the turnover of Car Parts signed a 5.2% decrease  primarily due to a different timing of supplies related to the production programs of certain important car manufacturers.The Other segment recorded a triple-digit growth (+108.7%)  mainly due to the sales of Racing Spirit branded products  following the acquisition of the entire project by the Group during 2022.Dealers remain the main sales channel for the Group  accounting for 62% of total sales in the first nine months of the year. Compared to 2022  revenues from Team & Car Manufacturers strongly increased (+24.3%)  due to important partnership agreements signed by the Group.Roberto Ferroggiaro  Chief Financial Officer of Racing Force Group  commented:""During the third quarter  the Group further consolidated the growth in the motorsport industry  proving once again its strength and resilience in an unfavorable macro-economic environment  characterized by uncertainty and weakening of global demand. At the same time  investments continue in the Group's main production facilities  aimed at strengthening the structure and increasing logistics and production capacity  with the goal of supporting the expected further growth in motorsport and diversification projects in the coming periods‚Äù.This publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: yGeclJeXaZycyp+el8aYZ2lomWhlmmLJmmqVxZOdlMubaHJlnGyTa8XJZnFjmWZt- Check this key: https://www.security-master-key.com .Regulated information:Inside Information:- News release on accounts  results Full and original press release in PDF: https://www.actusnews.com/news/82417-rfg-cs-q32023-eng.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2023 ActusNews",neutral,0.07,0.93,0.01,negative,0.01,0.27,0.72,True,English,"['Racing Force S.p', 'Racing Force Group', 'third quarter', 'growth', 'October', '01:20', 'Racing Force S.p.A.', 'constant exchange rates', 'important partnership agreements', 'Chief Financial Officer', 'unfavorable macro-economic environment', 'next press releases', 'first nine months', 'original press release', 'Racing Force Group', 'previous fiscal year', 'main sales channel', 'important car manufacturers', 'main racewear products', 'main production facilities', 'consolidated sales figures', 'SECURITY MASTER Key', 'Actusnews SECURITY MASTER', 'Euronext Growth segment', 'FIRST 9 MONTHS', 'Racing Spirit', 'main segment', 'News release', 'Car Parts', 'Other segment', 'total sales', 'Ronco Scrivia', 'safety components', 'third quarter', 'geographical areas', 'APAC macro-regions', 'slight decline', 'one-off supply', 'last year', 'double digits', 'product categories', 'different timing', 'production programs', 'entire project', 'Roberto Ferroggiaro', 'global demand', 'same time', 'production capacity', 'diversification projects', 'coming periods', 'consolidated revenues', 'significant growth', 'triple-digit growth', 'parent company', 'motorsport industry', 'Regulated information', '2023 REVENUES', 'Italy', 'development', 'marketing', 'motorsports', 'Milan', 'RFG', 'Paris', 'incidence', 'terms', 'countries', 'EMEA', 'Americas', 'weakening', 'dollar', 'highs', 'Net', 'effects', 'Driver', 'Equipment', 'increase', 'turnover', '5.2% decrease', 'supplies', 'acquisition', 'Dealers', 'Team', 'strength', 'resilience', 'uncertainty', 'investments', 'structure', 'increasing', 'logistics', 'goal', 'publication', 'accounts', 'results', 'Full', 'PDF', 'email']",2023-10-19,2023-10-20,marketscreener.com
31601,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/QUADIENT-S-A-4674/news/Quadient-experiences-strong-demand-for-integrated-cross-channel-communications-among-Mail-solutions-45106031/,Quadient experiences strong demand for integrated  cross-channel communications among Mail solutions customers,(marketscreener.com) Quadient   a leader in helping businesses create meaningful customer connections through digital and physical channels  experiences strong momentum on digital adoption among its Mail-Related Solution customers  with Quadient‚Äôs multi-chann‚Ä¶,"Quadient (Euronext Paris: QDT)  a leader in helping businesses create meaningful customer connections through digital and physical channels  experiences strong momentum on digital adoption among its Mail-Related Solution customers  with Quadient‚Äôs multi-channel document distribution software sales increasing fast  particularly in North America. By September 2023  these revenues had grown by 40% year-on-year  underpinned by the success of Quadient's cross-selling strategy.Recognizing that different businesses are at varying stages of their digital transformation journey - some rely heavily on paper-based processes  while others are poised for the next step - the company has been investing to provide a combination of advanced mailing systems and omnichannel communications software that  together  automate  secure and streamline document workflows.‚ÄúQuadient continues to differentiate itself by helping organizations navigate through the evolving changes of hybrid communications  enabling businesses to connect with customers more effectively through smart mailing solutions  package management solutions  and omni-channel customer communications platforms.‚Äù Source: IDC  Quadient Stresses Productivity and Security with Latest Intelligent Mailroom Solutions  October 10  2022 (lcUS49775122).Over the first half of the year  Quadient has experienced strong adoption of its newest range of intelligent mail solutions  the iX-Series  with 26.7% of its Mail-Related customer base already equipped with an upgraded system. The company anticipates this trend to continue to accelerate  with postal organizations also driving customers to upgrade to more advanced and secure technologies through new regulations  such as the Intelligent Mail Indicia (IMI) in the United States. Quadient is taking this opportunity to upgrade its installed base while giving customers the digital tools they need to meet customer expectations for new digital processes and interactions.""In today's fast-paced  digitally driven world  businesses need to adapt to the changing landscape of customer expectations ‚Äù notes Alain Fairise  Chief Solutions Officer for Mail-Related Solutions at Quadient. ‚ÄúQuadient is committed to ensuring our customers are equipped to excel in the digital age. We enable businesses to communicate with mail or through digital channels  or a mix of both  with solutions that provide the flexibility and scalability that our customers expect.‚ÄùQuadient's comprehensive suite of solutions goes beyond mail to provide businesses with the tools to modernize their operations and enhance their interactions with customers in an increasingly digital landscape. With a customer base of 440 000 businesses spanning the globe  Quadient enables billions of customer communications and transactions annually through its software  mail and smart parcel locker solutions.About Quadient¬ÆQuadient is the driving force behind the world‚Äôs most meaningful customer experiences. By focusing on three key solution areas  Intelligent Communication Automation  Parcel Locker Solutions and Mail-Related Solutions  Quadient helps simplify the connection between people and what matters. Quadient supports hundreds of thousands of customers worldwide in their quest to create relevant  personalized connections and achieve customer experience excellence. Quadient is listed in compartment B of Euronext Paris (QDT) and is part of the CAC¬Æ Mid & Small and EnterNext¬Æ Tech 40 indices. Quadient shares are eligible for PEA-PME investing.For more information about Quadient  visit www.quadient.com.ContactsJoe Scolaro  QuadientGlobal Press Relations Manager+1 203-301-3673j.scolaro@quadient.comSandy Armstrong  Sterling KilgoreDirector of Media & Communications+1-630-699-8979sarmstrong@sterlingkilgore.comAttachment",neutral,0.03,0.97,0.01,neutral,0.07,0.92,0.01,True,English,"['integrated, cross-channel communications', 'Mail solutions customers', 'strong demand', 'Quadient', 'multi-channel document distribution software sales', 'Global Press Relations Manager', 'three key solution areas', 'Latest Intelligent Mailroom Solutions', 'smart parcel locker solutions', 'omni-channel customer communications platforms', 'Intelligent Communication Automation', 'smart mailing solutions', 'relevant, personalized connections', 'EnterNext¬Æ Tech 40 indices', 'meaningful customer connections', 'customer experience excellence', 'package management solutions', 'Chief Solutions Officer', 'omnichannel communications software', 'digital transformation journey', 'Intelligent Mail Indicia', 'advanced mailing systems', 'intelligent mail solutions', 'meaningful customer experiences', 'Mail-Related Solution customers', 'Mail-Related customer base', 'new digital processes', 'Mail-Related Solutions', 'customer expectations', 'paper-based processes', 'new regulations', 'hybrid communications', 'digital adoption', 'digital age', 'digital channels', 'digital landscape', 'Euronext Paris', 'physical channels', 'strong momentum', 'North America', 'cross-selling strategy', 'varying stages', 'next step', 'evolving changes', 'first half', 'strong adoption', 'newest range', 'secure technologies', 'United States', 'changing landscape', 'Alain Fairise', 'comprehensive suite', 'driving force', 'compartment B', 'CAC¬Æ Mid', 'PEA-PME investing', 'Sandy Armstrong', 'Sterling Kilgore', 'digital tools', 'postal organizations', 'Joe Scolaro', 'different businesses', 'Quadient shares', '440,000 businesses', 'Quadient¬Æ', 'QDT', 'leader', 'September', 'revenues', 'year', 'success', 'others', 'company', 'combination', 'streamline', 'workflows', 'Source', 'IDC', 'Productivity', 'Security', 'iX-Series', 'trend', 'IMI', 'opportunity', 'interactions', 'today', 'world', 'mix', 'flexibility', 'scalability', 'operations', 'globe', 'billions', 'transactions', 'people', 'hundreds', 'thousands', 'quest', 'information', 'Contacts', 'Director', 'Media', 'Attachment']",2023-10-19,2023-10-20,marketscreener.com
31602,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/LINEDATA-SERVICES-4770/news/Linedata-Services-Nine-month-2023-revenue-132-0m-5-7--45105700/,Linedata Services: Nine-month 2023 revenue -October 19  2023 at 11:47 am EDT,(marketscreener.com) Linedata ServicesLinedata Services: Nine-month 2023 revenue: ‚Ç¨132.0m 19-Oct-2023 / 17:45 CET/CESTDissemination of a French Regulatory News  transmitted by EQS Group.The issuer is solely responsible for the content of‚Ä¶,Nine-month 2023 revenue: ‚Ç¨132.0m (+5.7%)‚Ç¨m 9 months 2022 9 months 2023 Change Change at constant structure and exchange rates ASSET MANAGEMENT 85.3 89.9 +5.4% +7.2% LENDING & LEASING 39.5 42.1 +6.5% +1.8% TOTAL LINEDATA 124.8 132.0 +5.7% +5.5%Neuilly-sur-Seine  19 October 2023 ‚Äì Linedata (Euronext Paris: LIN)  the global solutions and outsourcing services provider to the investment management and credit finance industries  generated revenue of ‚Ç¨132.0m over the first nine months of 2023  reflecting an increase of 5.7% compared with the same period of 2022. On a comparable basis  excluding the integration of Audaxys and at constant exchange rates  growth was 5.5%  driven mainly by the performance of North American markets.The recurring portion of revenue at end-September 2023 amounted to 77% of the total  i.e. ‚Ç¨101.7m  up ‚Ç¨2.9m compared with end-September 2022.Bookings were particularly strong in Q3 2023  at ‚Ç¨15.7m  versus ‚Ç¨9.0m for the same period last year and were driven by all business segments. Thus  bookings were up 19.4% to ‚Ç¨50.2m over the first nine months of the year.Performance by segment:ASSET MANAGEMENT (Q1: ‚Ç¨29.1m  +6.3%; Q2: ‚Ç¨30.5m  +3.9%; Q3: ‚Ç¨30.4m  +6.1%)Revenue generated in the Asset Management segment continued to grow in Q3 2023  with an increase of 6.1%. Over the first nine months of the year  growth reached 5.4% (+7.2% at constant structure and exchange rates). Commercial activity was robust with bookings of ‚Ç¨8.8m over the quarter. Since the start of the year  Asset Management bookings came to ‚Ç¨32.8m  up 25.9%.Revenue of the Software division came to ‚Ç¨65.4m over the first nine months of 2023 and was stable compared with the same period last year. The decline in the Fund Services business was offset by Front Office solutions  thanks notably to growth in AMP migration projects.Revenue of the Services division came to ‚Ç¨24.5m  showing strong growth of 23.6% since the beginning of the year  once again highlighting the group's sound positioning in co-sourcing  which perfectly meets the expectations of the investment management market.LENDING & LEASING (Q1: ‚Ç¨13.4m  +5.0%; Q2: ‚Ç¨14.5m  +7.8%; Q3: ‚Ç¨14.2m  +6.6%)Revenue at end-September 2023 for the Lending & Leasing segment was ‚Ç¨42.1m  up 6.5%. On a comparable basis  excluding the consolidation of Audaxys and at constant exchange rates  revenue was up 1.8%.During Q3 2023  the Lending & Leasing segment reported ‚Ç¨6.9m in new orders  bringing total bookings for this activity to ‚Ç¨17.4m  up 8.9% since the start of the year. These commercial results illustrate the success of the Linedata Ekip360 and Linedata Capitalstream solutions platforms.OutlookLinedata continues to pursue its goal of organic growth as well as improving operating margin during the second half of 2023.Next communication: Full-year 2023 revenue  6 February 2024  after trading.,neutral,0.02,0.97,0.01,positive,0.74,0.22,0.03,True,English,"['Linedata Services', 'Nine-month 2023 revenue', 'October', '11', '47', 'Linedata Capitalstream solutions platforms', 'credit finance industries', 'North American markets', 'Front Office solutions', 'AMP migration projects', 'outsourcing services provider', 'first nine months', 'Fund Services business', 'investment management market', 'constant exchange rates', 'Asset Management segment', 'Asset Management bookings', 'global solutions', 'Services division', 'constant structure', 'business segments', 'Euronext Paris', 'same period', 'comparable basis', 'recurring portion', 'Software division', 'sound positioning', 'new orders', 'commercial results', 'Linedata Ekip360', 'operating margin', 'second half', 'Next communication', 'TOTAL LINEDATA', 'Commercial activity', 'Leasing segment', 'strong growth', 'organic growth', 'total bookings', 'Nine-month 2023 revenue', 'Full-year 2023 revenue', '9 months', 'LENDING', 'Neuilly', 'Seine', 'increase', 'integration', 'Audaxys', 'performance', 'end-September', 'Q3', 'quarter', 'start', 'decline', 'beginning', 'group', 'expectations', 'consolidation', 'success', 'Outlook', 'goal', 'trading', '5.']",2023-10-19,2023-10-20,marketscreener.com
31603,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/CGG-4653/news/CGG-Opens-New-UK-HPC-Hub-Increasing-its-Global-Total-HPC-Capacity-to-500-Petaflops-45097747/,CGG Opens New UK HPC Hub  Increasing its Global Total HPC Capacity to 500 Petaflops,(marketscreener.com) Paris  France ‚Äì October 19  2023 CGG is pleased to announce the opening of its new UK HPC Hub in Southeast England. The initial capacity of the center is 100 petaflops  bringing the company‚Äôs global total to an industry-leading 500 petafl‚Ä¶,Paris  France ‚Äì October 19  2023CGG is pleased to announce the opening of its new UK HPC (High-Performance Computing) Hub in Southeast England. The initial capacity of the center is 100 petaflops  bringing the company‚Äôs global total to an industry-leading 500 petaflops.The UK HPC Hub leverages CGG‚Äôs decades of innovation in efficient  industrial HPC design and operations for the energy industry. The highly optimized environment features CGG‚Äôs proprietary immersion cooling infrastructure  which  together with the Hub‚Äôs use of 100% renewable energy  reflects the company‚Äôs commitment to sustainably meet the massive and rapidly increasing demands of high-end scientific and AI applications.CGG‚Äôs growing client base in a number of high-tech sectors will benefit from the Hub‚Äôs specialist computing capabilities through outcome-driven solutions. The additional capacity will also advance the ability to innovate and deploy the algorithm-intensive technology required for the clearest subsurface understanding and better decision-making.Agn√®s Boudot  EVP  HPC & Cloud Solutions  CGG  said: ‚ÄúCGG is a global leader in industrial and customized end-to-end HPC and AI services. Our innovative UK HPC Hub showcases this expertise and our drive to accelerate our Earth imaging workflows while expanding into other areas  such as generative AI and life sciences  where CGG offers outcome-focused  highly efficient  and scalable solutions in an industrial environment  from the infrastructure to the algorithm.‚ÄùAbout CGGCGG (www.cgg.com) is a global technology and HPC leader that provides data  products  services and solutions in Earth science  data science  sensing and monitoring. Our unique portfolio supports our clients in efficiently and responsibly solving complex digital  energy transition  natural resource  environmental  and infrastructure challenges for a more sustainable future. CGG employs around 3 400 people worldwide and is listed on the Euronext Paris SA (ISIN: 0013181864).ContactsGroup Communications & Investor RelationsChristophe BarniniTel: + 33 1 64 47 38 11E-Mail: christophe.barnini@cgg.comAttachment,neutral,0.05,0.95,0.01,positive,0.59,0.39,0.02,True,English,"['New UK HPC Hub', 'Global Total HPC Capacity', 'CGG', '500 Petaflops', 'new UK HPC (High-Performance Computing) Hub', 'The UK HPC Hub', 'innovative UK HPC Hub', 'complex digital, energy transition', 'proprietary immersion cooling infrastructure', 'efficient, industrial HPC design', 'specialist computing capabilities', 'growing client base', 'clearest subsurface understanding', 'Agn√®s Boudot', 'Contacts Group Communications', 'Earth imaging workflows', 'Euronext Paris SA', 'HPC leader', 'energy industry', '100% renewable energy', 'Earth science', 'infrastructure challenges', 'Southeast England', 'initial capacity', 'global total', 'increasing demands', 'high-end scientific', 'high-tech sectors', 'additional capacity', 'algorithm-intensive technology', 'global leader', 'other areas', 'life sciences', 'global technology', 'unique portfolio', 'natural resource', 'sustainable future', 'Investor Relations', 'industrial environment', 'outcome-driven solutions', 'Cloud Solutions', 'scalable solutions', 'AI applications', 'industry-leading 500 petaflops', 'data science', 'Christophe Barnini', 'AI services', '100 petaflops', 'France', 'October', 'CGG', 'opening', 'center', 'company', 'decades', 'innovation', 'operations', 'use', 'commitment', 'massive', 'rapidly', 'number', 'ability', 'decision-making', 'EVP', 'expertise', 'products', 'sensing', 'monitoring', 'clients', 'environmental', '3,400 people', 'Tel', 'Attachment']",2023-10-19,2023-10-20,marketscreener.com
31604,EuroNext,NewsApi.org,https://www.hospitalitynet.org/news/4118705.html,Accor and Adobe Sharing Insights Into Unlocking Opportunities Through Personalization at Scale,This conversation explores in more detail the insights from Accor‚Äôs ‚ÄòHospitality Ahead‚Äô Report published in March  exploring the ongoing changes impacting the hospitality industry at large  providing perspectives and examples to leverage these transformations‚Ä¶,This conversation explores in more detail the insights from Accor‚Äôs ‚ÄòHospitality Ahead‚Äô Report published in March  exploring the ongoing changes impacting the hospitality industry at large  providing perspectives and examples to leverage these transformations into opportunities.Discover the video‚ÄúUnlocking Opportunities Through Personalization At Scale‚ÄùSometimes technology and digital tools are put in opposition to hospitality and service. While there was an initial concern regarding digitally-driven services - such as AI or chatbots - replacing humans  it proved to be unfounded. We are  instead  witnessing a growing movement of brands exploring a variety of alternatives to deliver personalized services in a truly seamless manner: we balance our human touch with digital to ensure a consistent experience across all client touchpoints throughout their journey.At Accor  we made the decision to actually use technology and digital to enhance the experience and  in fact  to bring even more human touch  because it can ease operation and free up time for our team members to spend quality time with our guests. Alix Boulnois  Chief Digital Officer  AccorAt Adobe  we are proud to power the digitalization of our clients and help them become experience makers and benefit from what we call ‚Äòexperience-led growth ‚Äô which is the ability to merge content and data in a meaningful way so you can amplify the work you do through human and physical channels. Luc Dammann  President EMEA  AdobeDigital Today: Clients are Ready to Share Data if They Can Trust YouIn today‚Äôs marketplace  clients expect brands to deliver a highly personalized digital experience. It demonstrates that you value their business and will work hard to engage them both in ways they prefer as well as through opportunities they may have never expected. And the reward for these interactions will be ongoing loyalty. Yet in order for brands to be able to personalize a digital experience for guests  they need access to data  and this remains a point of contention regarding how much a client is willing to share. A recent study by Adobe shows nearly half of consumers (48%) place equal importance on digital and in-person experiences when it comes to earning their trust.Consumers are ready to share data  but they do expect in return they can trust you with the data. And when we look at studies  we see that 40% of consumers are putting trust as a number one criteria before engaging with a brand. Luc Dammann  President EMEA  AdobeReally knowing your guests  getting the right data to bring them the best experience is not easy. This is especially true when it comes to data because today clients don‚Äôt give data for no reason. It‚Äôs rather the opposite. So they need to see an interest in sharing this data. Alix Boulnois  Chief Digital Officer  AccorLeading The Future Of Personalization: Leveraging Data to Enrich Client RelationshipsToday  we have the ability to collect and amass enormous amounts of data on our guests and clients. Data is an integral component of a digital strategy and a driver of how to deliver content and value to our audience. How can we use data to build strength in our brands? How can data facilitate our connection with clients and enhance the client experience overall? There can be a point when the data collected is overwhelming  so how do we choose what to use and deliver a personalized experience for individual guests instead of overwhelming them with too much information just because we have it?Micro-personalization in both the digital and in-hotel experience ‚Äî really knowing your guests and getting the right data to really bring them the best experience and information at the right time is super important. At Accor  we‚Äôre using AI to generate more content  and content at scale  but we‚Äôre also using AI to be smarter about what we show to clients. Alix Boulnois  Chief Digital Officer  AccorBeing relevant is key. So is understanding that real-time is key as well. You need to be able to capture the moments in life to be relevant at each step of the customer journey. AI and generative AI open new frontiers in terms of creativity  productivity  and the ability to produce that and scale. Luc Dammann  President EMEA  AdobeDriving Change: How To Embark Everyone on the JourneyThe digital transformation many of us are already embracing - and which lies ahead - relies largely on a human component that needs to be taken into account in order to get everyone on board and embark on the journey.In any transformation there is indeed always a big human component and the transformation we are leading now is pushing us to work differently. How do we build teams that constantly embrace the change and actually see this change as a constant opportunity they proactively go after? We also need to ally people around the same goal wherever they sit in the organization. Alix Boulnois  Chief Digital Officer  AccorBrands who are seizing the opportunity to deploy omnichannel personalization at scale  in real time  while using and leveraging the power of AI in a responsible way  will have a massive win. Luc Dammann  President EMEA  AdobeTo find out more about our 'Hospitality Ahead' Report  please click here.About Accor  a world-leading hospitality groupAccor is a world leading hospitality group offering experiences across more than 110 countries in 5 500 properties  10 000 food & beverage venues  wellness facilities or flexible workspaces. The Group has one of the industry's most diverse hospitality ecosystems  encompassing more than 40 hotel brands from luxury to economy  as well as Lifestyle with Ennismore. Accor is committed to taking positive action in terms of business ethics & integrity  responsible tourism  sustainable development  community outreach  and diversity & inclusion. Founded in 1967  Accor SA is headquartered in France and publicly listed on the Euronext Paris Stock Exchange (ISIN code: FR0000120404) and on the OTC Market (Ticker: ACCYY) in the United States. For more information visit group.accor.com or follow us on Twitter  Facebook  LinkedIn  Instagram and TikTok.,neutral,0.17,0.82,0.01,mixed,0.48,0.24,0.28,True,English,"['Unlocking Opportunities', 'Accor', 'Adobe', 'Insights', 'Personalization', 'Scale', 'number one criteria', 'Chief Digital Officer', 'big human component', 'personalized digital experience', 'personalized services', 'integral component', 'personalized experience', 'digital tools', 'digital strategy', 'ongoing changes', 'initial concern', 'digitally-driven services', 'growing movement', 'seamless manner', 'human touch', 'consistent experience', 'team members', 'Alix Boulnois', 'experience makers', 'meaningful way', 'physical channels', 'Luc Dammann', 'President EMEA', 'ongoing loyalty', 'recent study', 'equal importance', 'person experiences', 'best experience', 'enormous amounts', 'hotel experience', 'new frontiers', 'same goal', 'client touchpoints', 'quality time', 'Client Relationships', 'client experience', 'right time', 'real time', 'digital transformation', 'constant opportunity', 'hospitality industry', 'Driving Change', 'omnichannel personalization', 'customer journey', 'individual guests', 'right data', 'today clients', 'conversation', 'detail', 'insights', 'Accor', 'March', 'perspectives', 'examples', 'transformations', 'opportunities', 'video', 'Scale', 'technology', 'opposition', 'chatbots', 'humans', 'brands', 'variety', 'alternatives', 'decision', 'fact', 'operation', 'Adobe', 'digitalization', 'ability', 'content', 'work', 'marketplace', 'business', 'ways', 'reward', 'interactions', 'order', 'access', 'half', 'consumers', 'trust', 'return', 'studies', 'reason', 'opposite', 'interest', 'The', 'Future', 'driver', 'value', 'audience', 'strength', 'connection', 'information', 'Micro-personalization', 'real-time', 'moments', 'life', 'step', 'terms', 'creativity', 'productivity', 'Everyone', 'account', 'board', 'teams', 'people', 'organization', 'power', 'respo']",2023-10-19,2023-10-20,hospitalitynet.org
31605,EuroNext,NewsApi.org,https://www.irishtimes.com/business/markets/2023/10/19/irish-stock-exchange-dividends-to-euronext-parent-near-65m-since-takeover/,Irish Stock Exchange dividends to Euronext parent near ‚Ç¨65m since takeover,Group has now taken close to 40% of purchase price out of Dublin exchange which saw new debt listings decline last year,The average daily value of trading in Irish equities on the Irish Stock Exchange rose marginally last year. Photograph: Dara Mac D√≥naillThe Irish Stock Exchange  which trades as Euronext Dublin  has paid almost ‚Ç¨65 million in dividends to its parent Euronext since its takeover in 2018.The sum equates to almost two-fifths of the ‚Ç¨167 million that Euronext paid five Irish finance houses ‚Äî Davy  Goodbody Stockbrokers  Cantor Fitzgerald  Investec and the now defunct Campbell O‚ÄôConnor ‚Äî to acquire the Irish exchange from them five years ago.The company behind the Irish bourse said in recently filed results for 2022 that it was proposing a ‚Ç¨19.2 million distribution to its parent  based on its financial performance for last year. A spokeswoman said that this has since been paid. Some ‚Ç¨20.6 million of dividends were paid up in each of the two previous years  the report said.Previous filings show that the Irish company paid ‚Ç¨4.39 million of dividends in 2020  the first distribution following the takeover.READ MOREThe exchange operator  which is known to make most of its money from international debt and fund listings rather than its cash equities business  saw its revenues dip 4.7 per cent to ‚Ç¨39.7 million last year as the rate of new debt listings declined amid a slump in bond sales globally as borrowing costs soared. Operating profit declined 8.2 per cent to ‚Ç¨22.5 million.Euronext Dublin is the world‚Äôs main market for bond listings  with a total of 3 000 issuers across 90 countries including sovereigns  corporates and financial institutions.The wider Euronext group saw its number of new bond listings fall last year by 42 per cent to 8 540. Euronext Dublin is the group‚Äôs main hub for debt listings  accounting for more than 80 per cent of the total  according to the report.Will co-hosting Euro 2028 be of any real benefit to Irish football? Listen | 48:25Some 100 new funds were listed in Euronext Dublin in 2022  down from 115 for the previous year ‚Äúreflecting the strong appetite for sustainable funds and exchange-traded funds (ETFs)‚Äù  it said. However  there were a number of investment fund delistings during the period as a result of heightened regulation and increased cost pressures on asset managers.The average daily value of trading in Irish equities on Euronext Dublin rose marginally last year to ‚Ç¨269 million from ‚Ç¨263 million in 2021. However  there were no initial public offerings on the market last year.That has continued to be the case in 2023. In addition  CRH  previously the largest company on the Iseq  delisted from Euronext Dublin last month as it moved its primary stock market quotation from London to New York.Smurfit Kappa  another market heavyweight that is looking to merge with a US rival  signalled recently that it also plans to quit the Irish exchange for New York.Flutter Entertainment  owner of Paddy Power  is also expected to depart the Irish market in the near future  having decided earlier this year to take out a listing in the US.,neutral,0.05,0.95,0.01,negative,0.02,0.28,0.7,True,English,"['Irish Stock Exchange dividends', 'Euronext parent', 'takeover', 'Dara Mac D√≥naill', 'defunct Campbell O‚ÄôConnor', 'five Irish finance houses', 'primary stock market quotation', 'The Irish Stock Exchange', 'average daily value', 'initial public offerings', 'investment fund delistings', 'two previous years', 'cash equities business', 'new debt listings', 'new bond listings', 'wider Euronext group', 'Irish exchange', 'fund listings', 'Irish equities', 'exchange operator', 'Irish bourse', 'Irish football', 'Irish market', '100 new funds', 'New York', 'Previous filings', 'international debt', 'bond sales', 'Irish company', 'Goodbody Stockbrokers', 'Cantor Fitzgerald', 'financial performance', 'last year', 'borrowing costs', 'Operating profit', 'main market', 'financial institutions', '42 per cent', 'main hub', '80 per cent', 'real benefit', 'strong appetite', 'sustainable funds', 'exchange-traded funds', 'cost pressures', 'asset managers', 'Smurfit Kappa', 'Flutter Entertainment', 'Paddy Power', 'near future', 'Euronext Dublin', 'largest company', 'first distribution', 'US rival', 'trading', 'Photograph', 'dividends', 'parent', 'takeover', 'sum', 'two-fifths', 'Davy', 'Investec', 'results', 'spokeswoman', 'report', 'READ', 'money', 'revenues', 'rate', 'slump', 'world', 'total', '3,000 issuers', '90 countries', 'sovereigns', 'number', 'Listen', 'ETFs', 'period', 'regulation', 'case', 'addition', 'CRH', 'Iseq', 'London', 'heavyweight', 'owner']",2023-10-19,2023-10-20,irishtimes.com
31606,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GLOBAL-BIOENERGIES-8071529/news/Global-Bioenergies-announces-the-appointment-of-Martin-Stephan-as-Chief-Business-Officer-45097840/,Global Bioenergies announces the appointment of Martin Stephan as Chief Business Officer,(marketscreener.com) PRESS RELEASE Global Bioenergies announces the appointment of Martin Stephan as Chief Business Officer Evry  19 October 2023 ‚Äì 7:45 a.m. : Martin Stephan joins Global Bioenergies as Chief Business Officer. Martin Stephan has spent his ent‚Ä¶,PRESS RELEASEGlobal Bioenergies announces the appointment ofMartin Stephan as Chief Business OfficerEvry  19 October 2023 ‚Äì 7:45 a.m. : Martin Stephan joins Global Bioenergies as Chief Business Officer.Martin Stephan has spent his entire career in the chemical industry  in France  Germany  Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022  he notably contributed to the strong growth of this major listed player in the green chemistry market.He previously held strategic positions as Head of International Sales in global groups  particularly in The Chemours Company and Du Pont de Nemours  the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.Martin Stephan comments: ‚Äú I am delighted to be joining the Global Bioenergies teams  whose technology is extremely well positioned to meet the challenge of energy and environmental transition. ‚ÄùThis appointment is intended to support the Company's scale-up  which includes the commissioning of a new plant with a capacity of 10 000 tonnes per year of isobutene and derivatives in 2027  to serve the cosmetics and sustainable aviation fuel markets.Marc Delcourt  co-founder and CEO of Global Bioenergies  adds: ‚ÄúMartin Stephan‚Äôs experience in promoting innovation will enable us to establish and strengthen strong commercial partnerships in our various markets.‚ÄùAbout GLOBAL BIOENERGIESGlobal Bioenergies substitutes products of fossil origin with products of natural origin. In their quest for naturalness without compromising on performance  the cosmetics players are the Company's first customers. By 2027  the Company will be operating its innovative process in a large-scale plant. By 2030  the Company plans to become a leader in the huge emerging market for sustainable aviation fuels  in order to fight against global warming. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 - ALGBE). L'Or√©al is its largest shareholder  with a 13.5% stake.ContactsGLOBAL BIOENERGIES+33 (0)1 64 98 20 50invest@global-bioenergies.comFollow our newsReceive information about Global Bioenergies directly by subscribing to our news feed on https://www.global-bioenergies.com/inscription-newsletter/Follow us on LinkedIn:Global BioenergiesNewCap ‚Äì Investor relationsLouis-Victor DelouvrierQuentin Mass√©globalbioenergies@newcap.eu+33 (0)1 44 71 94 94NewCap ‚Äì Media relationsNicolas Merigeauglobalbioenergies@newcap.eu+33 (0)1 44 71 94 98Attachment,neutral,0.06,0.94,0.01,positive,0.89,0.1,0.01,True,English,"['Chief Business Officer', 'Global Bioenergies', 'Martin Stephan', 'appointment', 'Du Pont de Nemours', 'Deputy Chief Executive Officer', 'sustainable aviation fuel markets', 'sustainable aviation fuels', 'Chief Business Officer', 'green chemistry market', 'huge emerging market', ""L'Or√©al"", 'strong commercial partnerships', 'The Chemours Company', 'Global Bioenergies teams', 'innovative specialty products', 'various markets', 'strong growth', 'innovative process', 'global groups', 'global warming', 'PRESS RELEASE', 'Martin Stephan', 'entire career', 'strategic positions', 'International Sales', 'environmental transition', 'new plant', 'Marc Delcourt', 'fossil origin', 'natural origin', 'first customers', 'large-scale plant', 'Euronext Growth', 'largest shareholder', 'Investor relations', 'Louis-Victor Delouvrier', 'Quentin Mass√©', 'Media relations', 'Nicolas Merigeau', 'chemical industry', 'world leader', 'cosmetics players', 'news feed', 'appointment', 'Evry', '19 October', '7:45 a', 'France', 'Germany', 'Italy', 'Switzerland', 'CARBIOS', 'major', 'Head', 'graduate', 'HEC.', 'technology', 'challenge', 'energy', 'scale-up', 'commissioning', 'capacity', '10,000 tonnes', 'year', 'isobutene', 'derivatives', 'founder', 'CEO', 'experience', 'innovation', 'quest', 'naturalness', 'performance', 'order', 'Paris', 'ALGBE', '13.5% stake', 'Contacts', 'information', 'global-bioenergies', 'newsletter', 'LinkedIn', 'NewCap', 'Attachment']",2023-10-19,2023-10-20,marketscreener.com
31607,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/EDP-RENOV-VEIS-S-A-3073163/news/EDP-Renov-veis-S-A-Renewables-surpasses-the-1-GWp-installed-capacity-milestone-in-Asia-Pacific-45101528/,EDP Renov√°veis S A : Renewables surpasses the 1 GWp installed capacity milestone in Asia Pacific -October 19  2023 at 06:33 am EDT,(marketscreener.com)  EDP Renewables has more than doubled its installed solar capacity in the Asia Pacific region  from approximately 480 MWp in February 2022 to more than 1 GWp. This is an important milestone for the company as it showcases its steadfast c‚Ä¶,"EDP Renewables (EDPR) has more than doubled its installed solar capacity in the Asia Pacific region  from approximately 480 MWp in February 2022 to more than 1 GWp. This is an important milestone for the company as it showcases its steadfast commitment to driving the energy transition across the Asia Pacific region.EDPR has a pan-regional presence across nine markets in Asia Pacific with a focused installed capacity  namely 510 MWp (50%) in Vietnam  335 MWp (33%) in Singapore  100 MWp (10%) in China  and 75 MWp (7%) in the rest of APAC markets  including Japan  Taiwan  and Malaysia.This 1 GWp installed capacity portfolio comprises 53% distributed solar generation (DG) and 47% utility-scale solar projects. Notably  DG solar has emerged as one of the company's fastest-growing segments  and installed capacity is expected to expand threefold in the Asia-Pacific region by 2026. Escalating decarbonization targets in the region underpin this growth.""This significant milestone of achieving 1 GW underscores our commitment to accelerate the energy transition in the Asia Pacific region. We continue to see attractive investment opportunities in APAC and have a target of 2.4 GW of renewable installed capacity in this region by 2026""  says Miguel Stilwell d'Andrade  EDP's CEO.Earlier this year  EDPR updated the market with its strategic plan  reinforcing its commitment to lead the energy transition through accelerated and sustainable growth while creating superior value for our shareholders and worldwide targets of ‚Ç¨20 billion investment  17GW total additions  and ramp-up yearly additions to 4GW for the 2023-26 period. 7% of this investment will be in Asia Pacific  where the company intends to surpass 2GW installed capacity by 2026  stepping up average yearly additions to 0.3GW. The expansion strategy encompasses behind-the-meter DG projects  serving businesses and governments  and in-front-of-the-meter projects contributing to grid sustainability.Since its establishment in the APAC platform  EDPR already doubled its installed capacity and has the ambition to  throughout this critical decade  become a leader in the region.About EDP Renewables APACEDP Renewables APAC is headquartered in Singapore and present across 9 markets currently with approximately 1.2 GWp of installed and under construction solar capacity. It is part of EDP Renewables (Euronext: EDPR)  a global leader in the renewable energy sector with 15.2 GW installed and present in 28 markets across Europe  North America  South America  and Asia Pacific.EDP is EDPR's main shareholder  operating across energy generation  networks  and supply  including a total installed capacity of 28.5 GW  networks of 376 thousand km and over 9 million clients.",neutral,0.03,0.96,0.01,neutral,0.05,0.94,0.01,True,English,"['EDP Renov√°veis S A', 'capacity milestone', 'Asia Pacific', 'Renewables', '1 GWp', 'October', '06', ""Miguel Stilwell d'Andrade"", '1 GWp installed capacity portfolio', '17GW total additions', 'up yearly additions', 'average yearly additions', 'Escalating decarbonization targets', '47% utility-scale solar projects', 'attractive investment opportunities', '53% distributed solar generation', 'total installed capacity', 'renewable energy sector', 'meter DG projects', 'Asia Pacific region', 'EDP Renewables APAC', 'meter projects', 'energy generation', 'worldwide targets', 'DG solar', 'solar capacity', 'energy transition', 'APAC platform', 'important milestone', 'pan-regional presence', 'growing segments', 'Asia-Pacific region', 'significant milestone', 'strategic plan', 'superior value', '‚Ç¨20 billion investment', '2023-26 period', 'expansion strategy', 'grid sustainability', 'critical decade', 'North America', 'South America', 'main shareholder', '376 thousand km', '9 million clients', 'APAC markets', 'nine markets', 'sustainable growth', 'global leader', '1.2 GWp', '9 markets', '28 markets', 'EDPR', '480 MWp', 'February', 'company', 'commitment', 'focused', '510 MWp', 'Vietnam', '335 MWp', 'Singapore', '100 MWp', 'China', '75 MWp', 'rest', 'Japan', 'Taiwan', 'Malaysia', '2.4 GW', 'CEO', 'accelerated', 'shareholders', '4GW', '2GW', '0.3GW', 'businesses', 'governments', 'establishment', 'ambition', 'construction', 'part', 'Euronext', '15.2 GW', 'Europe', 'networks', 'supply', '28.5 GW']",2023-10-19,2023-10-20,marketscreener.com
31608,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2763476/0/en/VEOS-FDA-510-k-clearance.html,VEOS FDA 510(k) clearance,Press release¬†¬†¬†¬†¬†¬†¬†¬†Ecully  October 19  2023 ‚Äì 6 p.m.    Spineway obtains 510(k) clearance from the FDAfor its VEOS spinal fixation system  Spineway......,"Press release Ecully  October 19  2023 ‚Äì 6 p.m.Spineway obtains 510(k) clearance from the FDAfor its VEOS spinal fixation systemSpineway Group  a specialist in innovative implants for the treatment of severe spinal conditions  is pleased to announce the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System.This clearance  which allows Spineway Group to market its VEOS system in the US  represents a significant achievement for the Group and reinforces its strategic approach to develop its business in the US market. This recognition also demonstrates the Group's commitment to provide innovative solutions to surgeons and to put the well-being of patients first.Presentation at the NASS Congress in Los AngelesThis innovative medical device is presented at the North American Spine Society (NASS) Congress in Los Angeles until 21 October 2023.The VEOS Spinal Fixation System is a complete platform that offers an innovative and versatile solution tailored to surgeons' needs. The VEOS platform is easy to use  fully modular and optimizes operational excellence in operating room.This new offering enables surgeons to perform open  minimally invasive and percutaneous surgery (MIS) for the treatment of a wide range of spinal pathologies  from degenerative spine to complex surgery and deformities.""We are very proud of this FDA clearance  which enables Spineway Group to take the first step in rolling out its new portfolio in the USA. This approval demonstrates our ability to develop innovative solutions for the treatment of spinal pathologies that perfectly meet the needs of surgeons and patients. ¬ª says St√©phane Le Roux  CEO of Spineway.Next events :18 to 20 October 2023: Participation in the NASS Congress - Los Angeles (USA)10 November 2023: Extraordinary General MeetingSPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)Find out all about Spineway at www.spineway.comThis press release has been prepared in both English and French. In case of discrepancies  the French version shall prevail.Spineway designs  manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.Spineway  which is eligible for investment through FCPIs (French unit trusts specializing in innovation)  has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rh√¥ne Alpes INPI Patent Innovation award (2013) ‚Äì INPI Talent award (2015).ISIN: FR001400BVK2 - ALSPWContacts:SPINEWAYShareholder-services lineAvailable Tuesday through Thursday+33 (0)806 706 060EligiblePEA / PMEALSPWEuronext GrowthAELIUMFinance & CommunicationInvestor relationsSol√®ne Kennisspineway@aelium.frAttachment",neutral,0.0,0.99,0.0,positive,0.79,0.2,0.01,True,English,"['VEOS FDA 510(k) clearance', 'The VEOS Spinal Fixation System', 'St√©phane Le Roux', 'North American Spine Society', 'INPI Patent Innovation award', 'The VEOS platform', 'INPI Talent award', 'Deloitte Fast 50 award', 'open, minimally invasive', 'Extraordinary General Meeting', 'EQUITY SAVINGS PLANS', 'Rh√¥ne Alpes', 'Sol√®ne Kennis', 'OSEO Excellence award', 'severe spinal conditions', 'innovative medical device', 'French unit trusts', 'recent 510(k) clearance', 'VEOS system', 'spinal pathologies', 'spinal column', 'degenerative spine', 'complete platform', 'operational excellence', 'severe disorders', 'Press release', 'innovative implants', 'Drug Administration', 'significant achievement', 'strategic approach', 'innovative solutions', 'NASS Congress', 'Los Angeles', 'NASS) Congress', 'versatile solution', 'operating room', 'new offering', 'percutaneous surgery', 'wide range', 'complex surgery', 'first step', 'new portfolio', 'Next events', 'French version', 'surgical instruments', 'international network', '50 independent distributors', 'Shareholder-services line', 'Euronext Growth', 'Investor relations', 'US Food', 'US market', 'ALSPW Contacts', 'FDA clearance', 'Spineway designs', 'Spineway Group', ""surgeons' needs"", 'Ecully', 'specialist', 'treatment', 'business', 'recognition', 'commitment', 'well-being', 'patients', 'Presentation', '21 October', 'MIS', 'deformities', 'USA', 'approval', 'ability', 'CEO', '20 October', 'Participation', '10 November', 'PEA-SME', 'SMES', 'English', 'case', 'discrepancies', 'revenue', 'exports', 'investment', 'FCPIs', 'ISIN', 'Tuesday', 'Thursday', 'PME', 'AELIUM', 'Finance', 'Communication', 'Attachment', '6']",2023-10-19,2023-10-20,globenewswire.com
31609,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/NETGEM-4779/news/Netgem-Trading-Update-Confirmation-of-the-ARR-growth-objective-of-30-in-2023-45098101/,Netgem : Trading Update - Confirmation of the ARR growth objective of 30% in 2023 -October 19  2023 at 02:15 am EDT,(marketscreener.com)  Strong commercial activity for Netgem's ‚ÄúImmersive TV‚Äù offer integrating Content and Cloud Gaming for operatorsContinuing integration of the acquired Eclair subsidiaries to provide new offers from 2024  and an axis of profitability a‚Ä¶,"Strong commercial activity for Netgem's ‚ÄúImmersive TV‚Äù offer integrating Content and Cloud Gaming for operatorsContinuing integration of the acquired Eclair subsidiaries to provide new offers from 2024  and an axis of profitability and complementary growthESG Gold mark (score 73/100) attributed by Ethifinance for year 2022.Paris  19 October 2023 Netgem confirms its objective of 30% growth of its subscriber base and its ARR[1] over the year 2023.During the IBC trade show  many telecom operators showed their interest in the group's new ‚ÄúImmersive TV‚Äù solution  integrating ‚ÄúContent-as-a-service‚Äù  ‚ÄúCloud Gaming‚Äù and‚ÄúFast Channel‚Äù.The group is also continuing to grow its subscriber base in its different geographic markets  in particular with its customers Zeop in France  Elisa in Finland and Talk Talk in the United Kingdom. British telecom operator brsk also launched its new television service""Better.TV"" with the Netgem TV platform. France Channel launched its service on Amazon Channel.The integration of the recently acquired companies Eclair Digital Services (EDS) and Eclair Pr√©servation (EP) is being implemented as planned in order to constitute a division Eclair Media Services by Netgem targeting publishers. This implementation must make possible the generation of commercial and cost structure synergies  through a renewed product policy and cross-functional teams.The group is continuing its sustainable development policy  which has enabled it to earn the Ethifinance ESG Gold mark for the first time (score 73/100) for the year 2022.For Mathias Hautefort  Managing Director of Netgem ‚ÄúOur strategy continues to bear fruit  with the group expected to improve over the year in both recurring revenue and profitability. The arrival of new services  with Cloud Gaming and the integration of EDS and EP  should result in a renewed commercial momentum in 2024. This strategy is carried out in accordance with the responsible growth objectives we have set for the Group. ‚ÄùFinancial communication calendarRevenue and gross profit 2023 Thursday 31 January 2024  before marketContactsInvestor and Analyst RelationsBertrand Soleilbertrand.soleil@double-digit.com+33 (0)6.23.31.06.53 Relations PressePatricia Ouakipatricia.ouaki@forcemedia.fr+33 (0)1.44.40.24.01About NetgemNetgem operates the netgem.tv platform of digital video entertainment services  integrating all live  on-demand and subscription content available on the market  and accessible by all family members on mobile  PC or TV screens.The netgem.tv product is distributed through a network of fixed telecom operators in Europe  under the operator's brand (B2B2C model) to over 600 000 subscriber households.Netgem is listed on Euronext Growth.(ISIN : FR0004154060  Reuters : ETGM.PA  Bloomberg: ALNTG FP)[1] Annual Recurring Revenue.This publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: nJlyZ5lnYWnImXFyl5ZqbZJqb5xjm2TIa2qeyJdvapjJaW+TxWhja5XIZnFjmWdp- Check this key: https://www.security-master-key.com .Regulated information:Inside Information:- other releases Full and original press release in PDF: https://www.actusnews.com/news/82423-2023-10-19-cp-pr-point-d_activite-oct-2023-netgem-eng-def.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2023 ActusNews",neutral,0.03,0.96,0.01,positive,0.63,0.35,0.02,True,English,"['ARR growth objective', 'Trading Update', 'Netgem', 'Confirmation', 'October', '02:15', 'digital video entertainment services', 'new ‚ÄúImmersive TV‚Äù solution', 'Ethifinance ESG Gold mark', 'Eclair Digital Services', 'IBC trade show', 'different geographic markets', 'cost structure synergies', 'Financial communication calendar', 'original press release', 'Eclair Pr√©servation', 'Eclair Media Services', 'sustainable development policy', 'next press releases', 'many telecom operators', 'fixed telecom operators', 'Strong commercial activity', 'British telecom operator', 'responsible growth objectives', 'Netgem TV platform', 'netgem.tv platform', 'new television service', 'SECURITY MASTER Key', 'netgem.tv product', 'Actusnews SECURITY MASTER', 'new services', 'product policy', 'Better.TV', 'TV screens', 'Eclair subsidiaries', 'new offers', 'other releases', 'Cloud Gaming', 'complementary growth', 'subscriber base', 'Fast Channel', 'Talk Talk', 'United Kingdom', 'Amazon Channel', 'cross-functional teams', 'first time', 'Mathias Hautefort', 'Managing Director', 'commercial momentum', 'gross profit', 'Analyst Relations', 'Bertrand Soleil', 'Relations Presse', 'family members', 'B2B2C model', '600,000 subscriber households', 'Euronext Growth', 'ALNTG FP', 'France Channel', 'recurring revenue', 'Patricia Ouaki', 'Regulated information', 'Continuing integration', 'subscription content', '30% growth', 'axis', 'profitability', 'year', 'Paris', '19 October', 'ARR', 'interest', 'group', 'customers', 'Zeop', 'Elisa', 'Finland', 'brsk', 'companies', 'EDS', 'EP', 'order', 'division', 'publishers', 'implementation', 'generation', 'strategy', 'fruit', 'accordance', 'Contacts', 'Investor', 'forcemedia', 'demand', 'mobile', 'PC', 'network', 'Europe', 'brand', 'ISIN', 'Reuters', 'ETGM', 'Bloomberg', 'publication', 'Full', 'PDF', 'point', 'activite', 'email', 'company']",2023-10-19,2023-10-20,marketscreener.com
31610,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/WOLTERS-KLUWER-6291/news/Wolters-Kluwer-s-Emmi-awarded-highest-client-satisfaction-award-from-Black-Book-Research-45104239/,Wolters Kluwer's Emmi awarded highest client satisfaction award from Black Book Research,(marketscreener.com) Recognized as top-performing member engagement and education solution by managed healthcare providershttps://www.marketscreener.com/quote/stock/WOLTERS-KLUWER-6291/news/Wolters-Kluwer-s-Emmi-awarded-highest-client-satisfaction-award-fr‚Ä¶,"Recognized as top-performing member engagement and education solution by managed healthcare providersWolters Kluwer Health today announced that the Emmi¬Æ patient engagement and education solution received a 2023 Black Book award for highest client/user satisfaction from managed care providers. The Wolters Kluwer solution received the highest satisfaction score in the Black Book client experience polls out of 15 scored vendors/products.‚ÄúThe Black Book award is a valuable recognition for the hard work by our customer success and support teams to managed care providers and payers ‚Äù said Chris Sullivan  Vice President  Commercial Segment for Clinical Effectiveness at Wolters Kluwer Health. ‚ÄúEmmi offers a full suite to help them educate  engage and outreach to members to drive better outcomes.‚ÄùThe client survey of managed care providers was conducted by Black Book Research. Solutions are measured over 18 performance areas of operational excellence.‚ÄúBlack Book is committed to recognizing top performers like Wolters Kluwer Health. The Emmi member engagement and education solutions stands out among others in the healthcare technology industry's most robust client satisfaction database "" said Doug Brown  President of Black Book Research.Top honors for Member Engagement and EducationEmmi is a part of the Wolters Kluwer Health award-winning suite of clinical effectiveness products which offers vetted content from medical experts that helps improve care and provides medical education content for clinicians  pharmacists  health systems  payers  patients  and members.Emmi is powered by evidence-based content developed by experts at UpToDate¬Æ  the Wolters Kluwer Health clinical decision support tool that is used by more than two million clinicians in more than 190 countries. Leveraging UpToDate content  Emmi provides empowering patient engagement content and personalized communications using resources like interactive videos. Emmi helps both providers and payers partner with patients/members to go beyond the point of care. The solution helps optimize care across the continuum to achieve better clinical  financial  and quality outcomes.Wolters Kluwer Health provides trusted clinical technology and evidence-based solutions that help engage clinicians  patients  researchers and students in effective decision-making and outcomes across healthcare. The division of Wolters Kluwer supports clinical effectiveness  learning and research  clinical surveillance and compliance  as well as data solutions.About Wolters KluwerWolters Kluwer (EURONEXT: WKL) is a global leader in information  software  and services for professionals in Health  Tax and Accounting  Financial Corporate Compliance  Legal & Regulatory  and Corporate Performance & ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.Wolters Kluwer reported 2022 annual revenues of ‚Ç¨5.5 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 20 900 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.For more information  visit www.wolterskluwer.com  follow us on LinkedIn  Twitter  Facebook  and YouTube.View source version on businesswire.com: https://www.businesswire.com/news/home/20231019181721/en/",neutral,0.3,0.69,0.01,positive,0.63,0.36,0.01,True,English,"['highest client satisfaction award', 'Black Book Research', 'Wolters Kluwer', 'Emmi', 'Wolters Kluwer Health clinical decision support tool', 'Black Book client experience polls', 'Wolters Kluwer Health award-winning suite', 'Alphen aan den Rijn', 'robust client satisfaction database', 'The Black Book award', 'The Wolters Kluwer solution', 'The Emmi member engagement', '2023 Black Book award', 'highest client/user satisfaction', 'highest satisfaction score', 'performing member engagement', 'Black Book Research', 'deep domain knowledge', 'trusted clinical technology', 'clinical effectiveness products', 'patient engagement content', 'Emmi¬Æ patient engagement', 'two million clinicians', 'healthcare technology industry', 'Financial Corporate Compliance', 'medical education content', 'support teams', 'client survey', 'full suite', 'health systems', 'clinical surveillance', 'specialized technology', 'Corporate Performance', 'education solution', 'evidence-based content', 'valuable recognition', 'hard work', 'customer success', 'Chris Sullivan', 'Commercial Segment', '18 performance areas', 'operational excellence', 'Doug Brown', 'medical experts', 'personalized communications', 'interactive videos', 'effective decision-making', 'global leader', 'critical decisions', '2022 annual revenues', 'source version', 'healthcare providers', 'evidence-based solutions', 'data solutions', 'expert solutions', 'UpToDate content', 'top performers', 'Top honors', 'Vice President', 'quality outcomes', 'UpToDate¬Æ', '15 scored', 'vendors/products', 'payers', 'members', 'others', 'part', 'patients', '190 countries', 'resources', 'point', 'continuum', 'researchers', 'students', 'division', 'learning', 'EURONEXT', 'WKL', 'information', 'software', 'services', 'professionals', 'Tax', 'Accounting', 'Legal', 'Regulatory', 'ESG', 'customers', 'group', '180 countries', 'operations', '40 countries', '20,900 people', 'company', 'Netherlands', 'LinkedIn', 'Twitter', 'Facebook', 'YouTube', 'businesswire']",2023-10-19,2023-10-20,marketscreener.com
31611,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/CTT-CORREIOS-DE-PORTUGAL--15132607/news/CTT-Correios-de-Portugal-S-A-Interim-report-on-the-transactions-carried-out-in-the-context-of-the-45106649/,CTT Correios de Portugal S A : Interim report on the transactions carried out in the context of the share buy-back program -October 19  2023 at 01:29 pm EDT,(marketscreener.com)    CTT - Correios de Portugal  S.A.   Av. dos Combatentes  43 - 14th Floor 1643-001LISBOA   Lisbon commercial registry and fiscal no. 500 077 568   Share Capital EUR 71 957 500.00   Announcement - Lisbon  19 October 2023..‚Ä¶,"CTT - Correios de Portugal  S.A.Av. dos Combatentes  43 - 14th Floor 1643-001LISBOALisbon commercial registry and fiscal no. 500 077 568Share Capital EUR 71 957 500.00Announcement - Lisbon  19 October 2023Interim report on the transactions carried out in the context of the share buy-back programCTT - Correios de Portugal  S.A. (""CTT"" or ""Company"") hereby informs that in the period from 13 to 19 October 2023 (inclusive) Banco BPI  S.A. has acquired 110 653 shares representing CTT's share capital  under the share buy-back program (""Buy-back Program"") and as the financial intermediary in charge of the execution of said program  in Euronext Lisbon regulated market  as detailed in the table below (aggregated information):ISIN Code: PTCTT0AM0001Date of the Aggregated Weighted % Session's Total % Share transaction Volume (shares) Average Price (‚Ç¨) Volume Capital 13-10-2023 21 800 3.3913 9.86% 0.02% 16-10-2023 12 602 3.4576 2.98% 0.01% 17-10-2023 36 150 3.5030 10.34% 0.03% 18-10-2023 17 500 3.4932 12.08% 0.01% 19-10-2023 22 601 3.4530 10.00% 0.02%As at 19 October 2023  the Company had already acquired 1 720 542 shares under the scope of the Buy-back Program announced to the market on 21 June 2023. The price paid for these acquisitions amounted to a total of ‚Ç¨5 913 047.As a consequence  on this date  the Company holds an aggregated total of 3 098 674 own shares  representing 2.15% of its share capital. Further detailed information on all transactions carried out under the Buy-back Program  in the period from 13 to 19 October 2023 (inclusive)  may be found in the tables attached hereto as Annexes 1 to 5.As disclosed to the market in due time  on 26 June 2023  CTT started trading in the context of the Buy-back Program  pursuant to the terms and limitations set forth in (i) the resolution adopted under item 9 of the Agenda of the 2023 General Shareholders' Meeting of CTT granting authorization for the acquisition and transfer of own shares by the Company and its subsidiaries  as set forth in such shareholders' resolution and subject to a decision of the Company's Board of Directors  and (ii) the resolution of the Board of Directors of CTT  of 21 June 2023  under which a share buy-back program",neutral,0.01,0.98,0.01,neutral,0.02,0.97,0.01,True,English,"['share buy-back program', 'CTT Correios', 'Interim report', 'Portugal', 'transactions', 'context', 'October', '01:29', 'Euronext Lisbon regulated market', 'Total % Share transaction Volume', 'Av. dos Combatentes', 'Lisbon commercial registry', ""2023 General Shareholders' Meeting"", 'share buy-back program', 'Volume Capital', 'Share Capital', 'aggregated total', '14th Floor', 'Interim report', 'S.A.', 'Banco BPI', 'financial intermediary', 'ISIN Code', 'Weighted % Session', 'due time', ""shareholders' resolution"", 'Correios de', 'Average Price', 'detailed information', 'CTT', 'Portugal', 'fiscal', 'Announcement', 'transactions', 'context', 'Company', 'period', '19 October', '110,653 shares', 'charge', 'execution', 'table', 'Date', '1,720,542 shares', 'scope', '21 June', 'acquisitions', 'consequence', 'Further', 'Annexes', '26 June', 'terms', 'limitations', 'item', 'Agenda', 'authorization', 'transfer', 'subsidiaries', 'decision', 'Board', 'Directors', '13', '3,098,674']",2023-10-19,2023-10-20,marketscreener.com
31612,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/TARKETT-14899990/news/Tarkett-2023-Q3-ResultsNew-window-45106248/,Tarkett : 2023 Q3 ResultsNew window -October 19  2023 at 12:31 pm EDT,(marketscreener.com)   Press release   ____________   Tarkett Group   Q3 2023 Revenue:   Organic sales growth of +6.0% Record revenue in Sports   Good levels of activity in CIS countries and resilience in the Commercial segments in North Amer‚Ä¶,"Press release ____________ Tarkett Group Q3 2023 Revenue: Organic sales growth of +6.0% Record revenue in Sports Good levels of activity in CIS countries and resilience in the Commercial segments in North America Third quarter 2023 results Revenue down -2.1% compared to Q3 2022 given the unfavourable exchange effects (-8.1%) due to the devaluation of the dollar and the rouble Organic growth of +6.0% driven by strong activity in Sports and volumes up in CIS In EMEA  volumes are down slightly compared to last year  affected by sluggish demand In North America  the slowdown in the Residential and Hospitality segments is partially offset by the good performance in the Commercial segments Good level of activity in CIS with volumes greater than those in Q3 2022  which nevertheless remain lower than those in 2021 over the same period In a dynamic market  Sports continues to grow at a sustained pace (+15.8% organic) despite a high basis for comparison in Q3 2022 Selling prices are generally stable compared to Q2 2023 Paris  19 October 2023: The Supervisory Board of Tarkett (Euronext Paris: FR0004188670 TKTT)  which met today  reviewed the Group's consolidated revenue for the third quarter of 2023. The Group uses alternative performance indicators (not defined under IFRS)  described in detail in the Appendix of this document: Revenue in millions of Q3 2023 Q3 2022 Change Of which euros organic growth EMEA 209.4 220.4 -5.0% -3.8% North America 228.4 251.4 -9.2% -2.6% CIS  APAC & Latin America 165.6 191.1 -13.3% +10.8% Sports 380.8 342.5 +11.2% +15.8% Group Total 984.3 1 005.4 -2.1% +6.0% 11. Revenue for the third quarter of 2023 Net revenue of the Group amounted to 984 million euros  down -2.1% compared to the third quarter of 2022. Organic growth was +6.0% (or +5.7% including sales price variations in the CIS region(1) ). The total effect of the selling price increases implemented across all segments is +3.1% on average compared to the third quarter of 2022. Sales prices were generally stable compared to Q2 2023. The EMEA segment achieved a net revenue of 209 million euros  down -5.0% compared to the third quarter of 2022  including an unfavourable currency effect of -1.2% and negative organic growth of -3.8%. The economic context of high inflation and interest rates is penalising renovation and new construction projects throughout the area. Activity in the Residential segment was significantly lower than in 2022 due to an unfavourable product mix  with vinyl rolls performing better than more expensive categories such as parquet. Activity in the Commercial segments fell only slightly compared to 2022 thanks to the good performance of volumes in the two main categories  vinyl products for the health and education sector and carpets for offices. The North American segment generated net revenue of 228 million euros  down -9.2% compared to the third quarter of 2022  with a negative currency effect linked to the depreciation of the dollar against the euro (-6.6%) and negative organic growth of -2.6%. Commercial segment volumes (offices  healthcare  education) are up slightly compared to 2022 in a market that is currently better positioned than in Europe. On the other hand  business volumes in the Residential and Hospitality segments are down in a market where demand is still suffering from inflation and the level of interest rates. Net revenue in the CIS  APAC and Latin America segment amounted to 166 million euros  down -13.3% compared to the third quarter of 2022  with a very unfavourable currency effect mainly resulting from the depreciation of the rouble (-31% compared to Q3 2022). Activity is well positioned with organic growth of +10.8% (excluding sales price effects in CIS countries). It benefited from the improvement in volumes in Russia and Ukraine compared to Q3 2022  which was marked by a significant decline compared with 2021. These countries respectively represent 8% and 0.8% of the Group's net sales over the quarter. In a complex market  selective price reduction contributed to the good performance of vinyl roll and LVT sales for the residential market. In Asia  activity was down  mainly due to a marked drop in sales in China. To optimise its cost base  the Group closed the commercial carpet production site located in Suzhou (China). Latin America remains slightly down compared to 2022 but volumes improved over the quarter in a more favourable economic environment. Sports net revenue continued to grow at a sustained pace  amounting to 381 million euros  up +11.2%  of which +15.8% organic growth compared to the third quarter of 2022. The market continues to be very dynamic  particularly for artificial turf and athletics tracks in North America. The segment also benefited from price increases which fully offset inflation in raw material costs. Selling price adjustments in the CIS countries are historically intended to offset currency fluctuations and are therefore excluded from the ""organic growth"" indicator (see Appendix 1) 22. Outlook for the end of 2023 and short-termobjectives Over the first nine months of the financial year  the Group's organic growth was positive (+4.7%). In an uncertain geopolitical and macroeconomic environment  Tarkett expects a further slowdown in demand in EMEA and a possible shift in business segment activity in North America. Nevertheless  the favourable business outlook in Sports should allow to compensate for this slowdown and to achieve a significantly higher Adjusted EBITDA  in value and in margin  compared to 2022. The Group expects a start to 2024 marked by low business volumes in EMEA  where market indicators continue to decline. In North America  the Commercial segments have so far been well oriented. However  market indicators reflect sluggish activity  which could lag behind in the context of maintaining high interest rates. Similarly  the residential market shows no signs of recovery. Conversely  activities in the Sports segment are still benefiting from a buoyant market which should allow the Group to continue to grow in this segment in 2024  albeit at a more moderate pace. Tarkett will continue to closely monitor energy price developments and possible impacts on the price of its raw materials. In a context of slowing volumes in the flooring business activity  the Group continues to adapt its production and cost structure. Furthermore  thanks to the rigorous control of working capital requirements  it anticipates an improvement in cash generation and a reduction in its debt. This press release may contain forward-looking statements. These statements do not constitute forecasts regarding results or any other performance indicator  but rather trends or targets. These statements are by their nature subject to risks and uncertainties as described in the Company's Registration Document available on its website (https://www.tarkett-group.com/en/category/urd/). They do not reflect the future performance of the Company  which may differ significantly. The Company does not undertake to provide updates to these statements. Financial calendar 15 February 2024 : Financial results for Q4 and FY2023 - Press release after close of trading: Financial results for Q4 and FY2023 25 April 2024: Financial results for Q1 2024 - Press release after close of trading- Press release after close of trading 25 July 2024 : Financial results for Q2 et H1 2024 - Press release after close of trading: Financial results for Q2 et H1 2024 24 October 2024 : Financial results for Q3 2024 - Press release after close of trading Investor Relations and Individual Shareholders Contact investors@tarkett.com Media contacts Brunswick - tarkett@brunswickgroup.com- Tel.: +33 (0) 1 53 96 83 83 Hugues Bo√´ton - Tel.: +33 (0) 6 79 99 27 15 - Benoit Grange - Tel.: +33 (0) 6 14 45 09 26 About Tarkett With a 140-year history  Tarkett is a worldwide leader in innovative and durable flooring and sports surface solutions  generating net sales of 3.4 billion euros in 2022. The Group has 12 000 employees and 25 R&D centres  8 recycling centres and 34 production sites. Tarkett designs and manufactures solutions for hospitals  schools  housing  hotels  offices  shops and sports fields  serving customers in more than 100 countries. To build ""The Way to Better Floors""  the Group is committed to the circular economy and sustainable development  in line with its Tarkett Human-Conscious Design¬Æ approach. Tarkett is listed on the Euronext regulated market (compartment B  ISIN: FR0004188670  ticker: TKTT). www.tarkett-group.com 3*** Appendices 1/ Definition of alternative performance indicators (not defined under IFRS) Organic growth measures the change in revenue as compared with the same period in the prior year  outside of the exchange rate effect and changes in scope. The foreign exchange effect is obtained by applying the prior year's exchange rate to sales for the current year and calculating the difference with sales for the current year. It also includes the effect of price adjustments in the CIS countries intended to offset the change in local currencies against the euro.measures the change in revenue as compared with the same period in the prior year  outside of the exchange rate effect and changes in scope. The foreign exchange effect is obtained by applying the prior year's exchange rate to sales for the current year and calculating the difference with sales for the current year. It also includes the effect of price adjustments in the CIS countries intended to offset the change in local currencies against the euro. The scope effect is composed of: current year sales by entities not included in the scope of consolidation in the same period of the prior year  until the anniversary of their consolidation. The reduction in sales due to discontinued operations that are not included in the current year's scope of consolidation but were included in sales for the same period of the prior year  until the anniversary of their disposal. Of which Of which Of which 2023 2022 Of which CIS Of which In millions of euros Revenue Revenue Change volume selling selling exchange scope effect prices prices rate effect Group Total Q1 698.5 684.7 +2.0% -7.8% +6.9% +0.4% +2.3% +0.2% Of which organic growth -0.9% Of which selling price increases +7.3% Group Total Q2 909.8 879.3 +3.5% +2.4% +5.2% -1.2% -2.9% +0.0% Of which organic growth +7.5% Of which selling price increases +4.0% Group Total S1 1 608.3 1 564.0 +2.8% -2.1% +5.9% -0.4% -0.7% +0.1% Of which organic growth +3.9% Of which selling price increases +5.5% Group Total Q3 984.3 1 005.4 -2.1% +2.8% +3.1% -0.2% -7.8% +0.0% Of which organic growth +6.0% Of which selling price increases +2.9% Group Total 9M 2 592.6 2 569.4 +0.9% -0.2% +4.8% -0.3% -3.5% +0.1% Of which organic growth +4.7% Of which selling price increases +4.5% 4",neutral,0.01,0.98,0.01,mixed,0.3,0.27,0.43,True,English,"['2023 Q3 ResultsNew window', 'Tarkett', 'October', '12:31', 'commercial carpet production site', 'The North American segment', 'unfavourable exchange effects', 'The Supervisory Board', 'new construction projects', 'unfavourable product mix', 'raw material costs', 'first nine months', 'selective price reduction', 'unfavourable currency effect', 'two main categories', 'negative currency effect', 'favourable economic environment', 'Selling price adjustments', 'alternative performance indicators', 'sales price variations', 'sales price effects', 'selling price increases', 'negative organic growth', 'organic growth"" indicator', 'The EMEA segment', 'Organic sales growth', 'Latin America segment', 'Sports Good levels', 'Commercial segment volumes', 'Sports net revenue', '+15.8% organic growth', 'total effect', 'currency fluctuations', 'Selling prices', 'economic context', 'expensive categories', 'net sales', 'good performance', 'Commercial segments', 'Sales prices', 'LVT sales', 'The Group', 'Residential segment', 'Press release', 'last year', 'same period', 'sustained pace', 'high basis', 'interest rates', 'vinyl rolls', 'vinyl products', 'other hand', 'significant decline', 'marked drop', 'cost base', 'artificial turf', 'athletics tracks', 'Hospitality segments', '984 million euros', '209 million euros', '228 million euros', '166 million euros', '381 million euros', '+6.0% Record revenue', 'Third quarter', 'consolidated revenue', 'sluggish demand', 'dynamic market', 'Euronext Paris', 'CIS region', 'education sector', 'complex market', 'business volumes', 'high inflation', 'CIS countries', 'strong activity', 'residential market', 'Q3 2023 Revenue', 'resilience', 'results', 'devaluation', 'dollar', 'slowdown', 'comparison', 'Q2', 'Tarkett', 'TKTT', 'IFRS', 'detail', 'Appendix', 'document', 'millions', 'APAC', 'renovation', 'area', 'parquet', 'health', 'carpets', 'offices', 'depreciation', 'Europe', 'improvement', 'Russia', 'Ukraine', 'Asia', 'China', 'Suzhou', 'Outlook', 'short-termobjectives']",2023-10-19,2023-10-20,marketscreener.com
31613,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ECONOCOM-GROUP-SE-35111311/news/Econocom-Group-Se-Slight-increase-in-9-month-2023-revenue-driven-by-performance-in-Services-an-45106312/,Econocom Group Se : Slight increase in 9-month 2023 revenue driven by performance in Services and resilience in TMF -October 19  2023 at 12:40 pm EDT,(marketscreener.com)  Press releaseREGULATORY INFORMATION19 October 2023Slight increase1 in 9-month 2023 revenue driven by performance in Services and resilience in TMFIn a deteriorated economic context  Econocom showed good resilience and posted revenu‚Ä¶,"Press releaseREGULATORY INFORMATION19 October 2023Slight increase1 in 9-month 2023 revenue driven by performance in Services and resilience in TMFIn a deteriorated economic context  Econocom showed good resilience and posted revenue at the end of September 2023 of 1 926 million euros  up1 0.9% (down 2.0% on an organic basis2) driven by the Services business but impacted by a declining market for Products & Solutions.The following developments were achieved during the first nine months of 2023:Products & Solutions (P&S) revenue amounted to ‚Ç¨862 million  representing limited growth 1 of 0.1%. Business continued to benefit from the successful integration of SEMIC in Spain and LYDIS in the Netherlands  but posted an organic 2 decline of 5.1% after strong growth during the equivalent period in 2022. Indeed  the current market environment  marked in particular by persistent component price inflation and a steady rise in interest rates  is less favourable than last year  causing companies to postpone their investment decisions. Nevertheless  Econocom held up better than the rest of its benchmark 3   mainly due to its cross-divisional combined offerings.of 0.1%. Business continued to benefit from the successful integration of SEMIC in Spain and LYDIS in the Netherlands  but posted an organic decline of 5.1% after strong growth during the equivalent period in 2022. Indeed  the current market environment  marked in particular by persistent component price inflation and a steady rise in interest rates  is less favourable than last year  causing companies to postpone their investment decisions. Nevertheless  Econocom held up better than the rest of its benchmark   mainly due to its cross-divisional combined offerings. Technology Management & Financing (TMF) revenue edged up 1 0.3% to ‚Ç¨689 million (down 1.0% on an organic basis 2 ). Since the beginning of the year  TMF has managed to match the level of almost all of the major revenue-generating contracts recorded in H1 2022. Econocom expects to return to stronger growth in the fourth quarter  traditionally a high seasonal peak.0.3% to ‚Ç¨689 million (down 1.0% on an organic basis ). Since the beginning of the year  TMF has managed to match the level of almost all of the major revenue-generating contracts recorded in H1 2022. Econocom expects to return to stronger growth in the fourth quarter  traditionally a high seasonal peak. In line with the second quarter  Services maintained a positive growth trajectory (total1 and organic2)  up 3.9% to ‚Ç¨374 million driven by buoyancy on markets outside France.End-of-year outlookGiven the level of growth at the end of September  the Group estimates that its 2023 revenue growth will be positive but below the 5% target  despite an expected fourth quarter increase in revenue compared to 2022.Thanks to an active policy of preserving margins and optimizing overheads  the Group nevertheless expects net income in 2023 to be of the same order of magnitude as in 2022.2024-2028 Strategic PlanEconocom will present its strategic plan to the financial community on 16 November in Brussels during a dedicated Capital Markets Day.Next publication: annual revenue 2023Econocom will post its 2024 financial information publication schedule on the company website by the end of the year.1 At constant standards2 At constant standards and scope3 The B2B IT distribution market has declined 15% on average according to several benchmark studies.Appendix: Reconciliation with first 9 months 2022 financial data published in the press release dated 14 October 2022‚ÄúFirst 9 months 2022 reported‚Äù corresponds to revenue as presented in the 14 October 2022 press release.‚ÄúFirst 9 months 2022 restated‚Äù corresponds to revenue for the first nine months of 2022 taking into account changes in discontinued operations as defined by IFRS 5 and changes in accounting policies. It serves as the basis for calculating growth rates at constant standards.‚ÄúFirst 9 months 2022 pro forma‚Äù corresponds to revenue for the first nine months of 2022 restated and adjusted for changes in exchange rates and consolidation scope (acquisitions and disposals). It serves as the basis for calculating growth rates at constant standards and scope.Revenue (‚Ç¨m) Group total TMF P&S Services First 9 months 2022 reported 1 826 706 759 360 Deconsolidation of discontinued activities and other adjustments for comparability purposes 83 (20) 102 - First 9 months 2022 restated 1 909 687 861 360 Forex impact (2) - (1) - Change in consolidation scope (acquisitions) 58 10 48 - First 9 months 2022 pro forma 1 965 696 909 360ABOUT ECONOCOMEconocom is a digital general contractor (DGC). The group conceives  finances and facilitates the digital transformation of large firms and public organisations. It has 50 years' experience and is the only market player offering versatile expertise through a combination of project financing  equipment distribution and digital services. The group operates in 16 countries  with over 8 750 employees. It made ‚Ç¨2 718m in revenue in 2022. Econocom is listed on Euronext in Brussels  on the BEL Mid and Family Business indexes.FOR MORE INFORMATIONwww.econocom.comFollow us on LinkedIn and TwitterInvestor and shareholder relations contact:benhjamin.pehau@econocom.comPress relations contact:info@capvalue.frTel. +33 (0)1 80 81 50 01This publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: xW5uZphmkprFxmpwkpplbWOYZ2iXx2iam5XHmpeZZpmYbnBhm5diaJ3HZnFjmWhv- Check this key: https://www.security-master-key.com .Regulated information:Inside Information:- other releases Full and original press release in PDF: https://www.actusnews.com/news/82439-econocom-cp-ca-t3-2023-19102023_eng.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2023 ActusNews",neutral,0.03,0.97,0.0,mixed,0.25,0.16,0.59,True,English,"['Econocom Group Se', 'Slight increase', '9-month 2023 revenue', 'performance', 'Services', 'resilience', 'TMF', 'October', '12:40', 'TMF P&S Services First 9 months', 'persistent component price inflation', 'dedicated Capital Markets Day', 'B2B IT distribution market', '2024 financial information publication schedule', 'first 9 months 2022 financial data', 'cross-divisional combined offerings', 'major revenue-generating contracts', 'high seasonal peak', 'first nine months', 'current market environment', 'digital general contractor', 'positive growth trajectory', 'several benchmark studies', 'fourth quarter increase', '14 October 2022 press release', 'financial community', 'REGULATORY INFORMATION', 'Next publication', 'equipment distribution', 'declining market', 'market player', 'digital services', 'digital transformation', 'second quarter', 'Slight increase1', 'economic context', '1,926 million euros', 'following developments', 'limited growth', 'successful integration', 'organic 2 decline', 'strong growth', 'equivalent period', 'steady rise', 'interest rates', 'investment decisions', 'organic decline', 'Technology Management', 'stronger growth', 'active policy', 'net income', 'same order', '28 Strategic Plan', 'company website', 'constant standards', 'accounting policies', 'growth rates', 'exchange rates', 'other adjustments', 'comparability purposes', '360 Forex impact', 'large firms', 'public organisations', ""50 years' experience"", 'versatile expertise', 'Services business', 'organic basis', 'TMF) revenue', 'good resilience', 'consolidation scope', 'project financing', '9-month 2023 revenue', 'last year', '2023 revenue growth', 'annual revenue', 'performance', 'Econocom', 'end', 'September', 'Products', 'Solutions', 'SEMIC', 'Spain', 'LYDIS', 'Netherlands', 'companies', 'beginning', 'level', 'H1', 'buoyancy', 'France', 'Group', '5% target', 'margins', 'overheads', 'magnitude', '16 November', 'Brussels', 'Reconciliation', 'changes', 'operations', 'IFRS', 'acquisitions', 'disposals', 'Deconsolidation', 'activities', 'DGC', 'finances', 'combination', '16 countries', '8,750 employees', '0.']",2023-10-19,2023-10-20,marketscreener.com
31614,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762864/0/en/BGHL-EUR-NAV-s.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED    Ordinary Shares   The Directors of Boussard & Gavaudan Holding...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 18 Oct 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 26.8415 ¬£ 23.8895 Estimated MTD return -0.12 % -0.05 % Estimated YTD return -3.34 % -2.20 % Estimated ITD return 168.42 % 138.89 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 24.20 N/A Premium/discount to estimated NAV -9.84 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 055.00 Premium/discount to estimated NAV N/A -13.98 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 296 208 126 294 Held in treasury N/A N/A Shares Issued 12 296 208 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.2911 Class GBP A Shares (estimated) ¬£ 127.7805The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,0.99,0.0,negative,0.01,0.27,0.72,True,English,"['BGHL', 'EUR', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-10-19,2023-10-20,globenewswire.com
31615,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-3840782/news/BGHL-GBP-NAV-s-45097754/,BGHL (GBP): NAV(s) -October 19  2023 at 01:31 am EDT,(marketscreener.com) ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-3840782/news/BGHL-GBP-NA‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 18 Oct 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 26.8415 ¬£ 23.8895 Estimated MTD return -0.12 % -0.05 % Estimated YTD return -3.34 % -2.20 % Estimated ITD return 168.42 % 138.89 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 24.20 N/A Premium/discount to estimated NAV -9.84 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 055.00 Premium/discount to estimated NAV N/A -13.98 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 296 208 126 294 Held in treasury N/A N/A Shares Issued 12 296 208 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.2911 Class GBP A Shares (estimated) ¬£ 127.7805The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.01,0.98,0.01,negative,0.01,0.27,0.72,True,English,"['BGHL', 'GBP', 'October', '01', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-10-19,2023-10-20,marketscreener.com
31616,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-36044/news/BGHL-EUR-NAV-s-45097752/,BGHL (EUR): NAV(s) -October 19  2023 at 01:31 am EDT,(marketscreener.com) ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDING-36044/news/BGHL-EU‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 18 Oct 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 26.8415 ¬£ 23.8895 Estimated MTD return -0.12 % -0.05 % Estimated YTD return -3.34 % -2.20 % Estimated ITD return 168.42 % 138.89 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 24.20 N/A Premium/discount to estimated NAV -9.84 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 055.00 Premium/discount to estimated NAV N/A -13.98 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 296 208 126 294 Held in treasury N/A N/A Shares Issued 12 296 208 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.2911 Class GBP A Shares (estimated) ¬£ 127.7805The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.01,0.98,0.01,negative,0.01,0.27,0.72,True,English,"['BGHL', 'EUR', 'NAV', 'October', '01', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-10-19,2023-10-20,marketscreener.com
31617,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762872/0/en/Trading-Update-RoodMicrotec-announces-total-income-for-the-third-quarter-of-2023.html,Trading Update: RoodMicrotec announces total income for the third quarter of 2023,Deventer  October 19  2023 ‚Äì RoodMicrotec N.V.  a leading independent company for semiconductors supply and quality services  today releases its trading update for the third quarter of 2023. The total income for the third quarter of 2023 was EUR 4.2 million  ‚Ä¶,Total income for the third quarter of 2023 was EUR 4.2 million (2022: EUR 4.3 million)Total income for the first nine months of 2023 was EUR 12.9 million (2022: EUR 11.7 million)Order book value increased compared to the beginning of the quarterDeventer  October 19  2023 ‚Äì RoodMicrotec N.V.  a leading independent company for semiconductors supply and quality services  today releases its trading update for the third quarter of 2023. The total income for the third quarter of 2023 was EUR 4.2 million  marginally lower than in the third quarter of 2022 (EUR 4.3 million). The total income for the first nine months of 2023 was EUR 12.9 million  an increase of 10% compared to the same period in 2022 (EUR 11.7 million). The good start in the first quarter of this year and the stable development in the second and third quarters are the base for this increase.The order book increased compared to the beginning of the quarter and continues to be filled with long-term contracts and engagements as well as short-term orders. The long-term contracts and engagements are mainly in the SCM and Test Operations units and the short-term orders in the Failure Analysis & Qualification unit.‚ÄúIt is encouraging to see that the total income for the first nine months is higher than for the same period last year even though the market situation with high inflation and rising interest rates is getting worse. We continue to support our customers with high quality services and they highly appreciate it.‚Äù  says Martin Sallenhag  CEO of RoodMicrotec. ‚ÄúThe steady increase in the order book value is building a good foundation for our future business.‚ÄùOutlookRoodMicrotec expects the total income for 2023 to be in the range of EUR 17.0 million to EUR 17.5 million  with a profit before tax ratio from 5 to 10% of total income  excluding the advisory expenses incurred for the public offering process. This projection is in line with the financial targets communicated to the financial market previously. The geopolitical situation in the world and the trends with higher inflation  rising prices  and increasing interest rates throughout Europe could have an impact on the Company‚Äôs business. The Management is keeping a close eye on the situation and is doing everything possible to mitigate any potentially negative impact.AuditThe financial data in this press release have not been audited.Today‚Äôs Extraordinary Meeting of ShareholdersRoodMicrotec will hold an Extraordinary Meeting of Shareholders at Amsterdam Stock Exchange (Euronext)  Beursplein 5  1012 JW in Amsterdam  the Netherlands  this afternoon starting at 14:00 CEST in relation to the recommended public offer by Microtest S.p.A. for all the issued and outstanding ordinary shares in the capital of RoodMicrotec N.V.About RoodMicrotecRoodMicrotec is a leading independent company for semiconductor supply and quality services. With more than 50 years of experience in the semiconductor and electronics industry  RoodMicrotec is well-established as a highly valued partner for many companies worldwide. The Company provides full-turnkey ASIC services for complex microchips that are customized to handle specific applications for individual customers. In cooperation with strong partners  RoodMicrotec manages the entire development and production flow of ASICs in the target volume  ranging from low quantities up to multiple millions per year. The turnkey solution includes project management  wafer test  assembly  final test  qualification  failure analysis and logistics. All services comply with the industrial and quality requirements of the high reliability  aerospace  automotive  healthcare and industrial sectors. RoodMicrotec‚Äôs headquarters are located in Deventer  Netherlands  with operational units in N√∂rdlingen and Stuttgart  GermanyFor more information visit https://www.roodmicrotec.comFurther informationMartin Sallenhag - CEO  Arvid Ladega ‚Äì CFOTelephone: +31 570 745623 Email: investor-relations@roodmicrotec.com Web: www.roodmicrotec.comThis press release is published in English and German. In case of conflict between these versions the English version shall prevail. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The company‚Äôs managing director and CEO Martin Sallenhag  is responsible for arranging the release of this document on behalf of RoodMicrotec.Attachment,neutral,0.04,0.96,0.01,mixed,0.65,0.23,0.12,True,English,"['Trading Update', 'total income', 'third quarter', 'RoodMicrotec', 'Microtest S.p.A.', 'EU Market Abuse Regulation', 'Further information Martin Sallenhag', 'increasing interest rates', 'outstanding ordinary shares', 'first nine months', 'rising interest rates', 'public offering process', 'Order book value', 'full-turnkey ASIC services', 'leading independent company', 'Amsterdam Stock Exchange', 'Test Operations units', 'RoodMicrotec N.V.', 'high quality services', 'financial market', 'N√∂rdlingen', 'first quarter', 'rising prices', 'operational units', 'high inflation', 'wafer test', 'final test', 'high reliability', 'market situation', 'quality requirements', 'Total income', 'semiconductors supply', 'trading update', 'same period', 'good start', 'stable development', 'third quarters', 'long-term contracts', 'short-term orders', 'Failure Analysis', 'good foundation', 'tax ratio', 'advisory expenses', 'financial targets', 'higher inflation', 'The Management', 'close eye', 'financial data', 'Extraordinary Meeting', 'electronics industry', 'many companies', 'The Company', 'complex microchips', 'specific applications', 'strong partners', 'entire development', 'production flow', 'target volume', 'low quantities', 'multiple millions', 'turnkey solution', 'project management', 'Arvid Ladega', 'inside information', 'managing director', 'geopolitical situation', 'press release', 'Qualification unit', 'future business', 'negative impact', 'semiconductor supply', 'individual customers', 'industrial sectors', 'English version', 'quarter Deventer', 'steady increase', 'beginning', 'year', 'second', 'base', 'engagements', 'SCM', 'CEO', 'Outlook', 'range', 'profit', 'projection', 'line', 'world', 'trends', 'Europe', 'everything', 'Audit', 'Shareholders', 'Euronext', 'Beursplein', '1012 JW', 'Netherlands', 'relation', 'capital', 'experience', 'cooperation', 'ASICs', 'assembly', 'logistics', 'aerospace', 'automotive', 'healthcare', 'headquarters', 'Stuttgart', 'Germany', 'CFO', 'Telephone', 'Email', 'investor', 'case', 'conflict', 'versions', 'communication', 'meaning', 'Article', 'document', 'behalf', 'Attachment', '14:00']",2023-10-19,2023-10-20,globenewswire.com
31618,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762934/0/en/Atos-to-deliver-foundational-IT-services-to-Special-Olympics-until-2027.html,Atos to deliver foundational IT services to Special Olympics until 2027,Press release  Atos to deliver foundational IT services to Special Olympics until 2027  Paris  France and Washington DC  United States ‚Äì October 19  2023...,Press releaseAtos to deliver foundational IT services to Special Olympics until 2027Paris  France and Washington DC  United States ‚Äì October 19  2023 ‚Äì Atos today announces its partnership with Special Olympics  Inc. (Special Olympics)  a global nonprofit organization that promotes understanding  acceptance  and inclusion among people with and without intellectual disabilities through sporting activities.As part of this partnership  Atos will provide several foundational digital services to Special Olympics around three pillars:Development and maintenance of the Special Olympics Games Management System   which includes software maintenance  IT security services  and innovations. The Games System allows organizers to manage staff  volunteers  and athletes by  among other things  distributing results and scoring and providing the competition calendars.  which includes software maintenance  IT security services  and innovations. The Games System allows organizers to manage staff  volunteers  and athletes by  among other things  distributing results and scoring and providing the competition calendars. Infrastructure services and security   including access management.  including access management. Events support  with remote and on-site experts delivering services for the Special Olympics World Winter Test Games 2024  Special Olympics World Winter Games 2025  Special Olympics USA Test Games 2025  Special Olympics USA Games 2026  Special Olympics Unified Cup 2026  Special Olympics World Test Games 2026  and Special Olympics World Summer Games 2027.The partnership with Special Olympics reflects Atos‚Äô longstanding commitment to build an inclusive digital world accessible to all through adapted digital solutions for all types of disabilities.The official signing took place on October 10  2023  in Washington  DC in the presence of Mary Davis  CEO  Special Olympics  and Nacho Moros  Chief Operations Officer Major Events  Atos.¬´ We are happy to see Atos join our family and bring us its technological expertise developed over more than 30 years with major sporting events. Alongside them  we want to innovate and continue to be as inclusive as possible so that all people who have an intellectual disability can thrive through sport. ¬ª said Mary Davis  CEO Special Olympics International.¬´ As a company with over 30 years of experience supporting major sporting events  it made sense for Atos to partner with Special Olympics  an organization which  through sport  wishes to create a more inclusive world. We are delighted to support them in their events all around the world  starting with the World Winter Test Games 2024. ¬ª added Nacho Moros  Chief Operations Officer  Major Event  Atos.To foster inclusive environments  Atos has developed a dedicated Accessibility & Digital Inclusion program that looks across all areas of its business  internally and externally  offering a range of accessible and assistive technology services to enable its customers to meet their legal and ethical commitments and maximize their employees‚Äô contribution regardless or disability or impairment. Atos has also implemented Digital Accessibility Specialist apprenticeships  an internal Accessibility Champions program  and created a range of job-specific curricula on how to embed Accessibility.Atos has been a partner of the Olympic Movement since 2002 and the Paralympic Movement since 2008 as a Worldwide IT Partner. Atos is also the Official Technology and Digital Services Partner of the European Olympic Committee for the 2023 and 2027 editions of the European Games and the Official Information Technology Partner of UEFA National Team Football until 2030.Atos is the only international IT services company with a sports and major events division (‚ÄúMajor Events‚Äù). To learn more about Atos solutions for sporting events and major events  visit the Atos website.***About AtosAtos is a global leader in digital transformation with 107 000 employees and annual revenue of c. ‚Ç¨ 11 billion. European number one in cybersecurity  cloud and high-performance computing  the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products  Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris.The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge  education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world  the Group enables its customers and employees  and members of societies at large to live  work and develop sustainably  in a safe and secure information space.About Tech FoundationsTech Foundations is the Atos Group business line leading in managed services  focusing on hybrid cloud infrastructure  employee experience and technology services  through decarbonized  automated and AI-enabled solutions. Its 52 000 employees advance what matters to the world‚Äôs businesses  institutions and communities. It is present in 69 countries  with an annual revenue of ‚Ç¨ 6 billion.About Special OlympicsFounded in 1968  Special Olympics is a global movement to end discrimination against people with intellectual disabilities. We foster acceptance of all people through the power of sport and programming in education  health  and leadership. With more than six million athletes and Unified Sports partners and one million coaches and volunteers in over 200 accredited Programs  Special Olympics delivers more than 30 Olympic-type sports and over 100 000 games and competitions every year.Engage with us on: Twitter  Facebook  YouTube  Instagram  LinkedIn and our blog on Medium. Learn more at www.SpecialOlympics.orgPress contactsAtos: Florence Vayleux | florence.vayleux@atos.net | +33 (0) 6 18 46 59 97Special Olympics International: Megan Gausemel | mgausemel@specialolympics.org | +1 202-570-8628Attachments,neutral,0.19,0.8,0.01,positive,0.81,0.18,0.01,True,English,"['foundational IT services', 'Special Olympics', 'Atos', 'Special Olympics World Winter Test Games', 'Special Olympics USA Test Games', 'Special Olympics World Winter Games', 'Special Olympics World Test Games', 'Special Olympics World Summer Games', 'Special Olympics Games Management System', 'Chief Operations Officer Major Events', 'UEFA National Team Football', 'Tech Foundations Tech Foundations', 'Special Olympics USA Games', 'Special Olympics Unified Cup', 'internal Accessibility Champions program', 'CEO Special Olympics International', 'Digital Accessibility Specialist apprenticeships', 'several foundational digital services', 'international IT services company', 'Official Information Technology Partner', 'The Games System', 'Atos Group business line', 'foundational IT services', 'Worldwide IT Partner', 'inclusive digital world', 'major events division', 'Digital Inclusion program', 'assistive technology services', 'Digital Services Partner', 'IT security services', 'major sporting events', 'European Olympic Committee', 'global nonprofit organization', 'secure information space', 'hybrid cloud infrastructure', 'European Games', 'inclusive world', 'Official Technology', 'Infrastructure services', 'access management', 'digital solutions', 'digital transformation', 'decarbonized digital', 'dedicated Accessibility', 'official signing', 'Events support', 'decarbonization services', 'managed services', 'sporting activities', 'Olympic Movement', 'global leader', 'inclusive environments', 'European number', 'Press release', 'United States', 'three pillars', 'other things', 'competition calendars', 'site experts', 'longstanding commitment', 'Mary Davis', 'Nacho Moros', 'ethical commitments', 'job-specific curricula', 'Paralympic Movement', 'annual revenue', 'high-performance computing', 'end solutions', 'Societas Europaea', 'multicultural approach', 'technological excellence', 'decarbonized, automated', 'AI-enabled solutions', 'software maintenance', 'intellectual disabilities', 'technological expertise', 'intellectual disability', 'Euronext Paris', 'employee experience', 'employees‚Äô contribution', 'Atos solutions', 'Atos website', 'Washington DC', '107,000 employees', '52,000 employees', 'France', 'October', 'partnership', 'understanding', 'acceptance', 'people', 'Development', 'innovations', 'organizers', 'staff', 'volunteers', 'athletes', 'results', 'remote', 'types', 'place', 'presence', 'family', '30 years', 'sense', 'areas', 'range', 'accessible', 'customers', 'legal', 'impairment', '2027 editions', 'sports', 'cybersecurity', 'tailored', 'industries', '69 countries', 'pioneer', 'products', 'clients', 'purpose', 'future', 'knowledge', 'education', 'research', 'scientific', 'members', 'societies', 'large', 'safe', '2023']",2023-10-19,2023-10-20,globenewswire.com
31619,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ROODMICROTEC-N-V-6435/news/Trading-Update-RoodMicrotec-announces-total-income-for-the-third-quarter-of-2023-45097881/,Trading Update: RoodMicrotec announces total income for the third quarter of 2023 -October 19  2023 at 01:56 am EDT,(marketscreener.com) Total income for the third quarter of 2023 was EUR 4.2 million Total income for the first nine months of 2023 was EUR 12.9 million Order book value increased compared to the beginning of the quarter Deventer  October 19  2023 ‚Äì RoodMicrot‚Ä¶,Total income for the third quarter of 2023 was EUR 4.2 million (2022: EUR 4.3 million)Total income for the first nine months of 2023 was EUR 12.9 million (2022: EUR 11.7 million)Order book value increased compared to the beginning of the quarterDeventer  October 19  2023 ‚Äì RoodMicrotec N.V.  a leading independent company for semiconductors supply and quality services  today releases its trading update for the third quarter of 2023. The total income for the third quarter of 2023 was EUR 4.2 million  marginally lower than in the third quarter of 2022 (EUR 4.3 million). The total income for the first nine months of 2023 was EUR 12.9 million  an increase of 10% compared to the same period in 2022 (EUR 11.7 million). The good start in the first quarter of this year and the stable development in the second and third quarters are the base for this increase.The order book increased compared to the beginning of the quarter and continues to be filled with long-term contracts and engagements as well as short-term orders. The long-term contracts and engagements are mainly in the SCM and Test Operations units and the short-term orders in the Failure Analysis & Qualification unit.‚ÄúIt is encouraging to see that the total income for the first nine months is higher than for the same period last year even though the market situation with high inflation and rising interest rates is getting worse. We continue to support our customers with high quality services and they highly appreciate it.‚Äù  says Martin Sallenhag  CEO of RoodMicrotec. ‚ÄúThe steady increase in the order book value is building a good foundation for our future business.‚ÄùOutlookRoodMicrotec expects the total income for 2023 to be in the range of EUR 17.0 million to EUR 17.5 million  with a profit before tax ratio from 5 to 10% of total income  excluding the advisory expenses incurred for the public offering process. This projection is in line with the financial targets communicated to the financial market previously. The geopolitical situation in the world and the trends with higher inflation  rising prices  and increasing interest rates throughout Europe could have an impact on the Company‚Äôs business. The Management is keeping a close eye on the situation and is doing everything possible to mitigate any potentially negative impact.AuditThe financial data in this press release have not been audited.Today‚Äôs Extraordinary Meeting of ShareholdersRoodMicrotec will hold an Extraordinary Meeting of Shareholders at Amsterdam Stock Exchange (Euronext)  Beursplein 5  1012 JW in Amsterdam  the Netherlands  this afternoon starting at 14:00 CEST in relation to the recommended public offer by Microtest S.p.A. for all the issued and outstanding ordinary shares in the capital of RoodMicrotec N.V.About RoodMicrotecRoodMicrotec is a leading independent company for semiconductor supply and quality services. With more than 50 years of experience in the semiconductor and electronics industry  RoodMicrotec is well-established as a highly valued partner for many companies worldwide. The Company provides full-turnkey ASIC services for complex microchips that are customized to handle specific applications for individual customers. In cooperation with strong partners  RoodMicrotec manages the entire development and production flow of ASICs in the target volume  ranging from low quantities up to multiple millions per year. The turnkey solution includes project management  wafer test  assembly  final test  qualification  failure analysis and logistics. All services comply with the industrial and quality requirements of the high reliability  aerospace  automotive  healthcare and industrial sectors. RoodMicrotec‚Äôs headquarters are located in Deventer  Netherlands  with operational units in N√∂rdlingen and Stuttgart  GermanyFor more information visit https://www.roodmicrotec.comFurther informationMartin Sallenhag - CEO  Arvid Ladega ‚Äì CFOTelephone: +31 570 745623 Email: investor-relations@roodmicrotec.com Web: www.roodmicrotec.comThis press release is published in English and German. In case of conflict between these versions the English version shall prevail. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The company‚Äôs managing director and CEO Martin Sallenhag  is responsible for arranging the release of this document on behalf of RoodMicrotec.Attachment,neutral,0.02,0.98,0.01,mixed,0.65,0.23,0.12,True,English,"['Trading Update', 'total income', 'third quarter', 'RoodMicrotec', 'October', '01:56', 'Microtest S.p.A.', 'EU Market Abuse Regulation', 'Further information Martin Sallenhag', 'increasing interest rates', 'outstanding ordinary shares', 'first nine months', 'rising interest rates', 'public offering process', 'Order book value', 'full-turnkey ASIC services', 'leading independent company', 'Amsterdam Stock Exchange', 'Test Operations units', 'RoodMicrotec N.V.', 'high quality services', 'financial market', 'N√∂rdlingen', 'first quarter', 'rising prices', 'operational units', 'high inflation', 'wafer test', 'final test', 'high reliability', 'market situation', 'quality requirements', 'Total income', 'semiconductors supply', 'trading update', 'same period', 'good start', 'stable development', 'third quarters', 'long-term contracts', 'short-term orders', 'Failure Analysis', 'good foundation', 'tax ratio', 'advisory expenses', 'financial targets', 'higher inflation', 'The Management', 'close eye', 'financial data', 'Extraordinary Meeting', 'electronics industry', 'many companies', 'The Company', 'complex microchips', 'specific applications', 'strong partners', 'entire development', 'production flow', 'target volume', 'low quantities', 'multiple millions', 'turnkey solution', 'project management', 'Arvid Ladega', 'inside information', 'managing director', 'geopolitical situation', 'press release', 'Qualification unit', 'future business', 'negative impact', 'semiconductor supply', 'individual customers', 'industrial sectors', 'English version', 'quarter Deventer', 'steady increase', 'beginning', 'year', 'second', 'base', 'engagements', 'SCM', 'CEO', 'Outlook', 'range', 'profit', 'projection', 'line', 'world', 'trends', 'Europe', 'everything', 'Audit', 'Shareholders', 'Euronext', 'Beursplein', '1012 JW', 'Netherlands', 'relation', 'capital', 'experience', 'cooperation', 'ASICs', 'assembly', 'logistics', 'aerospace', 'automotive', 'healthcare', 'headquarters', 'Stuttgart', 'Germany', 'CFO', 'Telephone', 'Email', 'investor', 'case', 'conflict', 'versions', 'communication', 'meaning', 'Article', 'document', 'behalf', 'Attachment', '14:00']",2023-10-19,2023-10-20,marketscreener.com
31620,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762868/0/en/BGHL-GBP-NAV-s.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED      Ordinary Shares      The Directors of Boussard & Gavaudan...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 18 Oct 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 26.8415 ¬£ 23.8895 Estimated MTD return -0.12 % -0.05 % Estimated YTD return -3.34 % -2.20 % Estimated ITD return 168.42 % 138.89 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 24.20 N/A Premium/discount to estimated NAV -9.84 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 055.00 Premium/discount to estimated NAV N/A -13.98 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 296 208 126 294 Held in treasury N/A N/A Shares Issued 12 296 208 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.2911 Class GBP A Shares (estimated) ¬£ 127.7805The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,0.99,0.0,negative,0.01,0.27,0.72,True,English,"['BGHL', 'GBP', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-10-19,2023-10-20,globenewswire.com
31621,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762856/0/en/Sequana-Medical-announces-additional-alfapump-data-supporting-strong-and-durable-clinical-profile-PMA-on-track-for-year-end-submission.html,Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission,PRESS RELEASEREGULATED INFORMATION ‚Äì INSIDE INFORMATION19 October 2023  07:00 am CEST   ¬†   One-year alfapump data from POSEIDON shows safety and...,"PRESS RELEASEREGULATED INFORMATION ‚Äì INSIDE INFORMATION19 October 2023  07:00 am CESTOne-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 monthsPatient preference study indicates that US patients have a strong preference for the alfapump vs large volume paracentesis iMatched interim analysis of patients from NACSELD ii registry and POSEIDON pivotal cohort indicates that alfapump safety profile is comparable to standard of carePositive pre-PMA iii meeting held with FDA to align on clinical data and benefit-risk analysis for the submission packageOn track for PMA submission by year endConference call with live webcast by Sequana Medical today at 03:00 pm CEST / 09:00 am ESTGhent  Belgium ‚Äì 19 October 2023 ‚Äì Sequana Medical NV (Euronext Brussels: SEQUA) (the ""Company"" or ""Sequana Medical"")  a pioneer in the treatment of fluid overload in liver disease  heart failure and cancer  today announces additional positive data supporting i) maintenance of alfapump‚Äôs safety and strong efficacy profile at 12 months  ii) safety in line with a matched cohort of patients from the NACSELD registry  and iii) strong preference amongst US patients for alfapump versus standard of care  as well as completion of a positive meeting with the FDA to align on clinical data and benefit-risk analysis for the PMA submission package which is on track for year end.Gijs Klarenbeek  Senior Medical Advisor of Sequana Medical  commented: ‚ÄúThese data are very positive and demonstrate that the alfapump continues to transform the lives of patients with recurrent or refractory ascites at one year post-implantation  maintaining the virtual elimination of needle paracentesis and clinically meaningful improvement in quality of life. The comparison of POSEIDON patients to a matched cohort of subjects in the NACSELD registry is reassuring as it reaffirms alfapump‚Äôs safety profile.‚ÄùIan Crosbie  Chief Executive Officer at Sequana Medical  added: ‚ÄúWe are delighted with these additional insights into alfapump‚Äôs long term benefit as well as the encouraging results from our patient preference study which indicates a strong preference amongst US patients for the alfapump. We are greatly encouraged by our recent pre-PMA meeting with the FDA  where we discussed the reported clinical data from our alfapump studies and benefit-risk analysis for the submission package. We look forward to submitting our PMA application by year end and continuing our preparations for launching the alfapump in the US and Canada.""One-year follow-up data from POSEIDON studyAs seen in months 0-6 post implant  patients maintained the 100% median reduction in therapeutic paracentesis in the 7-12 month post-implant period vs the three month pre-implant period (n = 19). These data show that the alfapump has a sustained effect on controlling ascites  virtually eliminating the need for therapeutic paracentesis.During the 7-12 month post-implant period  two patients had the alfapump explanted  one due to a urinary tract infection and one due to wound dehiscence and the number of Major Adverse Events (MAEsiv) and serious infections were in line with expectations. Importantly  creatine and eGFRv levels of alfapump-treated patients over 12-month follow-up indicated a stable renal function. Overall  these safety data indicate that the alfapump has a robust safety profile over long-term follow-up.Quality of life  assessed through the physical component score of SF36 (a general health quality of life measure) and the Ascites Q score (a quality of life measure specific for patients with ascites)  maintained a clinically meaningful improvement at 12 months post-implant vs three months pre-implant  despite disease progression.The overall trend in survivalvi in patients implanted with the alfapump remained positive over a longer term  with a Kaplan-Meier estimate indicating over 70% survival probability at 12 and 18 months post-implant. This compares favourably with the published literature reporting a predicted survival probability for refractory ascites patients with a similar MELDvii score and receiving paracentesis of approximately 17% at 12 months and 5% at 18 monthsviii.Data from the POSEIDON study will be submitted for publication in a peer-reviewed journal. The Company will update the market as soon as it is published.Outcome Patient Preference studyThe patient preference study was conducted by RTI Health Solutions  thought leaders in the field. The rigorous study design was pre-discussed with the FDA and utilizes a discrete-choice experiment (DCEix) methodology to elicit preferences of US patients with a physician-confirmed diagnosis of recurrent or refractory ascites due to liver cirrhosis for attributes of an implantable pump as a novel interventional treatment for ascites. Patients were surveyed for the risk of treatment-related adverse events they would be willing to accept (risk tolerance) to achieve specific improvements in treatment efficacy (desired benefits). In total  125 US patients with a comparable patient profile as the Pivotal Cohort in the POSEIDON study  completed the survey.Top-line results presented in the table below indicate that  on average  patients are willing to accept levels of risks greater than those observed in the POSEIDON study in exchange for improvements in treatment efficacy less than or equal to those observed in the POSEIDON study.Risk tolerance (over 6 months) Patient preference studyMaximum acceptable risk POSEIDON pivotal cohortObserved rate Major surgery or death >10% 0% Minor procedure >35% 20% Serious infection or AKI resulting in hospitalization >30% 20%Desired benefits Patient preference study POSEIDON pivotal cohort Reduction in frequency of paracentesis 100% 100% (median) Additional ascites good health days each month 10 >10 (mean)Reduction in paracentesis frequency and additional ascites good health days are important attributes for a novel interventional treatment for ascites. On average  patients responded with a 65% likelihood of selecting a treatment profile like the alfapump vs regular paracentesis procedures and no implanted pump.These data support the premise that alfapump is a desirable treatment option for the majority of patients.Matched interim analysis of NACSELD registry and POSEIDON pivotal cohortThe North American Consortium for the Study of End Stage Liver Disease (NACSELD) is a consortium of tertiary-care hepatology centers in North America formed to study patients with cirrhosis. NASCELD-III is an IRBx approved registry of outpatients with cirrhosis which was initiated in 2019 at ten centers in North America.A matched cohort analysis was conducted by an independent group comparing outcomes of decompensated cirrhosis patients from the NACSELD-III registry to those from the POSEIDON study. Forty decompensated ascites patients from NACSELD-III were matched to the forty patients from the Pivotal Cohort in the POSEIDON study  using baseline Ascites-Q score (reflecting burden of disease before alfapump implantation) and sex. Patients were also comparable for age and baseline MELD score after matching.Results for all cause hospitalization and death within six months were similar between the NACSELD-III registry matched patients and the POSEIDON pivotal cohort.Six month dataxi NACSELD-III Registry Matched Patients POSEIDON Pivotal Cohortxii Any Death or Hospitalization 55.0% (22/40) 55.0% (22/40) Death 12.5% (5/40) 12.5% (5/40) Hospitalization 42.5% (17/40) 42.5% (17/40) Median # of hospitalizations (min  max) 1 (0  5) 1 (0  4) Liver Transplant 7.5% (3/40) 5.0% (2/40)This analysis indicates that the safety profile of the alfapump is in line with expectations and comparable to standard paracentesis procedures.Data from the matched cohort analysis together with the positive data from the POSEIDON study indicate that patients implanted with the alfapump benefit from significantly reduced number of paracentesis procedures and an improved quality of life without an increased risk of death or hospitalization compared to standard of care.Details Conference Call and Webcast by Sequana MedicalSequana Medical management will host a conference call with a live webcast presentation today at 03:00 pm CEST / 09:00 am EST.Registration webcast: please click hereRegistration conference call (only if you wish to participate in the Q&A): please click here. Once registered  you will receive dial-in numbers and a confirmation code.The webcast and conference call will be conducted in English and a replay will be available on Sequana Medical‚Äôs website shortly after.For more information  please contact:Sequana MedicalLies VannesteDirector Investor RelationsE: IR@sequanamedical.comT: +32 (0)498 053579About Sequana MedicalSequana Medical NV is a pioneer in treating fluid overload  a serious and frequent clinical complication in patients with liver disease  heart failure and cancer. This causes major medical issues including increased mortality  repeated hospitalizations  severe pain  difficulty breathing and restricted mobility. Although diuretics are standard of care  they become ineffective  untolerable or exacerbate the problem in many patients. There are limited effective treatment options for these patients  resulting in poor clinical outcomes  high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing ‚Äúdiuretic-resistant‚Äù patient population. alfapump¬Æ and DSR¬Æ are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload  delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems.The Company has reported positive primary and secondary endpoint data from the North American pivotal POSEIDON trial of the alfapump in recurrent or refractory ascites due to liver cirrhosis and is on track to file a Pre-Market Approval (PMA) application with the FDA by year end.The Company has commenced MOJAVE  a US randomized controlled multi-center Phase 1/2a clinical trial of DSR 2.0 seeking to confirm the strong efficacy seen in the RED DESERT and SAHARA studies. The first two patients have been successfully treated with DSR 2.0  and top-line data from all of the first three patients is expected by year end. Sequana Medical recently reported that detailed biomarker analysis of RED DESERT and SAHARA patients indicates DSR‚Äôs mechanism of action as breaking the vicious cycle of cardiorenal syndrome.Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent  Belgium. For further information  please visit www.sequanamedical.com.Important Regulatory DisclaimersThe alfapump¬Æ system is currently not approved in the United States or Canada. In the United States and Canada  the alfapump system is currently under clinical investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to liver cirrhosis. DSR¬Æ therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the alfapump system in Europe  the United States or Canada.Note: alfapump¬Æ and DSR¬Æ are registered trademarks.Forward-looking statementsThis press release may contain predictions  estimates or other information that might be considered forward-looking statements.Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds  and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release  except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements  which reflect the opinions of Sequana Medical only as of the date of this press release.i Large volume paracentesis is paracentesis of more than 5 liters (and part of standard of care)ii NACSELD: North American Consortium for the Study of End stage Liver Diseaseiii PMA: Pre-Market Approvaliv MAEs were pre-defined in the protocol together with the principal investigators and FDA as one of the following events: AKI > stage 2  hepatorenal syndrome  hepatic encephalopathy > grade 2  spontaneous bacterial peritonitis and reccurent or refractory infection related to paracentesis or the alfapump system  procedure or therapy.v eGFR: estimated Glomerular Filtration Rate  a measure of kidney functionvi POSEIDON study not powered for survivalvii MELD: Model for End-Stage Liver Disease scoring system based on laboratory parameters  and is used to predict three-month survival rate and consider patients for liver transplantationviii Salerno et al.  Gastroenterology 2007; 133:825-834; figure 2: estimated probability of death according to treatment allocation (TIPS or paracentesis) in hypothetical patients with different MELD scoresix The DCE approach allows an analysis of individual stated preferences in response to hypothetical choices and enables the quantification of the relative importance of each attribute/level during the decision-making process.x IRB: Institutional Review Boardxi Deaths and serious adverse events (SAE) requiring hospitalization are presented hierarchically such that if a subject died and experienced an SAE requiring hospitalization  they are counted under ‚ÄúDeath‚Äùxii POSEIDON data are derived from adverse event data during six months post-implantAttachments",neutral,0.15,0.84,0.01,mixed,0.45,0.3,0.24,True,English,"['additional alfapump data', 'durable clinical profile', 'Sequana Medical', 'year-end submission', 'strong', 'PMA', 'track', '7-12 month post-implant period', 'Positive pre-PMA iii meeting', 'Outcome Patient Preference study', 'recent pre-PMA meeting', 'comparable patient profile', 'Chief Executive Officer', 'urinary tract infection', 'Major Adverse Events', 'stable renal function', 'physical component score', 'similar MELDvii score', 'RTI Health Solutions', 'treatment-related adverse events', 'rigorous study design', 'long term benefit', 'Senior Medical Advisor', 'large volume paracentesis', 'novel interventional treatment', 'strong efficacy profile', 'Ascites Q score', 'robust safety profile', 'NACSELD ii registry', 'Sequana Medical NV', 'additional positive data', '0-6 post implant', 'general health quality', 'One-year follow-up data', 'PMA submission package', 'POSEIDON pivotal cohort', 'One-year alfapump data', 'alfapump safety profile', 'positive meeting', 'three month', 'strong preference', 'POSEIDON study', 'NACSELD registry', 'treatment efficacy', 'additional insights', 'longer term', 'PMA application', '12-month follow-up', 'long-term follow-up', 'PRESS RELEASE', 'REGULATED INFORMATION', 'INSIDE INFORMATION', 'interim analysis', 'clinical data', 'benefit-risk analysis', 'year end', 'Conference call', 'live webcast', 'Euronext Brussels', 'fluid overload', 'liver disease', 'heart failure', 'Gijs Klarenbeek', 'one year', 'virtual elimination', 'needle paracentesis', 'meaningful improvement', 'Ian Crosbie', 'encouraging results', '100% median reduction', 'therapeutic paracentesis', 'sustained effect', 'wound dehiscence', 'serious infections', 'eGFRv levels', 'disease progression', 'overall trend', 'Kaplan-Meier estimate', '70% survival probability', 'peer-reviewed journal', 'thought leaders', 'discrete-choice experiment', 'physician-confirmed diagnosis', 'liver cirrhosis', 'implantable pump', 'specific improvements', 'safety data', 'refractory ascites', 'POSEIDON patients', 'two patients', 'alfapump-treated patients', 'life measure', 'The Company', 'risk tolerance', 'US patients', 'alfapump studies', '12 months', '18 months', '19 October', 'CEST', 'standard', 'care', 'FDA', 'track', 'Ghent', 'Belgium', 'pioneer', 'cancer', 'maintenance', 'line', 'completion', 'lives', 'recurrent', 'implantation', 'comparison', 'subjects', 'preparations', 'Canada', 'number', 'MAEsiv', 'expectations', 'creatine', 'SF36', 'survivalvi', 'literature', 'publication', 'market', 'field', 'DCEix', 'methodology', 'preferences', 'attributes', 'benefits', 'total', '03:00', '09:00']",2023-10-19,2023-10-20,globenewswire.com
31622,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SEQUANA-MEDICAL-N-V-54548256/news/Sequana-Medical-N-announces-additional-alfapump-data-supporting-strong-and-durable-clinical-profil-45097867/,Sequana Medical N : announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission -October 19  2023 at 01:53 am EDT,(marketscreener.com)   REGULATED INFORMATION - INSIDE INFORMATION   19 October 2023  07:00 am CEST    One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 months   Patient preference study indicates tha‚Ä¶,"REGULATED INFORMATION - INSIDE INFORMATION19 October 2023  07:00 am CESTOne-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 monthsPatient preference study indicates that US patients have a strong preference for the alfapump vs large volume paracentesis [i]Matched interim analysis of patients from NACSELD [ii] registry and POSEIDON pivotal cohort indicates that alfapump safety profile is comparable to standard of carePositive pre-PMA [iii] meeting held with FDA to align on clinical data and benefit-risk analysis for the submission packageOn track for PMA submission by year endConference call with live webcast by Sequana Medical today at 03:00 pm CEST / 09:00 am ESTGhent  Belgium - 19 October 2023 -Sequana Medical NV(Euronext Brussels: SEQUA)(the ""Company"" or ""SequanaMedical"")  a pioneer in the treatment of fluid overload in liver disease  heart failure and cancer  today announces additional positive data supporting i) maintenance ofalfapump's safety and strong efficacy profile at 12 months  ii) safety in line with a matched cohort of patients from the NACSELD registry  and iii) strong preference amongst US patients foralfapump versus standard of care  as well as completion of a positive meeting with the FDA to align on clinical data and benefit-risk analysis for the PMA submission package which is on track for year end.Gijs Klarenbeek  Senior Medical Advisor of Sequana Medical  commented:""These data are very positive and demonstrate that thealfapump continues to transform the lives of patients with recurrent or refractory ascites at one year post-implantation  maintaining the virtual elimination of needle paracentesis and clinically meaningful improvement in quality of life. The comparison of POSEIDON patients to a matched cohort of subjects in the NACSELD registry is reassuring as it reaffirmsalfapump's safety profile.""Ian Crosbie  Chief Executive Officer at Sequana Medical  added:""We are delighted with these additional insights intoalfapump's long term benefit as well as the encouraging results from our patient preference study which indicates a strong preference amongst US patients for thealfapump. We are greatly encouraged by our recent pre-PMA meeting with the FDA  where we discussed the reported clinical data from ouralfapump studies and benefit-risk analysis for the submission package. We look forward to submitting our PMA application by year end and continuing our preparations for launching thealfapump in the US and Canada.""One-year follow-up data from POSEIDON studyAs seen in months 0-6 post implant  patients maintained the 100% median reduction in therapeutic paracentesis in the 7-12 month post-implant period vs the three month pre-implant period (n = 19). These data show that thealfapump has a sustained effect on controlling ascites  virtually eliminating the need for therapeutic paracentesis.During the 7-12 month post-implant period  two patients had thealfapump explanted  one due to a urinary tract infection and one due to wound dehiscence and the number of Major Adverse Events (MAEs [iv] ) and serious infections were in line with expectations. Importantly  creatine and eGFR [v] levels ofalfapump-treated patients over 12-month follow-up indicated a stable renal function. Overall  these safety data indicate that thealfapump has a robust safety profile over long-term follow-up.Quality of life  assessed through the physical component score of SF36 (a general health quality of life measure) and the Ascites Q score (a quality of life measure specific for patients with ascites)  maintained a clinically meaningful improvement at 12 months post-implant vs three months pre-implant  despite disease progression.The overall trend in survival [vi] in patients implanted with thealfapump remained positive over a longer term  with a Kaplan-Meier estimate indicating over 70% survival probability at 12 and 18 months post-implant. This compares favourably with the published literature reporting a predicted survival probability for refractory ascites patients with a similar MELD [vii] score and receiving paracentesis of approximately 17% at 12 months and 5% at 18 months [viii] .Data from the POSEIDON study will be submitted for publication in a peer-reviewed journal. The Company will update the market as soon as it is published.Outcome Patient Preference studyThe patient preference study was conducted by RTI Health Solutions  thought leaders in the field. The rigorous study design was pre-discussed with the FDA and utilizes a discrete-choice experiment (DCE [ix] ) methodology to elicit preferences of US patients with a physician-confirmed diagnosis of recurrent or refractory ascites due to liver cirrhosis for attributes of an implantable pump as a novel interventional treatment for ascites. Patients were surveyed for the risk of treatment-related adverse events they would be willing to accept (risk tolerance) to achieve specific improvements in treatment efficacy (desired benefits). In total  125 US patients with a comparable patient profile as the Pivotal Cohort in the POSEIDON study  completed the survey.Top-line results presented in the table below indicate that  on average  patients are willing to accept levels of risks greater than those observed in the POSEIDON study in exchange for improvements in treatment efficacy less than or equal to those observed in the POSEIDON study.Risk tolerance (over 6 months) Patient preference studyMaximum acceptable risk POSEIDON pivotal cohortObserved rate Major surgery or death >10% 0% Minor procedure >35% 20% Serious infection or AKI resulting in hospitalization >30% 20%Desired benefits Patient preference study POSEIDON pivotal cohort Reduction in frequency of paracentesis 100% 100% (median) Additional ascites good health days each month 10 >10 (mean)Reduction in paracentesis frequency and additional ascites good health days are important attributes for a novel interventional treatment for ascites. On average  patients responded with a 65% likelihood of selecting a treatment profile like thealfapump vs regular paracentesis procedures and no implanted pump.These data support the premise thatalfapump is a desirable treatment option for the majority of patients.Matched interim analysis of NACSELD registry and POSEIDON pivotal cohortThe North American Consortium for the Study of End Stage Liver Disease (NACSELD) is a consortium of tertiary-care hepatology centers in North America formed to study patients with cirrhosis. NASCELD-III is an IRB [x] approved registry of outpatients with cirrhosis which was initiated in 2019 at ten centers in North America.A matched cohort analysis was conducted by an independent group comparing outcomes of decompensated cirrhosis patients from the NACSELD-III registry to those from the POSEIDON study. Forty decompensated ascites patients from NACSELD-III were matched to the forty patients from the Pivotal Cohort in the POSEIDON study  using baseline Ascites-Q score (reflecting burden of disease beforealfapump implantation) and sex. Patients were also comparable for age and baseline MELD score after matching.Results for all cause hospitalization and death within six months were similar between the NACSELD-III registry matched patients and the POSEIDON pivotal cohort.Six month data [xi] NACSELD-III Registry Matched Patients POSEIDON Pivotal Cohort [xii] Any Death or Hospitalization 55.0% (22/40) 55.0% (22/40) Death 12.5% (5/40) 12.5% (5/40) Hospitalization 42.5% (17/40) 42.5% (17/40) Median # of hospitalizations (min  max) 1 (0  5) 1 (0  4) Liver Transplant 7.5% (3/40) 5.0% (2/40)This analysis indicates that the safety profile of thealfapump is in line with expectations and comparable to standard paracentesis procedures.Data from the matched cohort analysis together with the positive data from the POSEIDON study indicate that patients implanted with thealfapump benefit from significantly reduced number of paracentesis procedures and an improved quality of life without an increased risk of death or hospitalization compared to standard of care.Details Conference Call and Webcast by Sequana MedicalSequana Medical management will host a conference call with a live webcast presentationtodayat 03:00 pm CEST / 09:00 am EST.Registration webcast: please click hereRegistration conference call (only if you wish to participate in the Q&A): please click here . Once registered  you will receive dial-in numbers and a confirmation code.The webcast and conference call will be conducted in English and a replay will be available on Sequana Medical's website shortly after.For more information  please contact:Sequana MedicalLies VannesteDirector Investor RelationsE: IR@sequanamedical.comT: +32 (0)498 053579About Sequana MedicalSequana Medical NV is a pioneer in treating fluid overload  a serious and frequent clinical complication in patients with liver disease  heart failure and cancer. This causes major medical issues including increased mortality  repeated hospitalizations  severe pain  difficulty breathing and restricted mobility. Although diuretics are standard of care  they become ineffective  untolerable or exacerbate the problem in many patients. There are limited effective treatment options for these patients  resulting in poor clinical outcomes  high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing ""diuretic-resistant"" patient population.alfapump¬Æ and DSR¬Æ are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload  delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems.The Company has reported positive primary and secondary endpoint data from the North American pivotal POSEIDON trial of thealfapump in recurrent or refractory ascites due to liver cirrhosis and is on track to file a Pre-Market Approval (PMA) application with the FDA by year end.The Company has commenced MOJAVE  a US randomized controlled multi-center Phase 1/2a clinical trial of DSR 2.0 seeking to confirm the strong efficacy seen in the RED DESERT and SAHARA studies. The first two patients have been successfully treated with DSR 2.0  and top-line data from all of the first three patients is expected by year end. Sequana Medical recently reported that detailed biomarker analysis of RED DESERT and SAHARA patients indicates DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome.Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent  Belgium. For further information  please visit www.sequanamedical.com .Important Regulatory DisclaimersThealfapump¬Æ system is currently not approved in the United States or Canada. In the United States and Canada  thealfapump system is currently under clinical investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to liver cirrhosis. DSR¬Æ therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with thealfapump system in Europe  the United States or Canada.Note:alfapump¬Æ and DSR¬Æ are registered trademarks.Forward-looking statementsThis press release may contain predictions  estimates or other information that might be considered forward-looking statements.Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds  and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release  except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements  which reflect the opinions of Sequana Medical only as of the date of this press release.[i] Large volume paracentesis is paracentesis of more than 5 liters (and part of standard of care)[ii] NACSELD: North American Consortium for the Study of End stage Liver Disease[iii] PMA: Pre-Market Approval[iv] MAEs were pre-defined in the protocol together with the principal investigators and FDA as one of the following events: AKI > stage 2  hepatorenal syndrome  hepatic encephalopathy > grade 2  spontaneous bacterial peritonitis and reccurent or refractory infection related to paracentesis or thealfapump system  procedure or therapy.[v] eGFR: estimated Glomerular Filtration Rate  a measure of kidney function[vi] POSEIDON study not powered for survival[vii] MELD: Model for End-Stage Liver Disease scoring system based on laboratory parameters  and is used to predict three-month survival rate and consider patients for liver transplantation[viii] Salerno et al.  Gastroenterology 2007; 133:825-834; figure 2: estimated probability of death according to treatment allocation (TIPS or paracentesis) in hypothetical patients with different MELD scores[ix] The DCE approach allows an analysis of individual stated preferences in response to hypothetical choices and enables the quantification of the relative importance of each attribute/level during the decision-making process.[x] IRB: Institutional Review Board[xi] Deaths and serious adverse events (SAE) requiring hospitalization are presented hierarchically such that if a subject died and experienced an SAE requiring hospitalization  they are counted under ""Death""",neutral,0.11,0.88,0.01,mixed,0.54,0.2,0.26,True,English,"['Sequana Medical N', 'additional alfapump data', 'durable clinical profile', 'year-end submission', 'strong', 'PMA', 'track', 'October', '01', '53', '7-12 month post-implant period', 'similar MELD [vii] score', 'three month pre-implant period', 'Positive pre-PMA [iii] meeting', 'year end Conference call', 'Outcome Patient Preference study', 'recent pre-PMA meeting', 'physical component score', 'comparable patient profile', 'Chief Executive Officer', 'urinary tract infection', 'Major Adverse Events', 'eGFR [v] levels', 'stable renal function', 'RTI Health Solutions', 'treatment-related adverse events', 'rigorous study design', 'long term benefit', 'Senior Medical Advisor', 'Ascites Q score', 'large volume paracentesis', 'novel interventional treatment', 'strong efficacy profile', 'robust safety profile', 'NACSELD [ii] registry', 'Sequana Medical NV', 'additional positive data', '0-6 post implant', 'general health quality', 'One-year alfapump data', 'One-year follow-up data', 'alfapump safety profile', 'PMA submission package', 'POSEIDON pivotal cohort', 'positive meeting', 'strong preference', 'POSEIDON study', 'NACSELD registry', 'treatment efficacy', 'one year', 'additional insights', 'longer term', 'PMA application', '12-month follow-up', 'long-term follow-up', 'three months', 'REGULATED INFORMATION', 'INSIDE INFORMATION', 'interim analysis', 'clinical data', 'benefit-risk analysis', 'live webcast', 'Euronext Brussels', 'fluid overload', 'liver disease', 'heart failure', 'Gijs Klarenbeek', 'virtual elimination', 'needle paracentesis', 'meaningful improvement', 'Ian Crosbie', 'encouraging results', '100% median reduction', 'therapeutic paracentesis', 'sustained effect', 'wound dehiscence', 'serious infections', 'disease progression', 'overall trend', 'Kaplan-Meier estimate', 'peer-reviewed journal', 'thought leaders', 'discrete-choice experiment', 'physician-confirmed diagnosis', 'liver cirrhosis', 'implantable pump', 'specific improvements', 'safety data', 'refractory ascites', '70% survival probability', 'The Company', 'risk tolerance', 'POSEIDON patients', 'two patients', 'US patients', 'life measure', '12 months', '18 months', '19 October', 'CEST', 'standard', 'care', 'FDA', 'track', 'Ghent', 'Belgium', 'SequanaMedical', 'pioneer', 'cancer', 'maintenance', 'line', 'foralfapump', 'completion', 'lives', 'recurrent', 'implantation', 'comparison', 'subjects', 'studies', 'preparations', 'Canada', 'number', 'MAEs', 'expectations', 'creatine', 'SF36', 'literature', 'publication', 'market', 'field', 'DCE', 'methodology', 'preferences', 'attributes', 'benefits', 'total', '03:00', '09:00']",2023-10-19,2023-10-20,marketscreener.com
31623,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/TARKETT-14899990/news/Q3-2023-Revenue-Organic-sales-growth-of-6-0-Record-revenue-in-Sports-Good-levels-of-activity-in-45105749/,Q3 2023 Revenue: Organic sales growth of +6.0% Record revenue in Sports Good levels of activity in CIS countries and resilience in the Commercial segments in North America -October 19  2023 at 11:50 a,(marketscreener.com) ¬† ¬† ¬† ¬† Q3 2023 Revenue: Organic sales growth of +6.0% Record revenue in Sports Good levels of activity in CIS countries and resilience in the Commercial segments in North America Third quarter 2023 results ¬† Revenue down -2.1% compared t‚Ä¶,Q3 2023 Revenue:Organic sales growth of +6.0%Record revenue in SportsGood levels of activity in CIS countries and resilience in the Commercial segments in North AmericaThird quarter 2023 resultsRevenue down -2.1% compared to Q3 2022 given the unfavourable exchange effects (-8.1%) due to the devaluation of the dollar and the roubleOrganic growth of +6.0% driven by strong activity in Sports and volumes up in CISIn EMEA  volumes are down slightly compared to last year  affected by sluggish demandIn North America  the slowdown in the Residential and Hospitality segments is partially offset by the good performance in the Commercial segmentsGood level of activity in CIS with volumes greater than those in Q3 2022  which nevertheless remain lower than those in 2021 over the same periodIn a dynamic market  Sports continues to grow at a sustained pace (+15.8% organic) despite a high basis for comparison in Q3 2022Selling prices are generally stable compared to Q2 2023Paris  19 October 2023: The Supervisory Board of Tarkett (Euronext Paris: FR0004188670 TKTT)  which met today  reviewed the Group‚Äôs consolidated revenue for the third quarter of 2023.The Group uses alternative performance indicators (not defined under IFRS)  described in detail in the Appendix of this document:Revenue in millions of euros Q3 2023 Q3 2022 Change Of which organic growth EMEA 209.4 220.4 -5.0% -3.8% North America 228.4 251.4 -9.2% -2.6% CIS  APAC & Latin America 165.6 191.1 -13.3% +10.8% Sports 380.8 342.5 +11.2% +15.8% Group Total 984.3 1 005.4 -2.1% +6.0%Revenue for the third quarter of 2023Net revenue of the Group amounted to 984 million euros  down -2.1% compared to the third quarter of 2022. Organic growth was +6.0% (or +5.7% including sales price variations in the CIS region(1) ). The total effect of the selling price increases implemented across all segments is +3.1% on average compared to the third quarter of 2022. Sales prices were generally stable compared to Q2 2023.The EMEA segment achieved a net revenue of 209 million euros  down -5.0% compared to the third quarter of 2022  including an unfavourable currency effect of -1.2% and negative organic growth of -3.8%. The economic context of high inflation and interest rates is penalising renovation and new construction projects throughout the area. Activity in the Residential segment was significantly lower than in 2022 due to an unfavourable product mix  with vinyl rolls performing better than more expensive categories such as parquet. Activity in the Commercial segments fell only slightly compared to 2022 thanks to the good performance of volumes in the two main categories  vinyl products for the health and education sector and carpets for offices.The North American segment generated net revenue of 228 million euros  down -9.2% compared to the third quarter of 2022  with a negative currency effect linked to the depreciation of the dollar against the euro (-6.6%) and negative organic growth of -2.6%. Commercial segment volumes (offices  healthcare  education) are up slightly compared to 2022 in a market that is currently better positioned than in Europe. On the other hand  business volumes in the Residential and Hospitality segments are down in a market where demand is still suffering from inflation and the level of interest rates.Net revenue in the CIS  APAC and Latin America segment amounted to 166 million euros  down -13.3% compared to the third quarter of 2022  with a very unfavourable currency effect mainly resulting from the depreciation of the rouble (-31% compared to Q3 2022). Activity is well positioned with organic growth of +10.8% (excluding sales price effects in CIS countries). It benefited from the improvement in volumes in Russia and Ukraine compared to Q3 2022  which was marked by a significant decline compared with 2021. These countries respectively represent 8% and 0.8% of the Group‚Äôs net sales over the quarter. In a complex market  selective price reduction contributed to the good performance of vinyl roll and LVT sales for the residential market. In Asia  activity was down  mainly due to a marked drop in sales in China. To optimise its cost base  the Group closed the commercial carpet production site located in Suzhou (China). Latin America remains slightly down compared to 2022 but volumes improved over the quarter in a more favourable economic environment.Sports net revenue continued to grow at a sustained pace  amounting to 381 million euros  up +11.2%  of which +15.8% organic growth compared to the third quarter of 2022. The market continues to be very dynamic  particularly for artificial turf and athletics tracks in North America. The segment also benefited from price increases which fully offset inflation in raw material costs.1) Selling price adjustments in the CIS countries are historically intended to offset currency fluctuations and are therefore excluded from the ‚Äúorganic growth‚Äù indicator (see Appendix 1)Outlook for the end of 2023 and short-term objectivesOver the first nine months of the financial year  the Group‚Äôs organic growth was positive (+4.7%).In an uncertain geopolitical and macroeconomic environment  Tarkett expects a further slowdown in demand in EMEA and a possible shift in business segment activity in North America.Nevertheless  the favourable business outlook in Sports should allow to compensate for this slowdown and to achieve a significantly higher Adjusted EBITDA  in value and in margin  compared to 2022.The Group expects a start to 2024 marked by low business volumes in EMEA  where market indicators continue to decline.In North America  the Commercial segments have so far been well oriented. However  market indicators reflect sluggish activity  which could lag behind in the context of maintaining high interest rates. Similarly  the residential market shows no signs of recovery.Conversely  activities in the Sports segment are still benefiting from a buoyant market which should allow the Group to continue to grow in this segment in 2024  albeit at a more moderate pace.Tarkett will continue to closely monitor energy price developments and possible impacts on the price of its raw materials.In a context of slowing volumes in the flooring business activity  the Group continues to adapt its production and cost structure. Furthermore  thanks to the rigorous control of working capital requirements  it anticipates an improvement in cash generation and a reduction in its debt.This press release may contain forward-looking statements. These statements do not constitute forecasts regarding results or any other performance indicator  but rather trends or targets. These statements are by their nature subject to risks and uncertainties as described in the Company‚Äôs Registration Document available on its website ( https://www.tarkett-group.com/en/category/urd/ ). They do not reflect the future performance of the Company  which may differ significantly. The Company does not undertake to provide updates to these statements.Financial calendar15 February 2024 : Financial results for Q4 and FY2023 ‚Äì Press release after close of trading: Financial results for Q4 and FY2023 ‚Äì Press release after close of trading 25 April 2024: Financial results for Q1 2024 ‚Äì Press release after close of tradingFinancial results for Q1 2024 ‚Äì Press release after close of trading 25 July 2024 : Financial results for Q2 et H1 2024 ‚Äì Press release after close of trading: Financial results for Q2 et H1 2024 ‚Äì Press release after close of trading 24 October 2024 : Financial results for Q3 2024 ‚Äì Press release after close of tradingInvestor Relations and Individual Shareholders Contactinvestors@tarkett.comMedia contactsBrunswick - tarkett@brunswickgroup.com - Tel.: +33 (0) 1 53 96 83 83Hugues Bo√´ton ‚Äì Tel.: +33 (0) 6 79 99 27 15 ‚Äì Benoit Grange ‚Äì Tel.: +33 (0) 6 14 45 09 26About TarkettWith a 140-year history  Tarkett is a worldwide leader in innovative and durable flooring and sports surface solutions  generating net sales of 3.4 billion euros in 2022. The Group has 12 000 employees and 25 R&D centres  8 recycling centres and 34 production sites. Tarkett designs and manufactures solutions for hospitals  schools  housing  hotels  offices  shops and sports fields  serving customers in more than 100 countries. To build ‚ÄúThe Way to Better Floors‚Äù  the Group is committed to the circular economy and sustainable development  in line with its Tarkett Human-Conscious Design¬Æ approach. Tarkett is listed on the Euronext regulated market (compartment B  ISIN: FR0004188670  ticker: TKTT). www.tarkett-group.com***Appendices1/ Definition of alternative performance indicators (not defined under IFRS)Organic growth measures the change in revenue as compared with the same period in the prior year  outside of the exchange rate effect and changes in scope. The foreign exchange effect is obtained by applying the prior year‚Äôs exchange rate to sales for the current year and calculating the difference with sales for the current year. It also includes the effect of price adjustments in the CIS countries intended to offset the change in local currencies against the euro.measures the change in revenue as compared with the same period in the prior year  outside of the exchange rate effect and changes in scope. The foreign exchange effect is obtained by applying the prior year‚Äôs exchange rate to sales for the current year and calculating the difference with sales for the current year. It also includes the effect of price adjustments in the CIS countries intended to offset the change in local currencies against the euro. The scope effect is composed of: current year sales by entities not included in the scope of consolidation in the same period of the prior year  until the anniversary of their consolidation. The reduction in sales due to discontinued operations that are not included in the current year's scope of consolidation but were included in sales for the same period of the prior year  until the anniversary of their disposal.is composed of:In millions of euros 2023 Revenue 2022 Revenue Change Of which volume Of which selling prices Of which CIS selling prices Of which exchange rate effect Of which scope effect Group Total Q1 698.5 684.7 +2.0%-7.8%+6.9%+0.4% +2.3% +0.2% Of which organic growth -0.9% Of which selling price increases +7.3% Group Total Q2 909.8 879.3 +3.5%+2.4%+5.2%-1.2% -2.9% +0.0% Of which organic growth +7.5% Of which selling price increases +4.0% Group Total S1 1 608.3 1 564.0 +2.8%-2.1%+5.9%-0.4% -0.7% +0.1% Of which organic growth +3.9% Of which selling price increases +5.5% Group Total Q3 984.3 1 005.4 -2.1%+2.8%+3.1%-0.2% -7.8% +0.0% Of which organic growth +6.0% Of which selling price increases +2.9% Group Total 9M 2 592.6 2 569.4 +0.9%-0.2%+4.8%-0.3% -3.5% +0.1% Of which organic growth +4.7% Of which selling price increases +4.5%Revenue in millions of euros 9M 2023 9M 2022 Change Of which organic growth Organic change incl. CIS price changes (1) EMEA 652.5 707.4 -7.8% -6.1% -6.1% North America 686.4 702.2 -2.2% -0.5% -0.5% CIS  APAC & Latin America 443.5 482.1 -8.0% +4.7% +2.7% Sports 810.1 677.7 +19.5% +21.3% +21.3% Group Total 2 592.6 2 569.4 +0.9% +4.7% +4.3%2/ Bridge in millions of euros 2023Revenue by segmentQ3 2022 1 005.4 +/- EMEA -8.3 +/- North America -6.6 +/- CIS  APAC & Latin America +20.6 +/- Sports +54.2 Q3 2023 at constant scope and exchange rates 1 065.3 +/- Scope effect +0.0 +/- Currencies -37.1 +/- ‚ÄúLag effect‚Äù in CIS -43.9 Q3 2023 984.39M 2022 2 569.4 +/- EMEA -43.3 +/- North America -3.5 +/- CIS  APAC & Latin America +22.6 +/- Sports +144.4 9M 2023 Like-for-Like 2 318.6 +/- Scope effect +1.7 +/- Currencies -40.3 +/- ‚ÄúLag effect‚Äù in CIS +99.3 9M 2023 2 592.6***Attachment,neutral,0.06,0.93,0.01,mixed,0.41,0.24,0.35,True,English,"['Organic sales growth', 'Q3 2023 Revenue', '+6.0% Record revenue', 'Good levels', 'CIS countries', 'Commercial segments', 'North America', 'Sports', 'activity', 'resilience', 'October', 'commercial carpet production site', 'The North American segment', 'unfavourable exchange effects', 'The Supervisory Board', 'new construction projects', 'unfavourable product mix', 'raw material costs', 'first nine months', 'selective price reduction', 'unfavourable currency effect', 'two main categories', 'negative currency effect', 'favourable economic environment', 'Selling price adjustments', 'alternative performance indicators', 'sales price variations', 'sales price effects', 'selling price increases', 'negative organic growth', 'organic growth‚Äù indicator', 'The EMEA segment', 'Organic sales growth', 'Latin America segment', 'Third quarter 2023 results', 'Commercial segment volumes', 'Sports net revenue', '+15.8% organic growth', 'total effect', 'currency fluctuations', 'Selling prices', 'economic context', 'expensive categories', 'net sales', 'Commercial segments', 'Sales prices', 'LVT sales', 'good performance', 'Residential segment', 'The Group', 'Good levels', 'last year', 'same period', 'sustained pace', 'high basis', 'interest rates', 'vinyl rolls', 'vinyl products', 'other hand', 'significant decline', 'marked drop', 'cost base', 'artificial turf', 'athletics tracks', 'short-term objectives', 'financial year', 'Hospitality segments', '984 million euros', '209 million euros', '228 million euros', '166 million euros', '381 million euros', 'Record revenue', 'consolidated revenue', 'sluggish demand', 'dynamic market', 'Euronext Paris', 'CIS region', 'education sector', 'complex market', 'business volumes', 'high inflation', 'CIS countries', 'strong activity', 'residential market', 'Q3 2023 Revenue', 'resilience', 'devaluation', 'dollar', 'slowdown', 'comparison', 'Q2', 'Tarkett', 'TKTT', 'IFRS', 'detail', 'Appendix', 'document', 'millions', 'APAC', 'renovation', 'area', 'parquet', 'health', 'carpets', 'offices', 'depreciation', 'Europe', 'improvement', 'Russia', 'Ukraine', 'Asia', 'China', 'Suzhou', 'Outlook']",2023-10-19,2023-10-20,marketscreener.com
31624,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2763468/0/en/Q3-2023-Revenue-Organic-sales-growth-of-6-0-Record-revenue-in-Sports-Good-levels-of-activity-in-CIS-countries-and-resilience-in-the-Commercial-segments-in-North-America.html,Q3 2023 Revenue: Organic sales growth of +6.0% Record revenue in Sports Good levels of activity in CIS countries and resilience in the Commercial segments in North America,Q3 2023 Revenue:   Organic sales growth of +6.0%   Record revenue in Sports    Good levels of activity in CIS countries and resilience in the......,Q3 2023 Revenue:Organic sales growth of +6.0%Record revenue in SportsGood levels of activity in CIS countries and resilience in the Commercial segments in North AmericaThird quarter 2023 resultsRevenue down -2.1% compared to Q3 2022 given the unfavourable exchange effects (-8.1%) due to the devaluation of the dollar and the roubleOrganic growth of +6.0% driven by strong activity in Sports and volumes up in CISIn EMEA  volumes are down slightly compared to last year  affected by sluggish demandIn North America  the slowdown in the Residential and Hospitality segments is partially offset by the good performance in the Commercial segmentsGood level of activity in CIS with volumes greater than those in Q3 2022  which nevertheless remain lower than those in 2021 over the same periodIn a dynamic market  Sports continues to grow at a sustained pace (+15.8% organic) despite a high basis for comparison in Q3 2022Selling prices are generally stable compared to Q2 2023Paris  19 October 2023: The Supervisory Board of Tarkett (Euronext Paris: FR0004188670 TKTT)  which met today  reviewed the Group‚Äôs consolidated revenue for the third quarter of 2023.The Group uses alternative performance indicators (not defined under IFRS)  described in detail in the Appendix of this document:Revenue in millions of euros Q3 2023 Q3 2022 Change Of which organic growth EMEA 209.4 220.4 -5.0% -3.8% North America 228.4 251.4 -9.2% -2.6% CIS  APAC & Latin America 165.6 191.1 -13.3% +10.8% Sports 380.8 342.5 +11.2% +15.8% Group Total 984.3 1 005.4 -2.1% +6.0%Revenue for the third quarter of 2023Net revenue of the Group amounted to 984 million euros  down -2.1% compared to the third quarter of 2022. Organic growth was +6.0% (or +5.7% including sales price variations in the CIS region(1) ). The total effect of the selling price increases implemented across all segments is +3.1% on average compared to the third quarter of 2022. Sales prices were generally stable compared to Q2 2023.The EMEA segment achieved a net revenue of 209 million euros  down -5.0% compared to the third quarter of 2022  including an unfavourable currency effect of -1.2% and negative organic growth of -3.8%. The economic context of high inflation and interest rates is penalising renovation and new construction projects throughout the area. Activity in the Residential segment was significantly lower than in 2022 due to an unfavourable product mix  with vinyl rolls performing better than more expensive categories such as parquet. Activity in the Commercial segments fell only slightly compared to 2022 thanks to the good performance of volumes in the two main categories  vinyl products for the health and education sector and carpets for offices.The North American segment generated net revenue of 228 million euros  down -9.2% compared to the third quarter of 2022  with a negative currency effect linked to the depreciation of the dollar against the euro (-6.6%) and negative organic growth of -2.6%. Commercial segment volumes (offices  healthcare  education) are up slightly compared to 2022 in a market that is currently better positioned than in Europe. On the other hand  business volumes in the Residential and Hospitality segments are down in a market where demand is still suffering from inflation and the level of interest rates.Net revenue in the CIS  APAC and Latin America segment amounted to 166 million euros  down -13.3% compared to the third quarter of 2022  with a very unfavourable currency effect mainly resulting from the depreciation of the rouble (-31% compared to Q3 2022). Activity is well positioned with organic growth of +10.8% (excluding sales price effects in CIS countries). It benefited from the improvement in volumes in Russia and Ukraine compared to Q3 2022  which was marked by a significant decline compared with 2021. These countries respectively represent 8% and 0.8% of the Group‚Äôs net sales over the quarter. In a complex market  selective price reduction contributed to the good performance of vinyl roll and LVT sales for the residential market. In Asia  activity was down  mainly due to a marked drop in sales in China. To optimise its cost base  the Group closed the commercial carpet production site located in Suzhou (China). Latin America remains slightly down compared to 2022 but volumes improved over the quarter in a more favourable economic environment.Sports net revenue continued to grow at a sustained pace  amounting to 381 million euros  up +11.2%  of which +15.8% organic growth compared to the third quarter of 2022. The market continues to be very dynamic  particularly for artificial turf and athletics tracks in North America. The segment also benefited from price increases which fully offset inflation in raw material costs.1) Selling price adjustments in the CIS countries are historically intended to offset currency fluctuations and are therefore excluded from the ‚Äúorganic growth‚Äù indicator (see Appendix 1)Outlook for the end of 2023 and short-term objectivesOver the first nine months of the financial year  the Group‚Äôs organic growth was positive (+4.7%).In an uncertain geopolitical and macroeconomic environment  Tarkett expects a further slowdown in demand in EMEA and a possible shift in business segment activity in North America.Nevertheless  the favourable business outlook in Sports should allow to compensate for this slowdown and to achieve a significantly higher Adjusted EBITDA  in value and in margin  compared to 2022.The Group expects a start to 2024 marked by low business volumes in EMEA  where market indicators continue to decline.In North America  the Commercial segments have so far been well oriented. However  market indicators reflect sluggish activity  which could lag behind in the context of maintaining high interest rates. Similarly  the residential market shows no signs of recovery.Conversely  activities in the Sports segment are still benefiting from a buoyant market which should allow the Group to continue to grow in this segment in 2024  albeit at a more moderate pace.Tarkett will continue to closely monitor energy price developments and possible impacts on the price of its raw materials.In a context of slowing volumes in the flooring business activity  the Group continues to adapt its production and cost structure. Furthermore  thanks to the rigorous control of working capital requirements  it anticipates an improvement in cash generation and a reduction in its debt.This press release may contain forward-looking statements. These statements do not constitute forecasts regarding results or any other performance indicator  but rather trends or targets. These statements are by their nature subject to risks and uncertainties as described in the Company‚Äôs Registration Document available on its website ( https://www.tarkett-group.com/en/category/urd/ ). They do not reflect the future performance of the Company  which may differ significantly. The Company does not undertake to provide updates to these statements.Financial calendar15 February 2024 : Financial results for Q4 and FY2023 ‚Äì Press release after close of trading: Financial results for Q4 and FY2023 ‚Äì Press release after close of trading 25 April 2024: Financial results for Q1 2024 ‚Äì Press release after close of tradingFinancial results for Q1 2024 ‚Äì Press release after close of trading 25 July 2024 : Financial results for Q2 et H1 2024 ‚Äì Press release after close of trading: Financial results for Q2 et H1 2024 ‚Äì Press release after close of trading 24 October 2024 : Financial results for Q3 2024 ‚Äì Press release after close of tradingInvestor Relations and Individual Shareholders Contactinvestors@tarkett.comMedia contactsBrunswick - tarkett@brunswickgroup.com - Tel.: +33 (0) 1 53 96 83 83Hugues Bo√´ton ‚Äì Tel.: +33 (0) 6 79 99 27 15 ‚Äì Benoit Grange ‚Äì Tel.: +33 (0) 6 14 45 09 26About TarkettWith a 140-year history  Tarkett is a worldwide leader in innovative and durable flooring and sports surface solutions  generating net sales of 3.4 billion euros in 2022. The Group has 12 000 employees and 25 R&D centres  8 recycling centres and 34 production sites. Tarkett designs and manufactures solutions for hospitals  schools  housing  hotels  offices  shops and sports fields  serving customers in more than 100 countries. To build ‚ÄúThe Way to Better Floors‚Äù  the Group is committed to the circular economy and sustainable development  in line with its Tarkett Human-Conscious Design¬Æ approach. Tarkett is listed on the Euronext regulated market (compartment B  ISIN: FR0004188670  ticker: TKTT). www.tarkett-group.com***Appendices1/ Definition of alternative performance indicators (not defined under IFRS)Organic growth measures the change in revenue as compared with the same period in the prior year  outside of the exchange rate effect and changes in scope. The foreign exchange effect is obtained by applying the prior year‚Äôs exchange rate to sales for the current year and calculating the difference with sales for the current year. It also includes the effect of price adjustments in the CIS countries intended to offset the change in local currencies against the euro.measures the change in revenue as compared with the same period in the prior year  outside of the exchange rate effect and changes in scope. The foreign exchange effect is obtained by applying the prior year‚Äôs exchange rate to sales for the current year and calculating the difference with sales for the current year. It also includes the effect of price adjustments in the CIS countries intended to offset the change in local currencies against the euro. The scope effect is composed of: current year sales by entities not included in the scope of consolidation in the same period of the prior year  until the anniversary of their consolidation. The reduction in sales due to discontinued operations that are not included in the current year's scope of consolidation but were included in sales for the same period of the prior year  until the anniversary of their disposal.is composed of:In millions of euros 2023 Revenue 2022 Revenue Change Of which volume Of which selling prices Of which CIS selling prices Of which exchange rate effect Of which scope effect Group Total Q1 698.5 684.7 +2.0%-7.8%+6.9%+0.4% +2.3% +0.2% Of which organic growth -0.9% Of which selling price increases +7.3% Group Total Q2 909.8 879.3 +3.5%+2.4%+5.2%-1.2% -2.9% +0.0% Of which organic growth +7.5% Of which selling price increases +4.0% Group Total S1 1 608.3 1 564.0 +2.8%-2.1%+5.9%-0.4% -0.7% +0.1% Of which organic growth +3.9% Of which selling price increases +5.5% Group Total Q3 984.3 1 005.4 -2.1%+2.8%+3.1%-0.2% -7.8% +0.0% Of which organic growth +6.0% Of which selling price increases +2.9% Group Total 9M 2 592.6 2 569.4 +0.9%-0.2%+4.8%-0.3% -3.5% +0.1% Of which organic growth +4.7% Of which selling price increases +4.5%Revenue in millions of euros 9M 2023 9M 2022 Change Of which organic growth Organic change incl. CIS price changes (1) EMEA 652.5 707.4 -7.8% -6.1% -6.1% North America 686.4 702.2 -2.2% -0.5% -0.5% CIS  APAC & Latin America 443.5 482.1 -8.0% +4.7% +2.7% Sports 810.1 677.7 +19.5% +21.3% +21.3% Group Total 2 592.6 2 569.4 +0.9% +4.7% +4.3%2/ Bridge in millions of euros 2023Revenue by segmentQ3 2022 1 005.4 +/- EMEA -8.3 +/- North America -6.6 +/- CIS  APAC & Latin America +20.6 +/- Sports +54.2 Q3 2023 at constant scope and exchange rates 1 065.3 +/- Scope effect +0.0 +/- Currencies -37.1 +/- ‚ÄúLag effect‚Äù in CIS -43.9 Q3 2023 984.39M 2022 2 569.4 +/- EMEA -43.3 +/- North America -3.5 +/- CIS  APAC & Latin America +22.6 +/- Sports +144.4 9M 2023 Like-for-Like 2 318.6 +/- Scope effect +1.7 +/- Currencies -40.3 +/- ‚ÄúLag effect‚Äù in CIS +99.3 9M 2023 2 592.6***Attachment,neutral,0.02,0.97,0.0,mixed,0.41,0.24,0.35,True,English,"['Organic sales growth', 'Q3 2023 Revenue', '+6.0% Record revenue', 'Good levels', 'CIS countries', 'Commercial segments', 'North America', 'Sports', 'activity', 'resilience', 'commercial carpet production site', 'The North American segment', 'unfavourable exchange effects', 'The Supervisory Board', 'new construction projects', 'unfavourable product mix', 'raw material costs', 'first nine months', 'selective price reduction', 'unfavourable currency effect', 'two main categories', 'negative currency effect', 'favourable economic environment', 'Selling price adjustments', 'alternative performance indicators', 'sales price variations', 'sales price effects', 'selling price increases', 'negative organic growth', 'organic growth‚Äù indicator', 'The EMEA segment', 'Organic sales growth', 'Latin America segment', 'Third quarter 2023 results', 'Commercial segment volumes', 'Sports net revenue', '+15.8% organic growth', 'total effect', 'currency fluctuations', 'Selling prices', 'economic context', 'expensive categories', 'net sales', 'Commercial segments', 'Sales prices', 'LVT sales', 'good performance', 'Residential segment', 'The Group', 'Good levels', 'last year', 'same period', 'sustained pace', 'high basis', 'interest rates', 'vinyl rolls', 'vinyl products', 'other hand', 'significant decline', 'marked drop', 'cost base', 'artificial turf', 'athletics tracks', 'short-term objectives', 'financial year', 'Hospitality segments', '984 million euros', '209 million euros', '228 million euros', '166 million euros', '381 million euros', 'Record revenue', 'consolidated revenue', 'sluggish demand', 'dynamic market', 'Euronext Paris', 'CIS region', 'education sector', 'complex market', 'business volumes', 'high inflation', 'CIS countries', 'strong activity', 'residential market', 'Q3 2023 Revenue', 'resilience', 'devaluation', 'dollar', 'slowdown', 'comparison', 'Q2', 'Tarkett', 'TKTT', 'IFRS', 'detail', 'Appendix', 'document', 'millions', 'APAC', 'renovation', 'area', 'parquet', 'health', 'carpets', 'offices', 'depreciation', 'Europe', 'improvement', 'Russia', 'Ukraine', 'Asia', 'China', 'Suzhou', 'Outlook']",2023-10-19,2023-10-20,globenewswire.com
31625,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2762972/0/en/Press-Release-Sanofi-delivers-first-medicines-from-Global-Health-Unit-s-Impact-brand-portfolio.html,Press Release: Sanofi delivers first medicines from Global Health Unit‚Äôs Impact brand portfolio,Sanofi delivers first medicines from Global Health Unit‚Äôs Impact brand portfolio      Paris  October 19  2023. Sanofi has delivered the first medicines......,"Sanofi delivers first medicines from Global Health Unit‚Äôs Impact brand portfolioParis  October 19  2023. Sanofi has delivered the first medicines from its Global Health Unit‚Äôs not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis  a potentially lethal disease often underdiagnosed on the African continent. With this first shipment to Djibouti  Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines  vaccines and healthcare for underserved populations.Sanofi's social model to broaden access is channeled through its Global Health Unit (GHU). The first global initiative of its kind  Sanofi‚Äôs GHU aims to provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs. To that point  the GHU created Impact  a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi  some of which are considered ""essential"" by the World Health Organization (WHO). The Impact medicines cover a wide range of therapeutic areas  including diabetes  cardiovascular disease  tuberculosis  malaria and cancer.Jon FairestHead  Global Health Unit  Sanofi‚ÄúI'm delighted to see the very first Impact brand medicine  Enoxaparin Sodium Impact  arrive on Djibouti soil. This is an important milestone in Sanofi‚Äôs long-term objective to reach 2 million people with noncommunicable diseases in underserved populations by 2030. But providing access to quality medicines and sustainable healthcare to people in the 40 most underserved countries is not a simple task. It requires cross-sector partnerships on a global  regional  and importantly  on a local scale ‚Äì work Sanofi does on the ground with the GHU teams. After Djibouti  we are now heading to Tanzania  scheduled to be the second country to receive an Impact brand medicine: Insulin Glargine Impact.‚ÄùThe delivery of Enoxaparin Sodium Impact comes months after the signature of a partnership with the Republic of Djibouti‚Äôs Caisse Nationale de S√©curit√© Sociale (CNSS)  the national social security fund. The partnership aims at improving diagnosis and management of cardiometabolic diseases and diabetes in Djibouti and to help local communities gain sustainable access to quality medicines at accessible pricing  medical training and capacity building.Deka Ahmed RoblehManaging Director  Caisse Nationale de S√©curit√© Sociale  Djibouti‚ÄúIn partnership with Sanofi‚Äôs Global Health Unit  we are working to remove barriers that limit access to quality treatment and care for noncommunicable disease patients in Djibouti. The availability of Enoxaparin Sodium Impact at accessible pricing addresses an unmet need in the management of venous thromboembolic disease  a condition often underdiagnosed. Moreover  working with Sanofi within the local community to help train healthcare professionals  drive awareness around the management of cardiometabolic diseases and diabetes  and build capacity is critical to improving patient outcomes throughout the country.‚ÄùAhead of the delivery of the first not-for-profit Impact brand medicines  Sanofi‚Äôs Global Health Unit has been working closely with local communities  authorities and non-governmental organizations to support the set up and development of sustainable healthcare systems for those who suffer from chronic diseases and require complex care  and to develop disease awareness programs. To date  over 1 800 healthcare professionals have been trained in GHU-sponsored programs globally.Tanzania is scheduled to be the second country to receive an Impact brand medicine : Insulin Glargine ImpactThe WHO estimates over 4.5 billion people  or half the world's population  lacks coverage for essential health services1. According to the WHO  noncommunicable diseases (NCDs) are responsible for 41 million people dying each year  with low- and middle-income countries accounting for 77% of all NCDs deaths2.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comSanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995  as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product  or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words ‚Äúexpects‚Äù  ‚Äúanticipates‚Äù  ‚Äúbelieves‚Äù  ‚Äúintends‚Äù  ‚Äúestimates‚Äù  ‚Äúplans‚Äù and similar expressions. Although Sanofi‚Äôs management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties  many of which are difficult to predict and generally beyond the control of Sanofi  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. These risks and uncertainties include among other things  unexpected regulatory actions or delays  or government regulation generally  that could affect the availability or commercial potential of the product  the fact that product may not be commercially successful  the uncertainties inherent in research and development  including future clinical data and analysis of existing clinical data relating to the product  including post marketing  unexpected safety  quality or manufacturing issues  competition in general  risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation  and volatile economic and market conditions  and the impact that pandemics or other global crises may have on us  our customers  suppliers  vendors  and other business partners  and the financial condition of any one of them  as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi  including those listed under ‚ÄúRisk Factors‚Äù and ‚ÄúCautionary Statement Regarding Forward-Looking Statements‚Äù in Sanofi‚Äôs annual report on Form 20-F for the year ended December 31  2022. Other than as required by applicable law  Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.1 https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)2 https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases#SnippetTabAttachment",neutral,0.11,0.88,0.01,mixed,0.21,0.29,0.49,True,English,"['Global Health Unit', 'Impact brand portfolio', 'Press Release', 'first medicines', 'Sanofi', 'Caisse Nationale de S√©curit√© Sociale', 'national social security fund', 'highest unmet medical needs', 'innovative global healthcare company', 'profit Impact brand portfolio', 'first Impact brand medicine', 'Global Health Unit', 'Enoxaparin Sodium Impact', 'deep vein thrombosis', 'Jon Fairest Head', 'Insulin Glargine Impact', 'Deka Ahmed Robleh', 'essential health services', 'life-saving vaccine protection', 'Arnaud Del√©pine', 'SNY Media Relations', 'first global initiative', 'Impact brand medicines', 'venous thromboembolic disease', 'World Health Organization', 'life-changing treatment options', 'noncommunicable disease patients', 'The Impact medicines', 'sustainable healthcare systems', 'disease awareness programs', '40 most underserved countries', 'profit brand', 'broad portfolio', 'medical training', 'unmet need', 'social model', 'social responsibility', 'anticoagulant medicine', 'lethal disease', 'cardiovascular disease', 'venous thromboembolism', 'GHU-sponsored programs', 'Investor Relations', 'first medicines', 'first shipment', 'underserved populations', 'noncommunicable diseases', 'healthcare professionals', 'quality medicines', 'African continent', 'wide range', 'therapeutic areas', 'important milestone', 'long-term objective', 'simple task', 'cross-sector partnerships', 'local scale', 'cardiometabolic diseases', 'local communities', 'accessible pricing', 'Managing Director', 'quality treatment', 'local community', 'patient outcomes', 'non-governmental organizations', 'set up', 'chronic diseases', 'one purpose', 'Corentine Driancourt', 'Felix Lauscher', 'The WHO', 'care medicines', 'middle-income countries', 'second country', 'complex care', 'sustainable access', '2 million people', 'capacity building', '4.5 billion people', '41 million people', 'NCDs deaths', 'Evan Berland', 'Sandrine Guendoul', 'Eva Schaefer-Jansen', 'GHU teams', 'Djibouti soil', 'Victor Rouault', '40 countries', '100 countries', 'Sanofi', 'Paris', 'October', 'Republic', 'commitment', 'affordable', 'vaccines', 'kind', 'point', 'unique', '30 standard', 'diabetes', 'tuberculosis', 'malaria', 'cancer', 'work', 'ground', 'Tanzania', 'delivery', 'signature', 'CNSS', 'diagnosis', 'management', 'barriers', 'availability', 'condition', 'authorities', 'development', 'date', 'coverage', 'miracles', 'science', 'lives', 'practice', 'impossible', 'millions', 'sustainability', 'center', 'ambitions', 'EURONEXT', 'NASDAQ']",2023-10-19,2023-10-20,globenewswire.com
31626,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/IP-GROUP-PLC-38908802/news/IP-Oxford-Nanopore-BioMerieux-makes-strategic-investment-in-Oxford-Nanopore-45101030/,IP : Oxford Nanopore - BioM√©rieux makes strategic investment in Oxford Nanopore -October 19  2023 at 05:43 am EDT,(marketscreener.com)   19 Oct 2023    THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION   Oxford  UK and Marcy-l'√âtoile  France  19 October 2023. Oxford Nanopore Technologies plc   the company delivering a new generation of nanopore-based molecular sensi‚Ä¶,"19 Oct 2023THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATIONOxford  UK and Marcy-l'√âtoile  France  19 October 2023. Oxford Nanopore Technologies plc (LSE: ONT) (""Oxford Nanopore"")  the company delivering a new generation of nanopore-based molecular sensing technology  and bioM√©rieux SA  a world leader in the field of in vitro diagnostics (""IVD"") today announce that bioM√©rieux is making an immediate ¬£70M investment in Oxford Nanopore.In addition  bioM√©rieux expects to make further market purchases of Oxford Nanopore's shares from time to time  up to a further 3.5% of Oxford Nanopore's shares  subject to availability and price.The investment strengthens the relationship between the two companies  further aligning with Oxford Nanopore's increasing focus on clinical markets through a partnership announced in April this year. This investment will support development for products in Oxford Nanopore's portfolio to serve IVD markets in conjunction with bioM√©rieux's commitment to advancing global public health.Through this partnership and this investment  the two companies intend to leverage Oxford Nanopore's ground-breaking nanopore-based IVD solution and bioM√©rieux's IVD expertise in R&D  Regulatory  Medical and Market Access. As part of the transaction  the two companies will establish an IVD Advisory Board to advance nanopore technology into routine clinical use.Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time  scalable features and advances in single-nucleotide sequencing accuracy of this technology make it ideal for the rapid and cost-effective characterization of pathogens in clinical samples.Together  the companies are driving to meet a significant unmet need in the clinical and diagnostic markets- an opportunity where nanopore sequencing is uniquely suited to deliver impact where information-rich  rapid  accessible  and affordable sequencing are critical.Oxford Nanopore reconfirms its guidance to be adjusted EBITDA breakeven by the end of 2026.Gordon Sanghera  Oxford Nanopore Technologies Chief Executive Officer  commented: ""With bioM√©rieux's strategic investment and our shared commitment to innovation  we are poised to accelerate the development of nanopore-based IVD solutions. This investment will enable us to deliver rapid  accessible  and affordable clinical tools more quickly to address unmet needs and improve healthcare worldwide.""Pierre Boulud  bioM√©rieux CEO  commented: ""This investment will reinforce our existing partnership with Oxford Nanopore and provide more resources for the development of innovative IVD solutions. Drawing on our six decades of expertise in the in vitro diagnostic space  we consider that the new generation of sequencing technology developed by Oxford Nanopore holds promise to answer future diagnostic needs and will further improve patient care  in particular against the ever-growing infectious diseases threat.""Transaction structurebioM√©rieux has agreed to subscribe for 29 025 326 ordinary shares (which equates to 3.5% of Oxford Nanopore's voting rights as at 13 October 2023) in Oxford Nanopore at a subscription price of 238.08p per share (the ""Subscription"")  conditional only upon Admission (as defined below) occurring. This represents a total investment of nearly ¬£70 million.Applications will be made to the Financial Conduct Authority and the London Stock Exchange for the shares issued pursuant to the Subscription to be admitted to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange (""Admission"").Admission is expected to occur on Monday 23 October 2023.The Subscription price of 238.08p per share is equal to the 6-month volume weighted average price as at 13 October 2023.As part of the Subscription  subject to certain customary exceptions  bioM√©rieux undertakes to:For a period of 5 years  not acquire or agree to acquire any interests in Oxford Nanopore's shares which would result in it and its affiliates having an interest exceeding 9.9% of the issued share capital of Oxford Nanopore (provided that this restriction shall be suspended for so long as Oxford Nanopore is in an offer period (included in the Definitions of the City Code on Takeovers and Mergers (the ""Code""))  and in the case of an offer period which is commenced by an announcement under Rule 2.4 of the Code  for a one month period after the cessation of such offer period);not dispose of any shares in Oxford Nanopore for 12 months  subject to certain limited exceptions; andcomply with certain orderly marketing obligations for a period of four years after expiry of the 12-months lock-up period  subject to certain limited exceptions.About Oxford Nanopore TechnologiesOxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything  by anyone  anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time  high-performance  accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer  plants  animals  bacteria  viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.www.nanoporetech.comForward-looking statementsThis announcement contains certain forward-looking statements. For example  statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as ""aim""  ""plan""  ""expect""  ""intend""  ""anticipate""  ""believe""  ""estimate""  ""target""  and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition  and by definition address matters that are  to different degrees  uncertain. Our results could be affected by macroeconomic conditions  the COVID-19 pandemic  delays in our receipt of components or our delivery of products to our customers  suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.BIOM√âRIEUX GAME CHANGERS FOR 60 YEARSPioneering DiagnosticsA world leader in the field of in vitro diagnostics since 1963  bioM√©rieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022  revenues reached ‚Ç¨3.6 billion  with over 90% of sales outside of France.bioM√©rieux provides diagnostic solutions (systems  reagents  software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food  pharmaceutical and cosmetic products.www.biomerieux.combioM√©rieux is listed on the Euronext Paris stock market.Symbol: BIM - ISIN Code: FR0013280286Reuters: BIOX.PA/Bloomberg: BIM.FPCONTACTSOxford Nanopore Media Relations Teneo (communication adviser to the Company) media@nanoporetech.com Tom Murray  Olivia Peters Investors Relations Tel.: +44 (0) 20 7353 4200 ir@nanoporetech.com OxfordNanoporeTechnologies@teneo.combioM√©rieux Media Relations Investors Relations Olivier Rescani√®re Aymeric Fichet Tel.: +33 (0)4 78 87 21 99 Tel.: +33 (0)4 78 87 20 00 media@biomerieux.com investor.relations@biomerieux.comThis announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU no. 596/2014)  which forms part of English law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of the Company is Hannah Coote  Company Secretary of Oxford Nanopore Technologies plc.END",neutral,0.04,0.95,0.01,positive,0.65,0.34,0.01,True,English,"['Oxford Nanopore', 'BioM√©rieux', 'strategic investment', 'IP', 'October', 'Oxford Nanopore Technologies Chief Executive Officer', 'unique real-time, scalable features', 'growing infectious diseases threat', 'ground-breaking nanopore-based IVD solution', 'nanopore-based molecular sensing technology', 'Oxford Nanopore Technologies plc', ""Oxford Nanopore Technologies' goal"", 'global public health', 'Financial Conduct Authority', 'London Stock Exchange', 'standard listing segment', 'orderly marketing obligations', 'nanopore-based IVD solutions', 'IVD Advisory Board', 'innovative IVD solutions', 'significant unmet need', 'routine clinical use', 'single-nucleotide sequencing accuracy', 'vitro diagnostic space', 'future diagnostic needs', 'one month period', '12-months lock-up period', 'affordable clinical tools', 'immediate ¬£70M investment', 'bioM√©rieux SA', 'bioM√©rieux CEO', 'Nanopore-based sequencing', 'unmet needs', 'affordable sequencing', 'diagnostic markets', 'nanopore technology', 'nanopore sequencing', 'IVD markets', 'vitro diagnostics', 'sequencing technology', 'protein nanopore', 'clinical markets', 'novel technology', 'clinical samples', 'IVD expertise', 'INSIDE INFORMATION', ""Marcy-l'√âtoile"", 'new generation', 'world leader', 'market purchases', 'increasing focus', 'R&D', 'Market Access', 'long DNA', 'electrical current', 'nucleic acids', 'resulting signal', 'specific DNA', 'cost-effective characterization', 'Gordon Sanghera', 'Pierre Boulud', 'six decades', 'patient care', 'voting rights', 'Official List', 'main market', 'listed securities', '6-month volume', 'customary exceptions', 'offer period', 'limited exceptions', 'widest benefits', 'two companies', 'average price', 'strategic investment', 'Transaction structure', 'total investment', 'four years', 'existing partnership', 'share capital', 'City Code', 'Monday 23 October', '29,025,326 ordinary shares', 'subscription price', '5 years', '19 October', '13 October', 'ANNOUNCEMENT', 'UK', 'France', 'LSE', 'company', 'field', 'addition', 'availability', 'relationship', 'April', 'development', 'products', 'portfolio', 'conjunction', 'commitment', 'Regulatory', 'Medical', 'analysis', 'fragments', 'changes', 'sequence', 'advances', 'rapid', 'pathogens', 'opportunity', 'impact', 'guidance', 'EBITDA', 'end', 'innovation', 'healthcare', 'resources', 'promise', 'Admission', 'Applications', 'interests', 'affiliates', 'restriction', 'Definitions', 'Takeovers', 'Mergers', 'case', 'Rule', 'cessation', '12 months', 'expiry', 'society']",2023-10-19,2023-10-20,marketscreener.com
31627,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SANOFI-4698/news/Press-Release-Sanofi-delivers-first-medicines-from-Global-Health-Unit-s-Impact-brand-portfolio-45101172/,Press Release: Sanofi delivers first medicines from Global Health Unit‚Äôs Impact brand portfolio -October 19  2023 at 06:01 am EDT,(marketscreener.com) Sanofi delivers first medicines from Global Health Unit‚Äôs Impact brand portfolio Paris  October 19  2023. Sanofi has delivered the first medicines from its Global Health Unit‚Äôs not-for-profit Impact brand portfolio to the Republic of Djib‚Ä¶,"Sanofi delivers first medicines from Global Health Unit‚Äôs Impact brand portfolioParis  October 19  2023. Sanofi has delivered the first medicines from its Global Health Unit‚Äôs not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis  a potentially lethal disease often underdiagnosed on the African continent. With this first shipment to Djibouti  Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines  vaccines and healthcare for underserved populations.Sanofi's social model to broaden access is channeled through its Global Health Unit (GHU). The first global initiative of its kind  Sanofi‚Äôs GHU aims to provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs. To that point  the GHU created Impact  a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi  some of which are considered ""essential"" by the World Health Organization (WHO). The Impact medicines cover a wide range of therapeutic areas  including diabetes  cardiovascular disease  tuberculosis  malaria and cancer.Jon FairestHead  Global Health Unit  Sanofi‚ÄúI'm delighted to see the very first Impact brand medicine  Enoxaparin Sodium Impact  arrive on Djibouti soil. This is an important milestone in Sanofi‚Äôs long-term objective to reach 2 million people with noncommunicable diseases in underserved populations by 2030. But providing access to quality medicines and sustainable healthcare to people in the 40 most underserved countries is not a simple task. It requires cross-sector partnerships on a global  regional  and importantly  on a local scale ‚Äì work Sanofi does on the ground with the GHU teams. After Djibouti  we are now heading to Tanzania  scheduled to be the second country to receive an Impact brand medicine: Insulin Glargine Impact.‚ÄùThe delivery of Enoxaparin Sodium Impact comes months after the signature of a partnership with the Republic of Djibouti‚Äôs Caisse Nationale de S√©curit√© Sociale (CNSS)  the national social security fund. The partnership aims at improving diagnosis and management of cardiometabolic diseases and diabetes in Djibouti and to help local communities gain sustainable access to quality medicines at accessible pricing  medical training and capacity building.Deka Ahmed RoblehManaging Director  Caisse Nationale de S√©curit√© Sociale  Djibouti‚ÄúIn partnership with Sanofi‚Äôs Global Health Unit  we are working to remove barriers that limit access to quality treatment and care for noncommunicable disease patients in Djibouti. The availability of Enoxaparin Sodium Impact at accessible pricing addresses an unmet need in the management of venous thromboembolic disease  a condition often underdiagnosed. Moreover  working with Sanofi within the local community to help train healthcare professionals  drive awareness around the management of cardiometabolic diseases and diabetes  and build capacity is critical to improving patient outcomes throughout the country.‚ÄùAhead of the delivery of the first not-for-profit Impact brand medicines  Sanofi‚Äôs Global Health Unit has been working closely with local communities  authorities and non-governmental organizations to support the set up and development of sustainable healthcare systems for those who suffer from chronic diseases and require complex care  and to develop disease awareness programs. To date  over 1 800 healthcare professionals have been trained in GHU-sponsored programs globally.Tanzania is scheduled to be the second country to receive an Impact brand medicine : Insulin Glargine ImpactThe WHO estimates over 4.5 billion people  or half the world's population  lacks coverage for essential health services1. According to the WHO  noncommunicable diseases (NCDs) are responsible for 41 million people dying each year  with low- and middle-income countries accounting for 77% of all NCDs deaths2.About SanofiWe are an innovative global healthcare company  driven by one purpose: we chase the miracles of science to improve people‚Äôs lives. Our team  across some 100 countries  is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally  while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comInvestor RelationsEva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.comArnaud Del√©pine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comCorentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comTarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comSanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995  as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product  or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words ‚Äúexpects‚Äù  ‚Äúanticipates‚Äù  ‚Äúbelieves‚Äù  ‚Äúintends‚Äù  ‚Äúestimates‚Äù  ‚Äúplans‚Äù and similar expressions. Although Sanofi‚Äôs management believes that the expectations reflected in such forward-looking statements are reasonable  investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties  many of which are difficult to predict and generally beyond the control of Sanofi  that could cause actual results and developments to differ materially from those expressed in  or implied or projected by  the forward-looking information and statements. These risks and uncertainties include among other things  unexpected regulatory actions or delays  or government regulation generally  that could affect the availability or commercial potential of the product  the fact that product may not be commercially successful  the uncertainties inherent in research and development  including future clinical data and analysis of existing clinical data relating to the product  including post marketing  unexpected safety  quality or manufacturing issues  competition in general  risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation  and volatile economic and market conditions  and the impact that pandemics or other global crises may have on us  our customers  suppliers  vendors  and other business partners  and the financial condition of any one of them  as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi  including those listed under ‚ÄúRisk Factors‚Äù and ‚ÄúCautionary Statement Regarding Forward-Looking Statements‚Äù in Sanofi‚Äôs annual report on Form 20-F for the year ended December 31  2022. Other than as required by applicable law  Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.1 https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)2 https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases#SnippetTabAttachment",neutral,0.05,0.94,0.01,mixed,0.21,0.29,0.49,True,English,"['Global Health Unit', 'Impact brand portfolio', 'Press Release', 'first medicines', 'Sanofi', 'October', '06', '01', 'Caisse Nationale de S√©curit√© Sociale', 'national social security fund', 'highest unmet medical needs', 'innovative global healthcare company', 'profit Impact brand portfolio', 'first Impact brand medicine', 'Global Health Unit', 'Enoxaparin Sodium Impact', 'deep vein thrombosis', 'Jon Fairest Head', 'Insulin Glargine Impact', 'Deka Ahmed Robleh', 'essential health services', 'life-saving vaccine protection', 'Arnaud Del√©pine', 'SNY Media Relations', 'first global initiative', 'Impact brand medicines', 'venous thromboembolic disease', 'World Health Organization', 'life-changing treatment options', 'noncommunicable disease patients', 'The Impact medicines', 'sustainable healthcare systems', 'disease awareness programs', '40 most underserved countries', 'profit brand', 'broad portfolio', 'medical training', 'unmet need', 'social model', 'social responsibility', 'anticoagulant medicine', 'lethal disease', 'cardiovascular disease', 'venous thromboembolism', 'GHU-sponsored programs', 'Investor Relations', 'first medicines', 'first shipment', 'underserved populations', 'noncommunicable diseases', 'healthcare professionals', 'quality medicines', 'African continent', 'wide range', 'therapeutic areas', 'important milestone', 'long-term objective', 'simple task', 'cross-sector partnerships', 'local scale', 'cardiometabolic diseases', 'local communities', 'accessible pricing', 'Managing Director', 'quality treatment', 'local community', 'patient outcomes', 'non-governmental organizations', 'set up', 'chronic diseases', 'one purpose', 'Corentine Driancourt', 'Felix Lauscher', 'The WHO', 'care medicines', 'middle-income countries', 'second country', 'complex care', 'sustainable access', '2 million people', 'capacity building', '4.5 billion people', '41 million people', 'NCDs deaths', 'Evan Berland', 'Sandrine Guendoul', 'Eva Schaefer-Jansen', 'GHU teams', 'Djibouti soil', 'Victor Rouault', '40 countries', '100 countries', 'Sanofi', 'Paris', 'October', 'Republic', 'commitment', 'affordable', 'vaccines', 'kind', 'point', 'unique', '30 standard', 'diabetes', 'tuberculosis', 'malaria', 'cancer', 'work', 'ground', 'Tanzania', 'delivery', 'signature', 'CNSS', 'diagnosis', 'management', 'barriers', 'availability', 'condition', 'authorities', 'development', 'date', 'coverage', 'miracles', 'science', 'lives', 'practice', 'impossible', 'millions', 'sustainability', 'center', 'ambitions', 'EURONEXT', 'NASDAQ']",2023-10-19,2023-10-20,marketscreener.com
31628,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/10/19/2763460/0/en/GUERBET-Revenue-at-30-September-2023.html,GUERBET : Revenue at 30 September 2023.,Revenue at 30 September 2023  Activity  9-month revenue: ‚Ç¨573.9 million  up 2.7% at......,Revenue at 30 September 2023Activity9-month revenue: ‚Ç¨573.9 million  up 2.7% at CER 1Third-quarter sales remained very strong in Asia (+15.2% at CER)  were stable in EMEA (+0.6%) and showed a smaller decline in the Americas (-5.2%)Expecting double-digit activity growth in the fourth quarter of 2023 thanks to the surge in sales of EluciremTM and strong momentum in Interventional ImagingFinancial targets confirmed2023 revenue up by more than 5% like-for-like and at CERRestated EBITDA margin2 of around 11% in 2023  before returning in 2024 to a higher level than in 2021 (14.4%)Villepinte  19 October 2023: Guerbet (FR0000032526 GBT)  a global specialist in contrast agents and solutions for medical imaging  is publishing its revenue for the period to 30 September 2023. Over the first nine months of the year  Group sales came to ‚Ç¨573.9 million  up 0.8% on the same period in 2022. Business activity reflected a negative forex effect of ‚Ç¨10.4 million. At CER1  revenue for the first nine months grew by 2.7%.Sales in the third quarter of 2023 came to ‚Ç¨195.2 million  up 2.3% at CER  after rising by 2.8% during the first half of the financial year. Taking into account the expected ramp-up in EluciremTM sales in the fourth quarter  this scenario supports Guerbet‚Äôs financial targets for the full year and for next year.Geographical breakdown of consolidated Group revenue (IFRS)In millions of euros at 30 September 2023 9 months 20229 months 2023At current exchange rates% change9 months 2023At CER1% changeSales in EMEA 245.2 258.5 +5.4% 258.6 +5.5% Sales in the Americas 182.5 160.9 -11.8% 161.5 -11.5% Sales in Asia 141.4 154.4 +9.2% 164.2 +16.1% Total 569.2 573.9 +0.8% 584.3 +2.7%1Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.In the EMEA region  the Group saw an increase in 9-month sales of 5.4% at current exchange rates and 5.5% at CER  driven by the increase in volumes and positive price effects. In the third quarter  revenue for the region came to ‚Ç¨79.9 million  with moderate growth (+0.6% at CER) linked to a particularly high comparison base.In the Americas  sales for the period to end-September 2023 fell by 11.8% at current exchange rates and by 11.5% at CER. As expected  the decline in revenue slowed significantly in the third quarter to -5.2% at CER. After the complete normalisation of production rates during the first half of 2023  the Raleigh (North Carolina) site was again able to increase its production capacity with a view to increasing its sales - of EluciremTM in particular - in the fourth quarter.In Asia  sales growth over the 9-month period was +9.2%  incorporating a particularly substantial negative forex effect of -‚Ç¨9.8m (depreciation of Chinese  Japanese and Korean currencies) during the period; at CER  growth was +16.1%  a remarkable performance driven mainly by China (+39%)  which continued to benefit from the introduction of direct distribution in 2022. In the third quarter alone  sales in Asia were up 15.2% at CER.Breakdown of consolidated Group revenue (IFRS) by activityIn millions of euros at 30 September 2023 9 months 20229 months 2023At current exchange rates% change9 months 2023At CER1% changeDiagnostic Imaging 502.2 506.4 +0.8% 515.3 +2.6% MRI 192.4 187.3 -2.7% 189.4 -1.6% X-ray 309.8 319.0 +3.0% 325.8 +5.2% Interventional Imaging 67.0 67.5 +0.7% 69.0 +3.0% Total 569.2 573.9 +0.8% 584.3 +2.7%1Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.Revenue from Diagnostic Imaging at CER was up 2.6% at 30 September 2023 (+0.8% at current exchange rates) and up 1.2% in the third quarter. Note that the X-ray division now includes the revenue of Intrasense  consolidated since 1 January 2023.In MRI   sales for the 9-month period were down 1.6% at CER due to a contraction in activity in the third quarter of 2023. This reflects: A negative price effect linked to the price pressure exerted by the generic product for Dotarem ¬Æ on the US market. Sales of Elucirem TM which slowed in the third quarter due to longer-than-expected approval times (formulary process) in US hospitals  with a strong catch-up effect expected from the fourth quarter of 2023.  sales for the 9-month period were down 1.6% at CER due to a contraction in activity in the third quarter of 2023. This reflects: In the X-ray division  revenue rose by 5.2% over the first nine months at CER  marked by a sharp acceleration in growth in the third quarter (+8.7%)  again due to a sharp increase in sales of Xenetix¬Æ.In Interventional Imaging  sales at CER were up 3.0% compared with the first nine months of 2022. After a negative comparison base effect in the Asia-Pacific region in the first half of 2023  revenue for the third quarter rose by a sharp 10.3%  driven by strong sales of Lipiodol¬Æ.Financial targets for 2023 and 2024 confirmedActivity continues to be underpinned by robust volumes and broadly positive price effects (with the exception of Dotarem¬Æ)  reflecting the Group‚Äôs ability to pass on cost increases to its customers (iodine in particular). In the fourth quarter of 2023  Guerbet expects double-digit sales growth driven by a very strong rebound in activity in the United States  linked in particular to the ramp-up of EluciremTM sales once the current approval processes are completed  and to continued favourable trends in Interventional Imaging.For the full year  Guerbet confirms that it is targeting revenue growth of more than 5% like-for-like and at CER. It still expects a restated EBITDA2 to revenue ratio of around 11% in 2023  before returning in 2024 to a higher level than in 2021 (14.4%).As a reminder  the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favourable opinion on the granting of marketing authorisation for Elucirem‚Ñ¢ in the European Union for use in adults and children aged two and older for contrast-enhanced MRI. The European Commission is expected to make its decision by the end of 2023.Next event:Publication of full-year revenue8 February 2024 after market closeAbout GuerbetAt Guerbet  we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide  offering a comprehensive range of pharmaceutical products  medical devices  and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years  with more than 2 600 employees worldwide  we continuously innovate and devote 10% of our sales to research and development in four centres in France  Israel  and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B ‚Äì mid caps) and generated ‚Ç¨753 million in revenue in 2022.Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates  forecasts  and assumptions  including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks  uncertainties  and other factors that may result in a significant difference between the Group‚Äôs actual performance and results and those presented explicitly or implicitly by these forward-looking statements.These forward-looking statements are valid only as of the date of this press release  and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions  events  conditions  or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group‚Äôs control.These risks and uncertainties include but are not limited to the uncertainties inherent in research and development  future clinical data and analyses (including after a marketing authorization is granted)  decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug  process  or biological product filed for any such product candidates  and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group‚Äôs activities can be found in Chapter 4.9 ‚ÄúRisk factors‚Äù of the Group‚Äôs Universal Registration Document filed with the AMF (French financial markets authority) under number D.23-0203 on March 31  2023  available on the Group‚Äôs website (www.guerbet.com).1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.2 Excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model.2 Excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model.Contacts :GuerbetJ√©r√¥me Estampes  Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.comClaire Lauvernier  Communications Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.comActifinMarianne Py  Financial Communications +33.1.80.48.25.31 / mpy@actifin.frJennifer Jullia  Press +33.1.56.88.11.19 / jjullia@actifin.frAttachment,neutral,0.01,0.98,0.01,mixed,0.14,0.25,0.61,True,English,"['GUERBET', 'Revenue', '30 September', 'substantial negative forex effect', 'negative comparison base effect', 'high comparison base', 'negative price effect', 'exchange rate impact', 'strong catch-up effect', 'positive price effects', 'current exchange rates', '1Constant exchange rates', 'previous financial year', 'first nine months', 'consolidated Group revenue', 'double-digit activity growth', 'production rates', 'price pressure', 'first half', 'strong momentum', 'Financial targets', 'full year', 'next year', 'fourth quarter', 'Interventional Imaging', 'EBITDA margin2', 'higher level', 'FR0000032526 GBT', 'global specialist', 'contrast agents', 'medical imaging', 'third quarter', 'complete normalisation', 'North Carolina', 'production capacity', 'Korean currencies', 'remarkable performance', 'direct distribution', 'Diagnostic Imaging', 'generic product', 'US market', 'Elucirem TM', 'approval times', 'formulary process', 'US hospitals', 'sharp acceleration', 'moderate growth', 'X-ray division', 'Asia-Pacific region', 'strong sales', 'Group sales', 'smaller decline', 'Business activity', 'Geographical breakdown', 'same period', '9-month period', '9-month revenue', 'sharp increase', 'Third-quarter sales', '9-month sales', 'sales growth', 'EMEA region', 'EluciremTM sales', '9 months', '2023 revenue', '30 September', 'CER', 'Americas', 'surge', 'Villepinte', '19 October', 'Guerbet', 'solutions', 'account', 'ramp-up', 'scenario', 'IFRS', 'millions', 'euros', 'basis', 'volumes', 'Raleigh', 'site', 'view', 'depreciation', 'Japanese', 'China', 'introduction', 'MRI', 'Intrasense', '1 January', 'contraction', 'Dotarem', 'expected', 'Xenetix¬Æ', 'Lipiodol¬Æ']",2023-10-19,2023-10-20,globenewswire.com
31629,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GUERBET-5011/news/GUERBET-Revenue-at-30-September-2023-45105691/,GUERBET : Revenue at 30 September 2023. -October 19  2023 at 11:46 am EDT,(marketscreener.com) Revenue at 30 September 2023 Activity 9-month revenue: ‚Ç¨573.9 million  up 2.7% at...https://www.marketscreener.com/quote/stock/GUERBET-5011/news/GUERBET-Revenue-at-30-September-2023-45105691/?utm_medium=RSS&utm_content=20231019,Revenue at 30 September 2023Activity9-month revenue: ‚Ç¨573.9 million  up 2.7% at CER 1Third-quarter sales remained very strong in Asia (+15.2% at CER)  were stable in EMEA (+0.6%) and showed a smaller decline in the Americas (-5.2%)Expecting double-digit activity growth in the fourth quarter of 2023 thanks to the surge in sales of EluciremTM and strong momentum in Interventional ImagingFinancial targets confirmed2023 revenue up by more than 5% like-for-like and at CERRestated EBITDA margin2 of around 11% in 2023  before returning in 2024 to a higher level than in 2021 (14.4%)Villepinte  19 October 2023: Guerbet (FR0000032526 GBT)  a global specialist in contrast agents and solutions for medical imaging  is publishing its revenue for the period to 30 September 2023. Over the first nine months of the year  Group sales came to ‚Ç¨573.9 million  up 0.8% on the same period in 2022. Business activity reflected a negative forex effect of ‚Ç¨10.4 million. At CER1  revenue for the first nine months grew by 2.7%.Sales in the third quarter of 2023 came to ‚Ç¨195.2 million  up 2.3% at CER  after rising by 2.8% during the first half of the financial year. Taking into account the expected ramp-up in EluciremTM sales in the fourth quarter  this scenario supports Guerbet‚Äôs financial targets for the full year and for next year.Geographical breakdown of consolidated Group revenue (IFRS)In millions of euros at 30 September 2023 9 months 20229 months 2023At current exchange rates% change9 months 2023At CER1% changeSales in EMEA 245.2 258.5 +5.4% 258.6 +5.5% Sales in the Americas 182.5 160.9 -11.8% 161.5 -11.5% Sales in Asia 141.4 154.4 +9.2% 164.2 +16.1% Total 569.2 573.9 +0.8% 584.3 +2.7%1Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.In the EMEA region  the Group saw an increase in 9-month sales of 5.4% at current exchange rates and 5.5% at CER  driven by the increase in volumes and positive price effects. In the third quarter  revenue for the region came to ‚Ç¨79.9 million  with moderate growth (+0.6% at CER) linked to a particularly high comparison base.In the Americas  sales for the period to end-September 2023 fell by 11.8% at current exchange rates and by 11.5% at CER. As expected  the decline in revenue slowed significantly in the third quarter to -5.2% at CER. After the complete normalisation of production rates during the first half of 2023  the Raleigh (North Carolina) site was again able to increase its production capacity with a view to increasing its sales - of EluciremTM in particular - in the fourth quarter.In Asia  sales growth over the 9-month period was +9.2%  incorporating a particularly substantial negative forex effect of -‚Ç¨9.8m (depreciation of Chinese  Japanese and Korean currencies) during the period; at CER  growth was +16.1%  a remarkable performance driven mainly by China (+39%)  which continued to benefit from the introduction of direct distribution in 2022. In the third quarter alone  sales in Asia were up 15.2% at CER.Breakdown of consolidated Group revenue (IFRS) by activityIn millions of euros at 30 September 2023 9 months 20229 months 2023At current exchange rates% change9 months 2023At CER1% changeDiagnostic Imaging 502.2 506.4 +0.8% 515.3 +2.6% MRI 192.4 187.3 -2.7% 189.4 -1.6% X-ray 309.8 319.0 +3.0% 325.8 +5.2% Interventional Imaging 67.0 67.5 +0.7% 69.0 +3.0% Total 569.2 573.9 +0.8% 584.3 +2.7%1Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.Revenue from Diagnostic Imaging at CER was up 2.6% at 30 September 2023 (+0.8% at current exchange rates) and up 1.2% in the third quarter. Note that the X-ray division now includes the revenue of Intrasense  consolidated since 1 January 2023.In MRI   sales for the 9-month period were down 1.6% at CER due to a contraction in activity in the third quarter of 2023. This reflects: A negative price effect linked to the price pressure exerted by the generic product for Dotarem ¬Æ on the US market. Sales of Elucirem TM which slowed in the third quarter due to longer-than-expected approval times (formulary process) in US hospitals  with a strong catch-up effect expected from the fourth quarter of 2023.  sales for the 9-month period were down 1.6% at CER due to a contraction in activity in the third quarter of 2023. This reflects: In the X-ray division  revenue rose by 5.2% over the first nine months at CER  marked by a sharp acceleration in growth in the third quarter (+8.7%)  again due to a sharp increase in sales of Xenetix¬Æ.In Interventional Imaging  sales at CER were up 3.0% compared with the first nine months of 2022. After a negative comparison base effect in the Asia-Pacific region in the first half of 2023  revenue for the third quarter rose by a sharp 10.3%  driven by strong sales of Lipiodol¬Æ.Financial targets for 2023 and 2024 confirmedActivity continues to be underpinned by robust volumes and broadly positive price effects (with the exception of Dotarem¬Æ)  reflecting the Group‚Äôs ability to pass on cost increases to its customers (iodine in particular). In the fourth quarter of 2023  Guerbet expects double-digit sales growth driven by a very strong rebound in activity in the United States  linked in particular to the ramp-up of EluciremTM sales once the current approval processes are completed  and to continued favourable trends in Interventional Imaging.For the full year  Guerbet confirms that it is targeting revenue growth of more than 5% like-for-like and at CER. It still expects a restated EBITDA2 to revenue ratio of around 11% in 2023  before returning in 2024 to a higher level than in 2021 (14.4%).As a reminder  the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favourable opinion on the granting of marketing authorisation for Elucirem‚Ñ¢ in the European Union for use in adults and children aged two and older for contrast-enhanced MRI. The European Commission is expected to make its decision by the end of 2023.Next event:Publication of full-year revenue8 February 2024 after market closeAbout GuerbetAt Guerbet  we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide  offering a comprehensive range of pharmaceutical products  medical devices  and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years  with more than 2 600 employees worldwide  we continuously innovate and devote 10% of our sales to research and development in four centres in France  Israel  and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B ‚Äì mid caps) and generated ‚Ç¨753 million in revenue in 2022.Forward-looking statementsCertain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates  forecasts  and assumptions  including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks  uncertainties  and other factors that may result in a significant difference between the Group‚Äôs actual performance and results and those presented explicitly or implicitly by these forward-looking statements.These forward-looking statements are valid only as of the date of this press release  and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions  events  conditions  or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group‚Äôs control.These risks and uncertainties include but are not limited to the uncertainties inherent in research and development  future clinical data and analyses (including after a marketing authorization is granted)  decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug  process  or biological product filed for any such product candidates  and their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group‚Äôs activities can be found in Chapter 4.9 ‚ÄúRisk factors‚Äù of the Group‚Äôs Universal Registration Document filed with the AMF (French financial markets authority) under number D.23-0203 on March 31  2023  available on the Group‚Äôs website (www.guerbet.com).1 Constant exchange rates: the exchange rate impact was eliminated by recalculating sales for the period on the basis of the exchange rates used for the previous financial year.2 Excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model.2 Excluding non-recurring costs related to the optimisation of the operating plan and changes in the sales model.Contacts :GuerbetJ√©r√¥me Estampes  Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.comClaire Lauvernier  Communications Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.comActifinMarianne Py  Financial Communications +33.1.80.48.25.31 / mpy@actifin.frJennifer Jullia  Press +33.1.56.88.11.19 / jjullia@actifin.frAttachment,neutral,0.02,0.97,0.01,mixed,0.14,0.25,0.61,True,English,"['GUERBET', 'Revenue', '30 September', 'October', '11:46', 'substantial negative forex effect', 'negative comparison base effect', 'high comparison base', 'negative price effect', 'exchange rate impact', 'strong catch-up effect', 'positive price effects', 'current exchange rates', '1Constant exchange rates', 'previous financial year', 'first nine months', 'consolidated Group revenue', 'double-digit activity growth', 'production rates', 'price pressure', 'first half', 'strong momentum', 'Financial targets', 'full year', 'next year', 'fourth quarter', 'Interventional Imaging', 'EBITDA margin2', 'higher level', 'FR0000032526 GBT', 'global specialist', 'contrast agents', 'medical imaging', 'third quarter', 'complete normalisation', 'North Carolina', 'production capacity', 'Korean currencies', 'remarkable performance', 'direct distribution', 'Diagnostic Imaging', 'generic product', 'US market', 'Elucirem TM', 'approval times', 'formulary process', 'US hospitals', 'sharp acceleration', 'moderate growth', 'X-ray division', 'Asia-Pacific region', 'strong sales', 'Group sales', 'smaller decline', 'Business activity', 'Geographical breakdown', 'same period', '9-month period', '9-month revenue', 'sharp increase', 'Third-quarter sales', '9-month sales', 'sales growth', 'EMEA region', 'EluciremTM sales', '9 months', '2023 revenue', '30 September', 'CER', 'Americas', 'surge', 'Villepinte', '19 October', 'Guerbet', 'solutions', 'account', 'ramp-up', 'scenario', 'IFRS', 'millions', 'euros', 'basis', 'volumes', 'Raleigh', 'site', 'view', 'depreciation', 'Japanese', 'China', 'introduction', 'MRI', 'Intrasense', '1 January', 'contraction', 'Dotarem', 'expected', 'Xenetix¬Æ', 'Lipiodol¬Æ']",2023-10-19,2023-10-20,marketscreener.com
31630,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ARTMARKET-COM-5174/news/Artmarket-com-Artprice-by-Artmarket-com-congratulates-the-artist-Tarik-Kiswanson-winner-of-th-45106546/,Artmarket.com : Artprice by Artmarket.com congratulates the artist Tarik Kiswanson  winner of the 2023 Marcel Duchamp Prize  sponsored by ADIAF -October 19  2023 at 01:20 pm EDT,(marketscreener.com)  Dedicated to the international promotion of the French contemporary art scene  the Marcel Duchamp Prize shortlisted four finalists at the beginning of this year: Bertille Back   Bouchra Khalili   Massinissa Selmani and finally Tarik Ki‚Ä¶,"Dedicated to the international promotion of the French contemporary art scene  the Marcel Duchamp Prize shortlisted four finalists at the beginning of this year: Bertille Back (represented by the Xippas gallery and The Gallery Apart)  Bouchra Khalili (represented by the Mor Charpentier gallery and ADN Galeria)  Massinissa Selmani (represented by the Anne-Sarah Benichou gallery  Selma Feriani and Jane Lombard) and finally Tarik Kiswanson (represented by the carlier | gebauer and Sfeir-Semler galleries) who has won the prize for this 23rd edition.For thierry Ehrmann  Artprice Founder and CEO of Artmarket  ‚ÄúOnce again this year  the four finalists whose works are currently being shown at the Pompidou Center illustrate the diversity and excellence of the French artistic scene. We extend our warm congratulations to them and  in particular  to Tarik Kiswanson  this year's Marcel Duchamp Prize winner. Artprice.com by Artmarket is proud to support ADIAF and the Prix Marcel Duchamp as a patron.‚ÄùImage: [ https://imgpublic.artprice.com/img/wp/sites/11/2023/10/HD-9473-TAE_Tarik_%C2%A9-julie-ansiau-1024px.jpg ]Tarik Kiswanson ¬© Julie AnsiauTarik KiswansonAs Matthieu Jacquet points out in an article for the Pompidou Center in Paris  Tarik Kiswanson was ‚Äúborn in the small town of Halmstad  in Sweden  to Palestinian parents exiled in the 1970s. He has always kept one foot in his native country and the other in the Middle East  where he has gone every year since his birth. Like many second-generation immigrants  the artist was exposed to the imperatives of conformism and integration in the country adopted by his parents but was constantly reminded of his roots by the predominantly white society in which he evolved. He moved from Sweden to Paris 14 years ago.‚ÄùThrough diverse and transversal practices such as sculpture  writing  performance  drawing  sound and video works  the thirty-year-old addresses the theses of uprooting  belonging  memory but also those of transformation and regeneration in his personal journey as well as in the history of the contemporary world.‚ÄúI am a second-generation immigrant and my work is largely inspired by notions of displacement and uprooting.‚Äù Tarik KiswansonObtaining the Marcel Duchamp Prize is the high point of a year 2023 marked by three solo exhibitions around the world: one at the Museo Tamayo in Mexico  one at the Bonniers Konsthall in Stockholm and another at the Salzburger Kunstverein in Salzburg. In 2022  Tarik Kiswanson's works were shown at the Lyon Biennale  at the Museum of Contemporary Art in Antwerp (Belgium) and at the Hallands Konstmuseum (Sweden). In 2021 he had an exhibition at the Carr√© d'Art - Museum of Contemporary Art in N√Æmes in 2021  and in 2019 he participated in New York's Performa 19 Biennale.Tarik Kiswanson graduated from Central Saint Martins  London (2010) and the √âcole Nationale Sup√©rieure des Beaux-arts in Paris (2014). The most recent winners of the Marcel Duchamp Prize were Mimosa Echard (2022)  Lili Reynaud Dewar (2021) and Kapwani Kiwanga (2020).The ADIAF and the Marcel Duchamp PrizeFounded by Gilles Fuchs and chaired since 2021 by Claude Bonnin  the ADIAF (Association for the International Diffusion of French Art) brings together 300 collectors of Contemporary French art. Supported by patrons  including Artprice  the ADIAF highlights the French scene and contributes to its international influence.The Marcel Duchamp Prize hands out a total of 90 000 euros  including 35 000 euros to the winner who also benefits from a residency in the United States at the Villa Albertine. Organized in collaboration with the Pompidou Center  the ADIAF offers an exhibition of the four finalists at the Pompidou Center as part of the Marcel Duchamp Prize. The exhibition currently dedicated to Bertille Bak  Bouchra Khalili  Massinissa Selmani and Tarik Kiswanson can be discovered on the fourth floor of the Parisian museum until 8 January 2024.According to Xavier Rey  Director of the National Museum of Modern Art  this ‚Äúexhibition represents  thanks to the excellence of the four finalists  the best of the French artistic scene. With Tarik Kiswanson we honor an extremely accomplished multidisciplinary work  both in its formal dimension and in its relationship to history. Based on the energetic relationships between various elements  his works aim  with great sensitivity  to convey a universal message.For this 23rd edition of the Marcel Duchamp Prize  the jury consisted of seven key figures from the art world: Xavier Rey  Director of the National Museum of Modern Art - Pompidou Center  Claude Bonnin  Collector and President of Adiaf  Akemi Shiraha  Representative of the Marcel Duchamp Association  Dr. Jimena Blazquez Abascal  Collector and Director of the Montenmedio Contemporary Foundation (Spain)  Jos√©e Gensollen  Collector  Collection Gensollen La Fabrique (Marseille)  B√©atrice Salmon  Director of the National Center for Plastic Arts (CNAP) and Adam D. Weinberg  Director of the Whitney Museum of American Art  in New York.Past winners of the Marcel Duchamp PrizeThomas Hirschhorn (2000-2001)Dominique Gonzalez-Foerster (2002)Matthew Mercier (2003)Carole Benzaken (2004)Claude Closky (2005)Philippe Mayaux (2006)Tatiana Trouv√© (2007)Laurent Grasso (2008)Sa√¢dane Afif (2009)Cyprien Gaillard (2010)Mircea Cantor (2011)Daniel Dewar and Gr√©gory Gicquel (2012)Latifa Echakhch (2013)Julien Pr√©vieux (2014)Melik Ohanian (2015)Kader Attia (2016)Joana Hadjithomas and Khalil Joreige (2017)Cl√©ment Cogitore (2018)Eric Baudelaire (2019)Kapwani Kiwanga (2020)Lili Reynaud Dewar (2021)Mimosa Echard (2022)Tarik Kiswanson (2023)Image: [ https://imgpublic.artprice.com/img/wp/sites/11/2023/10/HD-9473-TAE_Tarik_%C2%A9-julie-ansiau-1024px.jpg ]Copyright 1987-2023 thierry Ehrmann www.artprice.com - www.artmarket.comDon't hesitate to c ontact our E conometrics Department for your requirements regarding statistics and personalized studies: econometrics@artprice.comTry our services (free demo): https://www.artprice.com/demoSubscribe to our services: https://www.artprice.com/subscriptionAbout Artmarket:Artmarket.com is listed on Eurolist by Euronext Paris  SRD long only and Euroclear: 7478 - Bloomberg: PRC - Reuters: ARTF.Discover Artmarket and its Artprice department on video: www.artprice.com/videoArtmarket and its Artprice department was founded in 1997 by its CEO  thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur  created in 1987.See certified biography in Who's who ¬©:https://imgpublic.artprice.com/img/wp/sites/11/2023/04/2023_2_Biographie-thierry-Ehrmann_WhosWhoInFrance.pdfArtmarket is a global player in the Art Market with  among other structures  its Artprice department  world leader in the accumulation  management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results  covering more than 824 000 artists.Artprice by Artmarket  the world leader in information on the art market  has set itself the ambition through its Global Standardized Marketplace to be the world's leading Fine Art NFT platform.Artprice Images¬Æ allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day  commented by our art historians.Artmarket with its Artprice department accumulates data on a permanent basis from 7200 Auction Houses and produces key Art Market information for the main press and media agencies (7 200 publications). Its 7.2 million (‚Äòmembers log in'+social media) users have access to ads posted by other members  a network that today represents the leading Global Standardized Marketplace¬Æ to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France's Commercial Code).Artmarket  with its Artprice department  has twice been awarded the State label ""Innovative Company"" by the Public Investment Bank (BPI)  which has supported the company in its project to consolidate its position as a global player in the art market.Artprice by Artmarket publishes its 2023 Contemporary Art Market Report:https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2023Artprice by Artmarket's Global Art Market Report  ‚ÄúThe Art Market in 2022‚Äù  published in March 2023:https://www.artprice.com/artprice-reports/the-art-market-in-2022Artprice releases its 2022 Ultra-Contemporary Art Market Report:https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2022Index of press releases posted by Artmarket with its Artprice department:https://serveur.serveur.com/artmarket/press-release/en/Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:www.facebook.com/artpricedotcom/ (over 6.4 million followers)twitter.com/artmarketdotcomtwitter.com/artpricedotcomDiscover the alchemy and universe of Artmarket and its artprice department https://www.artprice.com/video headquartered at the famous Organe Contemporary Art Museum ‚ÄúThe Abode of Chaos‚Äù (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013La Demeure du Chaos / Abode of ChaosGESAMTKUNSTWERK & SINGULAR ACRHITECTUREConfidential bilingual work now public:https://ftp1.serveur.com/abodeofchaos_singular_architecture.pdfL'Obs - The Museum of the Future: https://youtu.be/29LXBPJrs-owww.facebook.com/la.demeure.du.chaos.theabodeofchaos999 (over 4 million followers)https://vimeo.com/124643720Contact Artmarket.com and its Artprice department - Contact: ir@artmarket.comThis publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: nW1xlclul2bJmJ+fZ8trb2iUl2ZlmZHKaGPGk2RtlMeWcJxpm21qb8qaZnFjmWln- Check this key: https://www.security-master-key.com .Unregulated information:Full and original press release in PDF: https://www.actusnews.com/news/82441-artprice-by-artmarket-com-congratulates-artist-tarik-kiswanson-winner-of-the-2023-marcel-duchamp-prize-sponsored-by-adiaf.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2023 ActusNews",neutral,0.34,0.65,0.01,positive,0.73,0.26,0.01,True,English,"['2023 Marcel Duchamp Prize', 'Artmarket.com', 'Tarik Kiswanson', 'Artprice', 'artist', 'winner', 'ADIAF', 'October', '01:20', 'Nationale Sup√©rieure des', 'Dr. Jimena Blazquez Abascal', 'Collection Gensollen La Fabrique', 'The Marcel Duchamp Prize', 'Marcel Duchamp Prize winner', 'French contemporary art scene', 'Jos√©e Gensollen', 'Prix Marcel Duchamp', 'three solo exhibitions', 'Central Saint Martins', 'Lili Reynaud Dewar', 'seven key figures', 'B√©atrice Salmon', 'Adam D. Weinberg', 'French artistic scene', 'The Gallery Apart', 'Mor Charpentier gallery', 'Anne-Sarah Benichou gallery', 'Montenmedio Contemporary Foundation', 'many second-generation immigrants', 'Marcel Duchamp Association', 'Contemporary French art', 'French scene', 'Xippas gallery', 'contemporary world', 'Modern Art', 'American Art', 'The ADIAF', 'international promotion', 'four finalists', 'Bertille Back', 'Bouchra Khalili', 'ADN Galeria', 'Massinissa Selmani', 'Selma Feriani', 'Jane Lombard', 'Tarik Kiswanson', 'Sfeir-Semler galleries', '23rd edition', 'thierry Ehrmann', 'Pompidou Center', 'warm congratulations', 'Julie Ansiau', 'Matthieu Jacquet', 'small town', 'one foot', 'Middle East', 'white society', 'transversal practices', 'personal journey', 'high point', 'Museo Tamayo', 'Bonniers Konsthall', 'Salzburger Kunstverein', 'Lyon Biennale', 'Hallands Konstmuseum', 'N√Æmes', 'New York', 'Performa 19 Biennale', 'recent winners', 'Mimosa Echard', 'Kapwani Kiwanga', 'Gilles Fuchs', 'Claude Bonnin', 'International Diffusion', 'international influence', 'United States', 'Villa Albertine', 'Bertille Bak', 'fourth floor', 'Xavier Rey', 'formal dimension', 'energetic relationships', 'various elements', 'great sensitivity', 'universal message', 'Akemi Shiraha', 'National Center', 'Plastic Arts', 'Past winners', 'art world', 'Parisian museum', 'National Museum', 'Whitney Museum', 'Palestinian parents', 'native country', 'multidisciplinary work', 'Artprice Founder', 'video works', 'beginning', 'year', 'carlier', 'gebauer', 'CEO', 'Artmarket', 'diversity', 'excellence', 'com', 'patron', 'Image', 'sites', 'article', 'Halmstad', 'Sweden', '1970s', 'birth', 'imperatives', 'conformism', 'integration', 'roots', 'diverse', 'sculpture', 'writing', 'performance', 'drawing', 'sound', 'old', 'theses', 'uprooting', 'belonging', 'memory', 'transformation', 'regeneration', 'history', 'notions', 'displacement', 'Mexico', 'Stockholm', 'Antwerp', 'Belgium', 'London', 'Beaux-arts', '300 collectors', 'total', '90,000 euros', '35,000 euros', 'residency', 'collaboration', '8 January', 'Director', 'jury', 'President', 'Representative', 'Spain', 'Marseille', 'CNAP', 'Thom']",2023-10-19,2023-10-20,marketscreener.com
31631,EuroNext,NewsApi.org,https://www.irishtimes.com/business/2023/10/19/double-whammy-on-jobs-pharmas-130m-tax-deal-and-energy-saving-tips-this-winter/,Double whammy on jobs; pharma‚Äôs ‚Ç¨130m tax deal; and energy saving tips this winter,The best news  analysis and comment from The Irish Times business desk,Not much cheer this morning as the world‚Äôs largest listed food company Nestl√© announced it was pulling the shutters down on its Irish infant formula business with the closure of a plant in Askeaton  Co Limerick that will see the loss of 542 jobs and knock-on effects throughout the community.And pharma giant Pfizer is also weighing up cutbacks in staff numbers as it sees where it can trim ‚Ç¨3.3 billion annually in costs from its operations globally as a result of sharply falling demand for Covid vaccines and antiviral medicines. Given the importance of Ireland in its Covid product line manufacture  any cuts seem very likely to impact ins 5 000-strong workforce here.Another pharma having a bad day was Japanese group Takeda which has agreed to pay ‚Ç¨130 million to settle a tax bill with Revenue that it inherited when it acquired Irish-headquartered Shire in 2019. It could have been worse though  as the original tax demand was for ‚Ç¨398 million. Peter Flanagan has the detailsEven on the pay front  despite a general view that the gender pay gap is closing  data from the CSO says that men earned close to 10 per cent more that women  on average  across the economy last year. Eoin Burke-Kennedy looks at the numbers.READ MOREEoin was also tuned in as the ESRI upbraided the Government for its ongoing penchant for one-off budget measures for households  saying falling inflation and rising wages mean they are no longer necessary. The think tank‚Äôs Karina Dooley told an Oireachtas committee that benchmarking social welfare payments instead would provide more certainty to those dependent on them.Meanwhile  Joe Brennan writes that the Irish Stock Exchange has paid almost ‚Ç¨65 million in dividends to its parent  Euronext  since its takeover in 2018 ‚Äì over 40 per cent of the price it paid five Irish stockbroking firms for the business.Ciara O‚ÄôBrien has some tips for people looking to keep a tighter rein on their energy bills  though all her tech friendly gadgets will carry some upfront costs.In her column  Karlin argues that  regardless of its outcome  the ongoing antitrust case against Google taken by the US justice department over its alleged abuse of its search dominance will influence the future of technology  and thus society  in ways we cannot yet imagine.Chris Horn looks at Nikola Tesla‚Äôs conviction about the potential for wireless transmission of electricity  which would end the need for unsightly and expensive grid infrastructure like electric pylons and towers and the cables strung between them or expensively buried underground. Some companies are playing with the concept but it could be some time yet before we know whether it is really possible.Finally  in Cantillon  we wonder whether Ireland‚Äôs abrupt departure from the Rugby World Cup could have an adverse impact on consumer sentiment.Stay up to date with all our business news: sign up to our Business Today daily email news digest. If you‚Äôd like to read more about the issues that affect your finances try signing up to On the Money  the weekly newsletter from our personal finance team  which will be issued every Friday to Irish Times subscribers.,positive,0.74,0.25,0.01,negative,0.02,0.17,0.8,True,English,"['‚Ç¨130m tax deal', 'energy saving tips', 'Double whammy', 'jobs', 'largest listed food company', 'five Irish stockbroking firms', 'Covid product line manufacture', 'daily email news digest', 'Irish infant formula business', 'Irish Stock Exchange', 'Irish Times subscribers', 'Japanese group Takeda', 'one-off budget measures', 'social welfare payments', 'Ciara O‚ÄôBrien', 'US justice department', 'expensive grid infrastructure', 'personal finance team', 'gender pay gap', 'ongoing antitrust case', 'original tax demand', 'Rugby World Cup', 'business news', 'Covid vaccines', 'falling demand', 'tax bill', 'pay front', 'ongoing penchant', 'Business Today', 'Co Limerick', 'giant Pfizer', 'antiviral medicines', '5,000-strong workforce', 'bad day', 'Irish-headquartered Shire', 'Peter Flanagan', 'general view', 'falling inflation', 'rising wages', 'think tank', 'Karina Dooley', 'Oireachtas committee', 'Joe Brennan', '40 per cent', 'tighter rein', 'energy bills', 'friendly gadgets', 'alleged abuse', 'search dominance', 'Chris Horn', 'Nikola Tesla', 'wireless transmission', 'electric pylons', 'abrupt departure', 'adverse impact', 'consumer sentiment', 'weekly newsletter', 'staff numbers', 'Eoin Burke-Kennedy', 'upfront costs', 'Nestl√©', 'shutters', 'plant', 'Askeaton', 'loss', '542 jobs', 'effects', 'community', 'cutbacks', 'operations', 'result', 'importance', 'Ireland', 'cuts', 'Revenue', 'details', 'data', 'CSO', 'women', 'economy', 'READ', 'ESRI', 'Government', 'households', 'certainty', 'dividends', 'parent', 'Euronext', 'takeover', 'price', 'tips', 'people', 'column', 'Karlin', 'outcome', 'Google', 'future', 'technology', 'society', 'ways', 'conviction', 'potential', 'electricity', 'need', 'unsightly', 'towers', 'cables', 'companies', 'concept', 'Cantillon', 'date', 'issues', 'finances', 'Money', '10']",2023-10-19,2023-10-20,irishtimes.com
31632,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SRP-GROUPE-24530545/news/Srp-Groupe-REVENUE-FOR-THE-FIRST-NINE-MONTHS-OF-2023-AND-3RD-QUARTER-45106066/,Srp Groupe : REVENUE FOR THE FIRST NINE MONTHS OF 2023 AND 3RD QUARTER -October 19  2023 at 12:20 pm EDT,(marketscreener.com)  REVENUE FOR THE FIRST NINE MONTHS OF 2023 AND 3RD QUARTEROver the first nine months of the year  Showroompriv√© recorded a 8.7% growth in GMV and 4.6% in net revenue.Continued strong momentum in the international segment  with a grow‚Ä¶,"REVENUE FOR THE FIRST NINE MONTHS OF 2023 AND 3RD QUARTEROver the first nine months of the year  Showroompriv√© recorded a 8.7% growth in GMV and 4.6% in net revenue.Continued strong momentum in the international segment  with a growth of 9.6% for the first 9 months and 6.2% over the 3 rd quarter compared to the same period last year.quarter compared to the same period last year. In Q3  weak household consumption led to a downturn in the core business  partially offset by the contribution of the Group's growth levers  already identified: Travel & Leisure segment  the Marketplace  SRP Media and the International segment.Good performance of the Travel & Leisure segment and the Marketplace  with GMV growing by 17% and 74% respectively in the first nine months of 2023  and 23% and 112% respectively in Q3 2023.The Bradery  the fashion site targeting millennials  confirms its potential  recording 84% growth in the first nine months of 2023.Launch of a major Ad campaign to recruit new members and foster members' commitment.Ongoing work to optimize cost structure  with further profitability gains expected by year-end.La Plaine Saint Denis  France  October 19  2023 ‚Äì Showroompriv√© (SRP Groupe)  a European group specializing in smart shopping  has published its sales for the first nine months of its financial year and its 3rd quarter ending September 30  2023.4.6% GROWTH OVER THE FIRST NINE MONTHS OF THE YEAR  DESPITE A PERSISTENTLY DIFFICULT ENVIRONMENT9-month sales(‚Ç¨ million) 9 months 2022 9 months 2023 23/22 % change Internet Revenue France 362.3 372.3 2.7% International 81.8 89.7 9.6% Total Internet Revenue 444.1 462.0 4.0% Other revenue 6.0 9.0 49.2% Net Revenue 450.1 471.0 4.6%In a gloomy economic climate with limited visibility  Showroompriv√© managed to maintain its growth momentum  recording net revenue of ‚Ç¨471.0m  up 4.6% compared to the same period in 2022. Continued high inflation weighed on online sales  particularly in apparel (-8% in H1 2023[1]). Its increase at the end of the period accelerated the trend  as materialized by total spending on clothing-textiles down -2.3% in August according to Insee. Against this backdrop  Showroompriv√© capitalized on its well-positioned offering  low-price DNA  revenue diversification and internationalization to reinforce its position on each of its markets. The successful integration of The Bradery has also extended the Group's growth potential  and the fashion site  targeting millenials  recorded strong revenue growth over the first nine months of the year  at 84% year-on-year.David Dayan  Chairman and CEO of Showroompriv√©  comments: ""As the first nine months of 2023 ended  Showroompriv√© has reaffirmed the strong resilience of its business model in an environment where consumption remains impacted by multiple exogenous shocks. This ability is the fruit of the measures implemented in previous years  which have enabled us to premiumize our offering and multiply our growth levers. Showroompriv√©'s teams are fully mobilized to pursue this work  and to continue to successfully complete the transforming projects that will enable the Group to consolidate its resilience in the face of the current context  while continuing to effectively capture growth opportunities. As a result  the Group will continue to develop market-leading offerings and leverage its capacity for innovation to multiply the sources of value creation  guided by the objective of sustainable  profitable growth despite the ups and downs of the economic climate"".Key performance indicators9 months 2022 9 months 2023 % change Gross Merchandise Volume (GMV)[2] 649.0 705.8 8.7% Cumulative buyers* (millions)[3] 11.7 12.4 6.1% Buyers** (millions ) 3[4] 2.37 2.35 (0.9)% of which loyal buyers *** 1.93 1.88 (2.4)% As % of total number of buyers 81% 80% (65) pts Number of orders (millions ) 34 7.86 7.50 (4.7)% Revenue by buyer (IFRS)34 172.0 172.4 0.3% Average number of orders per buyer 3.3 3.2 (3.8)% Average basket 51.8 54.0 4.2%* All buyers who have made at least one purchase on the Group's platform since its launch** Member who has placed at least one order during the year*** Member who has placed at least one order during the year and at least one order in previous yearsGMV reached ‚Ç¨705.8m  up +8.7% in the first nine months of 2022. The number of cumulative buyers exceeds 12.4 million  up 6.1% compared to the same period in 2022. The repeat buyer rate stabilizes at a high level of 80%.The average basket is up ‚Ç¨2.2  illustrating the trend towards the premiumization of the offer and bringing revenue per buyer to ‚Ç¨172.4.In Q3  GMV remained stable compared with Q3 2022  at ‚Ç¨208.1 million.SOLID PERFORMANCE OF GROWTH LEVERS IN Q3  DESPITE THE SIGNIFICANT IMPACT OF THE ECONOMIC SITUATION ON THE CORE BUSINESSQuarterly sales(Millions ‚Ç¨) Q3 2022 Q3 2023 Q3 23/22 % change Internet Revenue France 116.4 109.5 (5.9)% International 26.4 28.0 6.2% Total Internet Revenue 142.8 137.5 (3.7)% Other revenue 1.9 2.1 11.0% Net Revenue 144.7 139.6 (3.5)%In the 3rd quarter  traditionally the lowest contributor to full year revenue  the downturn in consumer spending worsened  adversely impacting flash sales  the Group's core business. Given the weight of this business  Group revenue was also down  from ‚Ç¨144.7m to ‚Ç¨139.6m. Showroompriv√© has  however  managed to mitigate the impact of this downturn  thanks to the contribution of growth levers that are bringing additional growth and margins. These efforts were complemented by the expansion of the offering to include new references  notably in the sport lifestyle segment  with well-known brands that have been very well received by members.The Travel & Leisure segment continued its rebound since the end of the confinements  posting growth of almost 23% in Q3  benefiting  in addition to its intrinsic good momentum  from tour operators' decision to run aggressive promotions with last-minute prices during the summer period.The Marketplace continues to gain momentum  recording GMV growth of 112%.In a very demanding environment  SRP Media posted growth of 28%  driven by retail media  which continues to attract advertisers  and whose offering has recently been strengthened by the Unlimitail solution launched in partnership with Carrefour.International revenues once again made a positive contribution  continuing their steady rise in the business mix  with particularly strong momentum in strategic regions.LAUNCH OF THE NEW AD CAMPAIGNAs announced  and in line with the ACE roadmap  Showroompriv√© has launched a major targeted advertising campaign to raise its awareness in France and resonate with its brand throughout the country  and particularly in major cities. The campaign  conducted with a holistic ROI approach  also aims at supporting the re-engagement of the member base.OUTLOOKIn the coming quarters  Showroompriv√© anticipates a steadily adverse market environment in the final months of the 2023 financial year. Against this backdrop  the Group intends to pursue the implementation of its ACE roadmap  which will result in increased vigilance over inventory levels and a determination to capitalize on its low-price DNA and growth levers to ensure profitable growth. The Group will continue its efforts to control its cost structure and optimize its logistics network  while reallocating its resources to accelerate the development of its high-potential activities and the management of its offering  particularly during the year-end period. Showroompriv√© is therefore concentrating its efforts on effectively implementing these strategic measures  in order to maximize their impact from the fourth quarter of this year.FURTHER INFORMATIONResults for fiscal year 2023: March 14  2024FORWARD-LOOKING STATEMENTSThis press release contains summary information only and is not intended to be comprehensive.This press release may contain forward-looking information and statements about the Group and its subsidiaries. These statements include financial projections and estimates and their underlying assumptions  statements regarding plans  objectives and expectations with respect to future operations  products and services  and statements regarding future performance. Forward-looking statements may be identified by the words ""believe""  ""anticipate""  ""objective"" or similar expressions. Although the Group believes that the expectations reflected in such forward-looking statements are reasonable  investors and shareholders of the Group are cautioned that forward-looking information and statements are subject to numerous risks and uncertainties  many of which are difficult to predict and generally beyond the control of the Group  that could cause actual results and events to differ materially and adversely from those communicated  implied or indicated by such forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents filed or to be filed with the Autorit√© des march√©s financiers by the Group (notably those detailed in chapter 4 of the Company's reference document). The Group undertakes no obligation to publicly update any forward-looking statements  whether as a result of new information  future events or otherwise.About showroompriveShowroompriv√© is an innovative European player in the online private sales industry  specialized in fashion. Showroompriv√© offers a daily selection of more than 3 000 brand partners via its mobile apps or website in France and six other countries. Since its launch in 2006  the company has enjoyed quick growth.Showroompriv√© is listed on Euronext Paris (code: SRP) and reported GMV of almost ‚Ç¨950 million incl. VAT in 2022  and net revenue of ‚Ç¨657 million. The Group is headed by David Dayan  the co-founder  and employs over 1 000 people.For more information: http://showroomprivegroup.comContactsShowroompriv√© NewCap Sylvie Chan Diaz  Investor Relations investor.relations@showroomprive.net Financial communicationTh√©o Martin  Louis-Victor Delouvrier Anne Charlotte Neau-JulliardRelations. presse@showroomprive.net Financial media relationsGaelle Fromaigeat  Nicolas Merigeaushowroomprive@newcap.eu[1] Source Fevad: e-commerce report for 2nd quarter 2023[2] Business volume (""GMV"") represents  all taxes included  the total amount of the invoiced transaction and therefore includes gross Internet sales  including Marketplace sales  other services and other revenues.[3] Excluding Beaut√© Priv√©e and The Bradery.[4] Excluding MarketplaceThis publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: ypufaZqYlmabymlsZ8aXb2RlbZpnmGCWaZObm2Jrap2ZmWplxm6Sl5TJZnFjmWhq- Check this key: https://www.security-master-key.com .Regulated information:Inside Information:- other releases Full and original press release in PDF: https://www.actusnews.com/news/82434-en-srp-q3-2023-pr_vfinal.pdfReceive by email the next press releases of the company by registering on www.actusnews.com   it's free¬© 2023 ActusNews",neutral,0.05,0.94,0.01,mixed,0.39,0.32,0.29,True,English,"['FIRST NINE MONTHS', 'Srp Groupe', '3RD QUARTER', 'REVENUE', 'THE', 'October', '12:20', 'La Plaine Saint Denis', 'major Ad campaign', 'multiple exogenous shocks', 'Gross Merchandise Volume', 'Continued high inflation', 'FIRST NINE MONTHS', 'Key performance indicators', 'weak household consumption', 'gloomy economic climate', 'sustainable, profitable growth', 'Total Internet Revenue', 'repeat buyer rate', 'Internet Revenue France', 'strong revenue growth', 'first 9 months', 'total spending', 'high level', 'strong momentum', 'Good performance', 'SOLID PERFORMANCE', 'ECONOMIC SITUATION', 'Other revenue', 'revenue diversification', 'core business', 'Leisure segment', 'SRP Media', 'fashion site', 'new members', ""members' commitment"", 'cost structure', 'profitability gains', 'SRP Groupe', 'smart shopping', 'limited visibility', 'low-price DNA', 'successful integration', 'David Dayan', 'business model', 'previous years', 'transforming projects', 'current context', 'market-leading offerings', 'value creation', 'total number', 'Average basket', 'one purchase', 'one order', 'SIGNIFICANT IMPACT', 'lowest contribu', 'strong resilience', 'growth levers', 'growth momentum', 'growth opportunities', '3RD QUARTER', '3 rd quarter', 'same period', '9-month sales', 'online sales', 'Quarterly sales', 'international segment', 'Ongoing work', 'DIFFICULT ENVIRONMENT', 'Cumulative buyers', 'loyal buyers', 'Average number', 'The Bradery', 'growth potential', 'European group', 'financial year', '8.7% growth', '84% growth', '4.6% GROWTH', 'Showroompriv√©', 'GMV', 'downturn', 'contribution', 'Travel', 'Marketplace', 'Q3', 'millennials', 'Launch', 'year-end', 'change', 'apparel', 'H1', 'increase', 'trend', 'clothing-textiles', 'August', 'Insee', 'backdrop', 'internationalization', 'position', 'markets', 'millenials', 'Chairman', 'CEO', 'fruit', 'measures', 'teams', 'face', 'result', 'capacity', 'innovation', 'sources', 'objective', 'ups', 'downs', 'millions', 'orders', 'IFRS', 'platform', 'premiumization', '2023']",2023-03-20,2023-10-20,marketscreener.com
31633,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SARTORIUS-STEDIM-BIOTECH-27471609/news/Sartorius-Stedim-Biotech-SA-Nine-month-results-2023-of-Sartorius-Stedim-Biotech-45097619/,Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech -October 19  2023 at 01:03 am EDT,(marketscreener.com) Sartorius Stedim Biotech SA / Key word: 9 Month figures/Quarter ResultsSartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech 19-Oct-2023 / 07:00 CET/CESTAubagne  October 19  2023Nine-m‚Ä¶,Sartorius Stedim Biotech SA / Key word(s): 9 Month figures/Quarter ResultsSartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech19-Oct-2023 / 07:00 CET/CESTAubagne  October 19  2023Nine-month results 2023 of Sartorius Stedim BiotechSales revenue of 2 069 million euros  in constant currencies 1 ‚Äì20.6 percent organically 1 and-19.0 percent including acquisitions 2 (reporte d: -20.5 percent )Underlying EBITDA 1 at 594 million euros  resulting margin at 28.7 percentFirst signs of demand recovery noticeable towards the end of the third quarter; however  industry normalization and soft business climate take longer than expectedFull-year 2023 outlook adapted on October 12; uncertainties remain high due to global political and economic situationDespite initial signs of recovery towards the end of the third quarter  longer-than-expected soft demand continued to impact the business development of Sartorius Stedim Biotech in the first nine months of 2023. The company recorded a decline in sales revenue and profitability after pandemic-related extraordinary business and additional inventory buildup by customers had triggered strong above average growth in previous years. Based on updated business expectations until year-end  management adapted its guidance for fiscal 2023 on October 12.‚ÄúThe timeline for market normalization has continuously expanded in the first nine months of the year: Customers are reducing inventories at a slower pace than initially assumed  while their investment activity and partially production levels remain muted. Signs of recovery in demand have become visible  and while they are progressing slower than anticipated  we expect the situation to continue to improve in the final quarter. Considering the strong fundamental growth drivers of our markets  we expect profitable growth in 2024 and beyond ‚Äù said Ren√© F√°ber  CEO of Sartorius Stedim Biotech.Business development1The longer-than-expected normalization of demand continued in all regions  with a recovery trend toward the end of the third quarter. After exceptionally strong growth in prior years due to the pandemic  Sartorius Stedim Biotech recorded consolidated sales revenue of 2 069 million euros in the first nine months of 2023  which corresponds to a decline of 19.0 percent in constant currencies (organic: -20.6 percent; reported: - 20.5 percent). This includes a growth contribution from acquisitions of around 2 percentage points. Excluding the Covid-19-related business  the decline was slightly below 13 percent in constant currencies. Main drivers were ongoing inventory reductions after the end of the pandemic  relatively low production levels at some customers  the largely discontinued business in Russia  and an overall muted investment activity of customers  primarily in China and the USA.The temporarily weaker market environment was also reflected in order intake  which decreased by 31.0 percent in constant currencies (reported: -32.4 percent) to 1 760 million euros in the first nine months. In line with progress made by customers in reducing their inventories  there were signs of a slight recovery in order intake at the end of the third quarter.Underlying EBITDA decreased by 34.9 percent to 594 million euros due to lower volume development and product mix effects. The resulting margin was 28.7 percent (prior-year period: 35.0 percent). Price effects on the procurement and customer sides largely offset each other.Relevant net profit totaled 320 million euros  compared with 607 million euros in the prior-year period. Underlying earnings per share were 3.47 euros (prior-year period: 6.58 euros). The number of employees worldwide stood at 10 849 on September 30  2023  compared with 11 934 at the end of 2022.Key financial indicatorsEquity was 2 629 million euros as of September 30  2023. Following the financing of the Polyplus acquisition  the equity ratio1 stood in line with expectations at 33.0 percent (December 31  2022: 2 514 million euros and 49.6 percent  respectively)  and gross debt was 3 794 million euros (December 31  2022: 1 136 million euros). Net debt stood at 3 695 million euros  resulting in a ratio of net debt to underlying EBITDA1 of 4.0 (December 31  2022: 1 029 million euros and 0.9  respectively). Cash flow from investing activities  excluding acquisitions  stood at -377 million euros  compared with -289 million euros in the prior-year period. The ratio of capital expenditures (capex) to sales revenue was 17.9 percent (prior-year period: 11.1 percent).Outlook for fiscal 2023 adapted on October 12Based on preliminary nine-month results  company management lowered its guidance for the fiscal year 2023 on October 12. Against the backdrop of a slower-than-anticipated industry recovery  Sartorius Stedim Biotech now forecasts a sales revenue decline of around 19 percent; excluding Covid-19-related business a decline of around 14 percent. Acquisitions are expected to contribute around 2 percentage points to the sales revenue development.Due to lower volume expectations and product mix effects  the underlying EBITDA margin is expected to be slightly above 28 percent.The capex ratio is projected at around 18 percent for 2023  with a ratio of net debt to underlying EBITDA at around 4.5.The company confirms its fundamentally positive medium- and long-term market outlook and continues to see itself in a strong competitive position. For 2024  management expects profitable growth and will issue quantitative guidance with the release of the 2023 full-year figures next January. Its mid-term ambition is currently under review  and an update will also be provided in January 2024.All forecast figures are based on constant currencies  as in the past years. Management points out that the dynamics and volatilities in the industry have increased significantly in recent years. In addition  uncertainties due to the changed geopolitical situation  such as the emerging decoupling tendencies of various countries  are playing a greater role. This results in higher uncertainty when forecasting business figures.1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.Constant currencies: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous periodOrganic: Organic growth figures exclude the impact from changes in exchange rates and changes in the scope of consolidationOrder intake: All customer orders contractually concluded and booked during the respective reporting periodUnderlying EBITDA: Earnings before interest  taxes  depreciation  and amortization and adjusted for extraordinary itemsRelevant net profit: Profit for the period after non-controlling interest  adjusted for extraordinary items and amortization  as well as based on the normalized financial result and the normalized tax rateEquity ratio: Equity in relation to the balance sheet totalRatio of net debt to underlying EBITDA: Quotient of net debt and underlying EBITDA over the past 12 months  including the pro forma amount contributed by acquisitions for this period2 Acquisitions of Polyplus  the Novasep chromatography division and AlbumedixThis press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks  uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.Conference callRen√© F√°ber  CEO of the Sartorius Stedim Biotech Group  will discuss the company‚Äôs business results with analysts and investors in a conference call at 12.30 p.m. CEST on October 19  2023. Please click on the link to register:https://media.choruscall.eu/mediaframe/webcast.html?webcastid=zhpcEBhZFurther information and media content:www.sartorius.com/newsroomKey Performance Indicators for the Nine Months of 2023in millions of ‚Ç¨ unless otherwise specified 9 months2023 9 months2022 ¬π Œî in % Œî in % cc¬≤ Order Intake and Sales Revenue Order intake 1 759.6 2 601.2 -32.4 -31.0 Sales revenue 2 068.7 2 602.7 -20.5 -19.0 EMEA3 804.3 989.6 -18.7 -18.4 Americas3 798.9 927.3 -13.8 -12.4 Asia | Pacific3 465.6 685.8 -32.1 -28.7 Results EBITDA4 594.0 911.9 -34.9 EBITDA margin4 in % 28.7 35.0 Underlying net profit5 319.9 606.6 -47.3 Earnings per share5 in ‚Ç¨ 3.47 6.58 -47.3 Net profit6 269.9 685.6 -60.61 Prior-year figures have been slightly adjusted due to finalization of purchase price allocation for the acquisition of Albumedix Ltd.2 cc = constant currency3 According to customer location4 Underlying EBITDA = earnings before interest  taxes  depreciation and amortization  and adjusted for extraordinary items5 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and amortization  as well as based on a normalized financial result and normalized tax rate6 After non-controlling interestReconciliation between EBIT and underlying EBITDAIn millions of ‚Ç¨unless otherwise specified 9 months2023 9 months2022 ¬π EBIT (operating result) 343.6 773.0 Extraordinary items 75.9 13.4 Depreciation and amortization 174.6 125.6 Underlying EBITDA 594.0 911.9 In millions of ‚Ç¨unless otherwise specified 9 months2023 9 months2022 ¬π EBIT (operating result) 343.6 773.0 Extraordinary items 75.9 13.4 Amortization | IFRS 3 72.5 43.6 Normalized financial result2 -58.3 -9.2 Normalized income tax (26%)3 -112.8 -213.4 Underlying net result after taxes 320.9 607.4 Non-controlling interest -1.0 -0.8 Underlying net result after taxes and non-controlling interest 319.9 606.6 Underlying earnings per share (in ‚Ç¨) 3.47 6.581 Prior-year figures have been slightly adjusted due to finalization of purchase price allocation for the acquisition of Albumedix Ltd.2 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities and change in valuation of earn-out liability3 Normalized income tax based on the underlying profit before taxes and amortizationin millions of ‚Ç¨unless otherwise specified 9 months2023 9 months2022 ¬π Gross debt 3 794.0 1 165.6 -Cash & cash equivalents 99.3 145.5 Net debt 3 694.7 1 020.1 Underlying EBITDA (12 months) 903.5 1 179.8 + Pro forma EBITDA from acquisitions (12 months) 22.5 17.6 Pro forma underlying EBITDA (12 months) 926.0 1 197.5 Ratio of net debt to underlying EBITDA 4.0 0.9in millions of ‚Ç¨unless otherwise specified 9 months2023 9 months2022 ¬π Sales revenue 2 068.7 2 602.7 Capital expenditures 370.8 288.7 Capital expenditures as % of sales revenue 17.9 11.11 Prior-year figures have been slightly adjusted due to finalization of purchase price allocation for the acquisition of Albumedix Ltd.A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions  the company based in Aubagne  France  helps its customers to manufacture biotech medications safely  rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe  North America and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies. In 2022  the company generated sales revenue of around 3.5 billion euros. Currently  around 11 000 employees are working for customers around the globe.ContactPetra KirchhoffHead of Corporate Communications & Investor Relations+49 (0)551 308 1686petra.kirchhoff@sartorius.com,neutral,0.01,0.98,0.01,mixed,0.08,0.3,0.62,True,English,"['Sartorius Stedim Biotech SA', 'Nine-month results', 'October', '01:03', 'Sartorius Stedim Biotech SA', 'strong fundamental growth drivers', 'additional inventory buildup', 'Ren√© F√°ber', 'ongoing inventory reductions', 'first nine months', 'lower volume development', 'weaker market environment', 'product mix effects', 'Key financial indicators', 'Relevant net profit', 'pandemic-related extraordinary business', 'consolidated sales revenue', 'low production levels', 'lower volume expectations', 'sales revenue development', 'soft business climate', 'preliminary nine-month results', 'sales revenue decline', 'strong growth', 'Main drivers', 'business development', 'strong above', 'Key word', 'Price effects', 'average growth', 'profitable growth', 'growth contribution', 'Net debt', 'First signs', 'Quarter Results', 'market normalization', 'business expectations', 'Covid-19-related business', '9 Month figures', 'constant currencies', 'third quarter', 'global political', 'soft demand', 'previous years', 'investment activity', 'final quarter', 'prior years', '2 percentage points', 'order intake', 'prior-year period', 'customer sides', 'Underlying earnings', 'Polyplus acquisition', 'gross debt', 'underlying EBITDA1', 'Cash flow', 'investing activities', 'capital expenditures', '2,069 million euros', '594 million euros', '1,760 million euros', '607 million euros', '29 million euros', '2,514 million euros', '794 million euros', '1,136 million euros', '377 million euros', 'industry normalization', 'recovery trend', 'slight recovery', 'industry recovery', 'Full-year 2023 outlook', 'economic situation', 'initial signs', 'slower pace', 'resulting margin', 'equity ratio1', 'demand recovery', 'company management', 'fiscal year', '6.58 euros', '695 million', '07:00 CET', 'Aubagne', 'acquisitions', '28.7 percent', 'October', 'uncertainties', 'profitability', 'customers', 'year-end', 'guidance', 'timeline', 'inventories', 'markets', 'CEO', 'expected', 'regions', '19.0 percent', 'organic', '20.5 percent', '13 percent', 'Russia', 'overall', 'China', 'USA', '31.0 percent', '32.4 percent', 'progress', '34.9 percent', '35.0 percent', 'procurement', 'share', 'number', 'employees', 'September', 'financing', '33.0 percent', 'December', '49.6 percent', 'capex', '17.9 percent', '11.1 percent', 'backdrop', 'anticipated', '19 percent', '14 percent', '2024', '3.47']",2023-10-19,2023-10-20,marketscreener.com
31634,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/TERACT-141268668/news/Teract-Annual-results-2022-2023-45097639/,Teract : Annual results 2022-2023 -October 19  2023 at 01:05 am EDT,(marketscreener.com)   PRESS RELEASE   Paris  19 October 2023   Consolidated annual results 2022-2023   TERACT showed good resilience:    Continued work on building a committed retail model   Good cash generation despite the macroeconomic...‚Ä¶,"PRESS RELEASE Paris  19 October 2023 Consolidated annual results 2022-2023 TERACT showed good resilience: Continued work on building a committed retail modelGood cash generation despite the macroeconomic environmentGroup net income impacted by a non-current and non-cash technical listing service charge of ‚Ç¨91.4 million as part of the combination of InVivo Retail and the 2MX Organic SPAC.TERACT (Euronext Paris: TRACT  ISIN: FR001400BMH7) is publishing its consolidated results for the financial year ended 30 June 2023 1 as approved by the Board of Directors at its meeting of 18 October 2023.Moez-Alexandre Zouari  Chief Executive Officer of TERACT  stated: ""The results for the past year show that TERACT held up well despite persistent macroeconomic pressures. The Group was able to continue generating cash without compromising its ability to invest for its development. With uncertainty around price and cost inflation expected to continue in 2023-2024  TERACT is targeting growth in its business volume primarily through the development of the growing bakery-snacks market and an acceleration of the franchise model and its own-brands in the Garden Centre segment. The Group remains open to alliances and acquisitions that make good business sense  where the market positioning would be relevant and complement the downstream activity of InVivo group by which it is backed.""Guillaume Darrasse  Deputy Chief Executive Officer of TERACT  stated: ""In 2023-2024  TERACT will continue to implement the operational plans put in place last year  involving strict management of inventories and costs  the efficient execution of which has enabled it to reduce the impact of inflationary pressures on its results. Additionally  it will forge ahead with the development of its own-brands with the goal of achieving 24% of revenue this year  thus responding effectively to the purchasing power constraints of our customers."" 1The consolidated financial statements have been audited. The auditor's report will be issued after approval of the management report and finalisation of the procedures for filing the Universal Registration Document. 1 / 14PRESS RELEASE Foreword on the key figures TERACT's 2022-2023 consolidated financial statements have been exceptionally impacted by a listing expense as a result of the combination of InVivo Retail with the 2MX Organic SPAC. This listing expense was recognised as a non-cash listing service charge  of ‚Ç¨91.4 million  which was classified under ""Other operating income and expenses"". Key figures in 2022-2023 Breakdown of revenue by segment (in ‚Ç¨m) 30/06/2023 30/06/2022 Change 12 months2 12 months3 Reported Like-for-like4 Revenue 902.1 813.7 10.9% -1.9% Garden Centre/Pet Retail 808.6 794.9 1.7% -1.8% Food Retail 93.5 18.8 X5 NC Financial indicators (in ‚Ç¨m) 30/06/2023 30/06/2022 12 months 9 months5 Revenue 902.1 648.9 Adjusted EBITDA6 67.5 68.9 As a % of revenue 7.5% 10.6% Current operating income 2.1 26.3 Group net income (106.6) 12.0 Free cash flow7 56.88 16.2 Additional information on the length of the 2022-2023 financial year is provided in the press release dated 6 June 2023. For the purpose of comparability of this indicator  revenue is reconstituted over 12 months. As a reminder  TERACT's consolidated financial statements for the 2021-2022 financial year covered a period of nine months (1 October 2021 to 30 June 2022) due to the change in closing date for InVivo Retail which was applied in 2022.The Bio&Co food stores were also restated over 12 months (acquisition by InVivo Retail on 1 June 2022). Constant scope restating all changes in the scope of consolidation. TERACT's consolidated financial statements for the 2021-2022 financial year covered a period of nine months (1 October 2021 to 30 June 2022) due to the change in closing date for InVivo Retail which was applied in 2022. Defined as current operating income plus the elimination of expenses (or income) related to depreciation/ amortisation or impairment (or reversals of depreciation/amortisation or impairment) of fixed assets. Based on net cash flow from operating activities  plus disposals and deductions of property  plant and equipment and intangible assets and after the deduction of acquisition of in property  plant and equipment and intangible assets. Restated for the outflow of non-recurring expenses related to the combination transaction in the amount of ‚Ç¨11 million. 2 / 14PRESS RELEASE Analysis of the 2022-2023 consolidated results Revenue for the 2022-2023 financial year came to ‚Ç¨902.1 million  an increase of +10.9% in reported data and a decrease of -1.9%like-for-like over 12 months versus 2021-2022. The consolidated annual revenue for the 2022-2023 financial year of the Garden Centre/Pet Retail business  which includes the Jardiland  Gamm Vert (and Frais d'ICI range)  Delbard  Jardineries du Terroir and Noa brands  came to ‚Ç¨808.6 million. This represents an increase of +1.7% in reported data and a decrease of -1.8%like-for-like  of which -1.1% in the second half of the year  marked by ongoing macroeconomic pressures. In this highly inflationary environment that also put pressure on purchasing power  TERACT decided to forge ahead and step up the development of its exclusive brands. The penetration rate of its own-brands has thus improved by five points compared with 30 June 2022 (20.6% of the revenue of integrated stores at 30 June 2023). The e-commerce websites (Gammvert.fr and Jardiland.com) saw further growth during the second half of the year  benefiting from the ongoing rollout of the digital plan. The consolidated annual revenue of the Food Retail business  which includes the Bio&Co (consolidated over 12 months)  Boulangerie Louise (consolidated over 7 months) and Grand March√© La Marni√®re (consolidated over 7 months) banners  reached ‚Ç¨93.5 million. The period was impacted by the integration of Boulangerie Louise and Grand March√© la Marni√®re and their teams  and by the ongoing overhaul of Boulangerie Louise's offering with a particular focus on snack products. Adjusted EBITDA came to ‚Ç¨67.5 million in 2022-2023. It was impacted in particular by an increase in inflation across all cost items which did not slow down at the end of the fiscal year. The increase in energy costs was partly offset by the energy savings plan initiated by the Group in September 2022. This notably included the launch of a new platform for the management of electricity consumption  which helped to reduce the latter by 30% versus the previous year. Costs relating to the successful integration of the newly acquired companies and their teams  a priority goal for the Group  and the significant rise in purchasing costs  which were not passed on to selling prices immediately and then only in a limited manner to help preserve purchasing power  also impacted EBITDA. The latter was also impacted by closing effects linked in particular to IFRS consolidation  which explains the difference in relation to the EBITDA estimate of ‚Ç¨75-85 million communicated at the end of July9. Consequently  the adjusted EBITDA margin rate is 7.5%. Current operating income came to ‚Ç¨2.1 million at 30 June 2023. There was an operating loss of ‚Ç¨90.6 million after factoring in non-current expenses of ‚Ç¨92.7 million  mainly attributable to the recognition in 2022-2023 of a non-cash listing service charge of ‚Ç¨91.4 million in the context of the combination of InVivo Retail with the 2MX Organic SPAC. 9 https://www.teract.com/wp-content/uploads/2023/07/TERACT_CP_CA-S2-et-FY-2022-23_20230727_EN.pdf 3 / 14PRESS RELEASE TERACT made a Group net loss of ‚Ç¨106.6 million at 30 June 2023  primarily incorporating the aforementioned impact of the listing expense as part of the combination of InVivo Retail with the 2MX Organic SPAC of ‚Ç¨91.4 million (a non-cash listing service charge)  a net financial loss of ‚Ç¨17.6 million and a tax expense of ‚Ç¨2.3 million. The net income from discontinued operations of ‚Ç¨3.2 million corresponds to a rotation policy applicable to non-strategic assets. Financial structure in 2022-2023 Free cash-flow (in ‚Ç¨m) 30/06/2023 30/06/2022 12 months 9 months Net cash flow from activities 87.910 32.4 Acquisition of property  plant and equipment and intangible assets (33.4) (25.2) Disposals and deductions of property  plant and equipment and intangible assets 2.3 9.0 Free cash flow 56.8 16.2 The Group's free cash flow in 2022-2023 was ‚Ç¨56.8 million. TERACT chose to focus its financial priorities on recurring cash generation. On the one hand  it maintained sound cost management and  on the other  introduced efficient management of existing inventories. At ‚Ç¨33.4 million  investment in operating activities was preserved as part of a rigorous selection process. The difference with the free cash flow estimate of ‚Ç¨60-65 million communicated at the end of July11 is due to the aforementioned lag in relation to EBITDA. Net debt (in ‚Ç¨m) 30/06/2023 30/06/2022 Medium- and long-term debt 468.8 377.8 Of which debt in relation to InVivo Group  the parent company of TERACT 222.8 160.0 Of which rental liabilities (IFRS 16) 225.0 216.4 Net cash 21.4 25.1 Net debt 447.4 352.7 The Group had net debt of ‚Ç¨447.4 million at 30 June 2023 (of which ‚Ç¨222.8 million with its parent company InVivo Group and ‚Ç¨225 million in rental liabilities). The change is mainly attributable to the development of the Food Retail activity and in particular the acquisition over the year of two companies (Boulangerie Louise and Grand March√© La Marni√®re) and their impact in terms of rental payments. Restated for the outflow of non-recurring expenses related to the combination transaction in the amount of ‚Ç¨11 million. https://www.teract.com/wp-content/uploads/2023/07/TERACT_CP_CA-S2-et-FY-2022-23_20230727_EN.pdf 4 / 14PRESS RELEASE Outlook Commitments and outlook concerning CSR In line with its commitments  in 2023  TERACT will submit a proposal to its Shareholders' Meeting for a change of status to ""soci√©t√© √† mission""  with its purpose being ""To help make the benefits of nature accessible to all"". This will entail the Group building and providing access to an offering of products and services that are healthy and responsible  applying operating practices that promote well-being and the environment and mobilising its employees and stakeholders in the regions in order to achieve the Group's societal ambition and meet new consumption expectations. To this end  it will implement and commit to a series of operational objectives that it will also track. The Group's main CSR objectives over the coming years are as follows12: Between now and 2025: 50% of managers to be hired through internal promotion (14.7% in 2022-2023)2022-2023) 50% less workplace accidents compared with 202090% of exclusive own-brandplant-based products of French origin (excluding greenhouse) (83% in 2022-2023) and 50% of plant products from sector commitments (43% in 2022-2023)own-brandplant-based products of French origin (excluding greenhouse) (83% in 2022-2023) and 50% of plant products from sector commitments (43% in 2022-2023) 80% of exclusive own-brands with a positive impact (54.4% in 2022-2023) By 2030:own-brands with a positive impact (54.4% in 2022-2023) By 2030: 10% less water consumption compared with 2022-20232022-2023 100% of stores accredited an animal welfare label (35% in 2022-2023)2022-2023) 70% of waste sorted and recycled (59% in 2022-2023)2022-2023) -46% reduction in greenhouse gas emissions versus 2019-2020 (scopes 1 and 2) (47.6% reduction in 2022-2023). The target has therefore already been achieved for the Garden Centre/Pet Retail scope thanks to the effectiveness of TERACT's multi-annual energy savings and efficiency plan. Operating and financial outlook Amid persistent macroeconomic pressures in the second half of 2023 (first half of TERACT's 2023-2024 financial year) and uncertainty as to how the situation will evolve in the first half of 2024 (second half of TERACT's 2023-2024 financial year)  the Group is maintaining a prudent approach in order to limit the effects of inflation and reduced purchasing power while also improving the seasonal aspect of its business model in order to generate growth. New store openings  particularly in the bakery/snacks line (around ten to be opened between now and June 2024)  will enable to bolster revenue in a sector that continues to offer high margins and a strong growth outlook and in which the potential for greater regional coverage is strong. TERACT will also continue to roll out its own Garden Centre brands  for which it targets an increase in the penetration rate of 2 to 3 percentage points to 24% of the revenue of integrated stores in 2023-2024. The company will also continue to ensure effective management and optimisation of its store network while pursuing the development of its franchise model. This will be underpinned by an attractive omnichannel model that is a leader in the sector in France  as part of an overhaul of the e-commerce websites and a focus on stores put back at the core of the digital strategy  through the repayment of the revenue 12 The scope of indicators for 2022-2023 does not include the entities integrated since 1 December 2022  i.e. Boulangerie Louise and Grand March√© La Marni√®re. It will be expanded for the 2023-2024 financial year. 5 / 14PRESS RELEASE concerned. The strict cost management policy  particularly in relation to energy  will be maintained while the integration of companies acquired during the year is being completed. Taking into account these elements  and barring any further deterioration in the environment  TERACT estimates it will generate revenue in 2023-2024 of ‚Ç¨900-950 million. The ongoing work to control costs and inventories should continue to have a positive impact on free cash flow generation while maintaining a capex level enabling to effectively pursue the company's development. In line with the projects undertaken over the past year  TERACT remains open to alliances that make good business sense and which would generate growth  improve the margin and integrate effectively with the upstream/downstream activities of InVivo. *** 6 / 14PRESS RELEASE Appendix 1. Store network 30/06/2022 30/06/2023 Garden Centre/Pet Retail 1 581 1 576 Jardiland 175 172 Integrated stores 110 105 Franchises/Affiliates 65 67 Gamm vert (including Frais d'Ici range) 1 158 1 153 Integrated stores 98 98 Franchises/Affiliates 1 060 1 055 Delbard and Jardineries du Terroir 245 248 Franchises/Affiliates 245 248 Noa 3 3 Integrated stores 3 3 Food Retail 7 138 Boulangerie Louise 128 Integrated stores 119 Franchises/Affiliates 9 Grand March√© La Marni√®re 3 Integrated stores 3 Bio&Co 7 7 Integrated stores 7 7 Group 1 588 1 714 7 / 14PRESS RELEASE 2. Sales volume13 (in ‚Ç¨m) 30/06/2023 30/06/2022 Change 12 months 12 months 14 Reported 15 Like-for-like Estimated annual gross sales under banner excluding VAT 2 483.4 2 389.6 3.9% 0.9% Garden Centre/Pet Retail 2 388.4 2 370.8 0.7 % 0.9% Food Retail 95.0 18.8 X5 NC Unaudited figures Sales volume and revenue from the brands include the revenue generated by the integrates stores and by the franchised/affiliated stores. For the purpose of comparability of this indicator  revenue is reconstituted over 12 months. TERACT's consolidated financial statements for the 2021-2022 financial year covered a period of nine months (1 October 2021 to 30 June 2022) due to the change in closing date for InVivo Retail which was applied in 2022. Constant scope restating all changes in the scope of consolidation. Excluding affiliates. 8 / 14PRESS RELEASE 3. Reconciliation of non-IFRS financial indicators Adjusted EBITDA (in ‚Ç¨m) 30/06/2023 30/06/2022 12 months 9 months Current operating income 2.1 26.3 Elimination of expenses (or income) related to depreciation/ amortisation or impairment (or reversals of depreciation/amortisation or impairment) of fixed assets 65.4 42.6 Adjusted EBITDA 67.5 68.9 9 / 14",neutral,0.01,0.98,0.01,mixed,0.54,0.26,0.2,True,English,"['Annual results', 'Teract', 'October', '01', '05', 'non-cash technical listing service charge', 'The Bio&Co food stores', 'macroeconomic environment Group net income', 'cash listing service charge', 'Deputy Chief Executive Officer', 'Garden Centre/Pet Retail business', '2022-2023 consolidated financial statements', 'net cash flow', 'persistent macroeconomic pressures', 'ongoing macroeconomic pressures', '2MX Organic SPAC', 'purchasing power constraints', 'Universal Registration Document', 'Jardineries du Terroir', 'NC Financial indicators', 'Free cash flow7', 'Other operating income', 'good business sense', '2022-2023 financial year', 'growing bakery-snacks market', 'PRESS RELEASE Foreword', 'PRESS RELEASE Analysis', 'Good cash generation', '2021-2022 financial year', 'Current operating income', 'PRESS RELEASE Paris', '2022-2023 consolidated results', 'committed retail model', 'Garden Centre segment', 'Food Retail', 'The Group', 'listing expense', 'business volume', 'InVivo group', 'operating activities', 'good resilience', 'inflationary pressures', 'Euronext Paris', 'past year', 'franchise model', 'market positioning', 'InVivo Retail', 'Moez-Alexandre Zouari', 'cost inflation', 'downstream activity', 'Guillaume Darrasse', 'operational plans', 'strict management', 'efficient execution', 'key figures', 'Additional information', 'closing date', 'depreciation/ amortisation', 'fixed assets', 'intangible assets', 'Gamm Vert', 'ICI range', 'second half', 'annual results', 'management report', 'Constant scope', 'nine months', 'non-recurring expenses', 'combination transaction', 'Noa brands', 'annual revenue', '12 months', 'TERACT', 'work', 'part', 'TRACT', 'ISIN', 'Board', 'Directors', 'meeting', '18 October', 'ability', 'development', 'uncertainty', 'price', 'growth', 'acceleration', 'alliances', 'acquisitions', 'place', 'inventories', 'costs', 'impact', 'goal', 'customers', 'auditor', 'approval', 'finalisation', 'procedures', 'Breakdown', 'Change', '9 months5', 'EBITDA6', 'length', 'June', 'purpose', 'reminder', 'period', 'consolidation', 'elimination', 'impairment', 'reversals', 'depreciation/amortisation', 'disposals', 'deductions', 'property', 'plant', 'equipment', 'outflow', 'amount', 'increase', 'data', 'decrease', 'Jardiland', 'Frais', 'Delbard']",2023-10-19,2023-10-20,marketscreener.com
31635,EuroNext,NewsApi.org,https://www.marketwatch.com/story/abivax-increases-size-of-nasdaq-uplisting-deal-e93c193b,: Abivax increases size of Nasdaq uplisting deal,Abivax S.A. FR:ABVX has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol ‚ÄúABVX‚Äù from Euronext Paris  according to a filing late Wednesday. Abivax plans t‚Ä¶,Abivax S.A. ABVX  -26.06% has increased the size of its global offering to 20.33 million shares from 18.68 million shares as part of its uplisting to the Nasdaq under the ticker symbol ‚ÄúABVX‚Äù from Euronext Paris  according to a filing late Wednesday. Abivax plans to raise about $250 million with underwriters Morgan Stanley and Leerink at an estimated price range of $11.60 a share to $13 a share. The stock is expected to begin trading on Friday on the Nasdaq  according to IPOScoop.com. The deal will result in newly-listed stock on the Nasdaq  but it‚Äôs not technically an initial public offering. Abivax is a clinical stage biotechnology company with a drug  obefazimod  in Phase III trials to treat ulcerative colitis. The company is offering American depositary shares in the U.S. and selling additional shares through a private placement in Europe.,neutral,0.07,0.93,0.01,neutral,0.01,0.96,0.03,True,English,"['Nasdaq uplisting deal', 'Abivax', 'size', 'clinical stage biotechnology company', 'Abivax S.A. ABVX', 'Phase III trials', 'initial public offering', 'American depositary shares', 'U.S.', 'global offering', '20.33 million shares', '18.68 million shares', 'additional shares', 'ticker symbol', 'Euronext Paris', 'Morgan Stanley', 'price range', 'ulcerative colitis', 'private placement', 'size', 'part', 'uplisting', 'Nasdaq', 'filing', 'underwriters', 'Leerink', 'stock', 'Friday', 'IPOScoop', 'deal', 'drug', 'obefazimod', 'Europe']",2023-10-19,2023-10-20,marketwatch.com
31636,EuroNext,Bing API,https://www.bignewsnetwork.com/news/274006128/wall-street-joins-global-meltdown-dow-jones-dives-287-points,Wall Street joins global meltdown  Dow Jones dives 287 points,CAC 40 - Euronext Paris France's CAC 40 exhibited a decline of 1.52 percent  shedding 105.15 points to end the trading day at 6 816.22. ESTX 50 PR.EUR - Euronext The ESTX 50 PR.EUR index  which represents the Eurozone  closed with a decrease of 1.61 ...,CAC 40 - Euronext Paris France's CAC 40 exhibited a decline of 1.52 percent  shedding 105.15 points to end the trading day at 6 816.22. ESTX 50 PR.EUR - Euronext The ESTX 50 PR.EUR index  which represents the Eurozone  closed with a decrease of 1.61 ...,neutral,0.02,0.89,0.08,neutral,0.02,0.86,0.12,True,English,"['Wall Street', 'global meltdown', 'Dow Jones', 'Euronext Paris France', 'The ESTX 50 PR', 'trading day', 'EUR index', 'CAC', 'decline', '1.52 percent', '105.15 points', 'Eurozone', 'decrease']",2023-10-20,2023-10-20,bignewsnetwork.com
31637,EuroNext,Bing API,https://www.malaysiasun.com/news/274006128/us-stocks-tack-on-to-world-markets-sell-off,U.S. stocks tack on to World markets sell-off,CAC 40 - Euronext Paris France's CAC 40 exhibited a decline of 1.52 percent  shedding 105.15 points to end the trading day at 6 816.22. ESTX 50 PR.EUR - Euronext The ESTX 50 PR.EUR index  which represents the Eurozone  closed with a decrease of 1.61 ...,CAC 40 - Euronext Paris France's CAC 40 exhibited a decline of 1.52 percent  shedding 105.15 points to end the trading day at 6 816.22. ESTX 50 PR.EUR - Euronext The ESTX 50 PR.EUR index  which represents the Eurozone  closed with a decrease of 1.61 ...,neutral,0.04,0.95,0.01,neutral,0.02,0.86,0.12,True,English,"['U.S. stocks', 'World markets', 'Euronext Paris France', 'The ESTX 50 PR', 'trading day', 'EUR index', 'CAC', 'decline', '1.52 percent', '105.15 points', 'Eurozone', 'decrease']",2023-10-20,2023-10-20,malaysiasun.com
31638,EuroNext,Bing API,https://www.tmcnet.com/usubmit/2023/10/20/9902848.htm,Mdxhealth's New Share Capital Amount and New Number of Shares,"IRVINE  CA  and HERSTAL  BELGIUM ‚Äì October 20  2023 ‚Äì MDxHealth SA (NASDAQ/Euronext: MDXH) (""mdxhealth"" or the ""Company"")  a commercial-stage precision diagnostics company  today a announces  in accordance with Article 15 of the Belgian Act of May 2 ...","IRVINE  CA  and HERSTAL  BELGIUM ‚Äì October 20  2023 ‚Äì MDxHealth SA (NASDAQ/Euronext: MDXH) (""mdxhealth"" or the ""Company"")  a commercial-stage precision diagnostics company  today a announces  in accordance with Article 15 of the Belgian Act of May 2 ...",neutral,0.02,0.98,0.0,neutral,0.12,0.86,0.03,True,English,"['New Share Capital Amount', 'New Number', 'Mdxhealth', 'Shares', 'commercial-stage precision diagnostics company', 'Belgian Act', 'MDxHealth SA', 'IRVINE', 'CA', 'HERSTAL', 'BELGIUM', 'October', 'NASDAQ/Euronext', 'accordance', 'Article', 'May']",2023-10-20,2023-10-20,tmcnet.com
31639,EuroNext,Bing API,https://finance.yahoo.com/news/oxurion-receives-transparency-notifications-atlas-180000186.html,Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC,October 20  2023 ‚Äì 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR)  a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with clinical stage assets in vascular retinal disorders ,Regulated InformationLeuven  BELGIUM  Boston  MA  US ‚Äì October 20  2023 ‚Äì 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR)  a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with clinical stage assets in vascular retinal disorders  today announced that  pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:Oxurion received a first transparency notification on October 19  2023  from Atlas Special Opportunities  LLC indicating that as of October 10  2023  it held 134 526 711 shares of the then outstanding 2 758 351 314 shares  and therefore crossed above the threshold (3%) by virtue of the acquisition of voting securities. See Annex 1.Oxurion received a second transparency notification on October 19  2023  from Atlas Special Opportunities  LLC indicating that as of October 13  2023  it held 52 513 222 shares of the then outstanding 2 758 351 314 shares  and therefore crossed under the threshold (3%) by virtue of the sale of voting securities. See Annex 2.About OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.Story continuesFor further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMichael DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.comUSConway CommunicationsMary T. Conwaymtconway@conwaycommsir.com________1. Article 14  first paragraph  of the Law of 2 May 2007 on disclosure of major holdings.ANNEX 1ANNEX 2Attachments,neutral,0.04,0.95,0.01,mixed,0.14,0.42,0.44,True,English,"['Atlas Special Opportunities LLC', 'Transparency Notifications', 'Oxurion', 'applicable U.S. state securities laws', 'U.S. Securities Act', 'potent plasma kallikrein inhibitor', 'next generation standard', 'Atlas Special Opportunities', 'diabetic macular edema', 'Chief Executive Officer', 'Belgian Transparency legislation1', 'second transparency notification', 'potential new standard', 'Mary T. Conway', 'first transparency notification', 'clinical stage assets', 'Chief Business Officer', 'vascular retinal disorders', 'Such forward-looking statements', 'Regulated Information Leuven', 'CET Oxurion NV', 'care ophthalmic therapies', 'transparency notifications', 'voting securities', 'new information', 'Conway Communications', 'first paragraph', 'More information', 'Important information', 'Additional information', 'further information', 'Euronext Brussels', 'leading cause', 'working-age people', 'other conditions', 'important role', 'successful development', 'novel therapeutic', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'Annual Report', 'United States', 'major holdings', 'biopharmaceutical company', 'The Company', 'vision loss', 'various risks', 'Tom Graney', 'ANNEX 2 Attachments', 'Michael Dillen', 'DME patients', 'ANNEX 1', 'BELGIUM', 'Boston', 'October', 'LLC', '134,526,711 shares', '2,758,351,314 shares', 'threshold', 'virtue', 'acquisition', '52,513,222 shares', 'sale', 'treatment', 'THR-149', 'uncertainties', 'assurance', 'obligation', 'offer', 'invitation', 'purchase', 'jurisdiction', 'registration', 'compliance', 'exemption', 'accordance', 'Story', 'Tel', 'Article', '2 May', 'disclosure', '8.00', '32']",2023-10-20,2023-10-20,finance.yahoo.com
31640,EuroNext,Bing API,https://uk.finance.yahoo.com/news/information-total-number-voting-rights-180100501.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas,Regulated Information - Denominator Atlas Special Opportunities  LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100 000 capital increase. This is part of Atlas Special Opportunities ,Regulated Information - DenominatorAtlas Special Opportunities  LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100 000 capital increase. This is part of Atlas Special Opportunities  LLC‚Äôs EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US ‚Äì October 20  2023 ‚Äì 08.00 PM CET ‚Äì In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the ‚ÄúCompany‚Äù or ‚ÄúOxurion‚Äù)  announces the below information  following the issuance of 120 772 946 new ordinary shares on October 20  2023  for a total amount of EUR 100 000  as the result of the conversion of 4 convertible bonds  pursuant to the Capital Commitment entered into with Atlas Special Opportunities  LLC.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 2 879 124 260 outstanding ordinary shares carrying voting rights (compared to 2 758 351 314 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 82 956 161.32Total number of securities with voting rights (all ordinary shares) 2 879 124 260 Total number of ordinary shares (= denominator) 2 879 124 260 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 590 500 subscription rights (‚ÄúSRs‚Äù) issued on November 20  2017  entitling their holders to subscribe to a total number of 590 500 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);972 250 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 972 250 securities carrying voting rights (all ordinary shares);532 500 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 532 500 securities carrying voting rights (all ordinary shares);604 405 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 604 405 securities carrying voting rights (all ordinary shares);182 convertible bonds issued on March 14  2023  April 20  2023  May 22  2023  June 15  2023  August 10  2023  September 15  2023  October 10  2023  and October 20 entitling its holder  Atlas Special Opportunities  LLC  to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities  LLC on March 1  2023  as amended on October 3  2023.100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021 (as amended from time to time).ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Story continuesImportant information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMicha√´l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsMary T. Conwaymtconway@conwaycommsir.com1 Press release Oxurion  02/03/2023Attachments,neutral,0.01,0.99,0.0,mixed,0.24,0.33,0.43,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'Atlas', 'potent plasma kallikrein inhibitor', 'EUR 20 million Capital Commitment1', 'Atlas Special Opportunities', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'potential new standard', 'EUR 100,000 capital increase', 'Kreos Capital VI', 'potential market opportunities', 'care ophthalmic therapies', 'Such forward-looking statements', '120,772,946 new ordinary shares', '2,879,124,260 outstanding ordinary shares', 'Israel) L.P.', 'Share capital', 'regulated market', '4 convertible bonds', 'drug candidate', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', '182 convertible bonds', '100 convertible bonds', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'press release', 'current expectations', 'various risks', 'voting rights', '590,500 subscription rights', 'total number', 'Regulated Information', 'updated information', 'More information', 'Important information', 'Subscription Agreement', 'vision loss', 'novel therapeutic', 'biopharmaceutical company', 'The Company', 'other conditions', 'Oxurion NV', 'DME patients', 'Denominator', 'LLC', 'back', 'eye', 'Leuven', 'BELGIUM', 'Boston', 'October', '08.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'result', 'conversion', 'completion', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'March', 'June', 'August', 'terms', 'UK', 'Cayman', 'Limited', 'time', 'treatment', 'THR-149', 'Story', 'uncertainties', 'assurance', 'obligation']",2023-10-20,2023-10-20,uk.finance.yahoo.com
31641,EuroNext,Bing API,https://www.finanznachrichten.de/nachrichten-2023-10/60426165-abivax-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris-200.htm,Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris,"PARIS  FRANCE / ACCESSWIRE / October 20  2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (""Abivax"" or the ""Company"")  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to ...","PARIS  FRANCE / ACCESSWIRE / October 20  2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (""Abivax"" or the ""Company"")  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases  announced the trading resumption of its ordinary shares on Euronext in Paris (""Euronext Paris"") as from 4:20 p.m. CEST.Trading of the ordinary shares of Abivax was halted at the request of the Company on October 20  2023 from 9:00 a.m. CEST in connection with its previously announced initial public offering of the Company's American Depositary Shares (""ADSs"") on the Nasdaq Global Market (the ""Global Offering"")  in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company's ADSs on the Nasdaq Global Market.***About AbivaxAbivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S.  Abivax's lead drug candidate  obefazimod (ABX464)  is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.Contacts:Abivax CommunicationsRegina Jehleregina.jehle@abivax.com+33 6 24 60 69 63 Abivax Investor RelationsPatrick Malloypatrick.malloy@abivax.com+1 847 987 487***DisclaimersThis press release does not constitute an offer to sell nor a solicitation of an offer to buy  nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer  solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The distribution of this document may  in certain jurisdictions  be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.A French listing prospectus comprising (i) the 2023 Universal Registration Document (Document d'Enregistrement Universel 2023) filed with the French Autorit√© des march√©s financiers (""AMF"") on May 4  2023  under number D.23-0394  as amended by a first amendment filed with the AMF on September 29  2023 under number D.23-0394-A01  as completed by a second amendment to such 2023 Universal Registration Document  which will be filed with the AMF  and (ii) a Securities Note (Note d'op√©ration)  including a summary of the prospectus  will be submitted to the approval by the AMF and will be published on the AMF's website at www.amf-france.org. Following the filing of the second amendment to the 2023 Universal Registration Document with the AMF  copies of Company's 2023 Universal Registration Document  as amended  will be available free of charge at the Company's head office located at 7-11 boulevard Haussmann  75009 Paris  France.European Economic AreaIn relation to each Member State of the European Economic Area (each  a ""Relevant State"")  no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than:to any legal entity which is a qualified investor as defined Article 2 (e) of under the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation)  subject to obtaining the prior consent of the representatives for any such offer; or in any other circumstances falling within Article 1(4) of the Prospectus Regulation provided that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.For the purposes of this provision  the expression an ""offer to the public"" in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities  and the expression ""Prospectus Regulation"" means Regulation (EU) 2017/1129 of June 14  2017  as amended.FranceThe securities have not been and will not be offered or sold to the public in the Republic of France  and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute  directly or indirectly  an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier)).The securities may only be offered or sold in France pursuant to article L. 411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier) to qualified investors (investisseurs qualifi√©s) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account  and in accordance with articles L. 411-1  L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code (Code mon√©taire et financier).This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.SOURCE: ABIVAXView source version on accesswire.com:https://www.accesswire.com/794978/abivax-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris",neutral,0.03,0.96,0.01,negative,0.01,0.24,0.75,True,English,"['Trading Resumption', 'Ordinary Shares', 'Euronext Paris', 'Abivax', 'French Autorit√© des march√©s financiers', 'chronic inflammatory diseases', 'lead drug candidate', 'Phase 3 clinical trials', 'active ulcerative colitis', '7-11 boulevard Haussmann', 'European Economic Area', 'Nasdaq Global Market', 'potential local restrictions', 'Code mon√©taire', 'natural regulatory mechanisms', 'American Depositary Shares', 'French listing prospectus', '2023 Universal Registration Document', 'clinical-stage biotechnology company', 'initial public offering', 'Abivax Investor Relations', 'U.S.', 'French Monetary', 'Global Offering', 'local legislations', 'Financial Code', 'ordinary shares', 'immune response', 'press release', 'Enregistrement Universel', 'first amendment', 'second amendment', 'op√©ration', 'amf-france.org', 'head office', 'legal entity', 'qualified investor', 'prior consent', 'other circumstances', 'sufficient information', 'marketing materials', 'Member State', 'Relevant State', 'Prospectus Regulation', 'Regina Jehle', 'Patrick Malloy', 'legal persons', 'public offerings', 'Abivax SA', 'Abivax Communications', 'trading resumption', 'Article L.', 'securities laws', 'Euronext Paris', 'Securities Note', '150 natural', 'investors', '75009 Paris', 'ACCESSWIRE', 'October', 'ABVX', 'therapeutics', 'body', 'patients', 'CEST', 'request', '9:00 a', 'connection', 'ADSs', 'order', 'confirmation', 'allocations', 'commencement', 'obefazimod', 'treatment', 'Contacts', 'Disclaimers', 'solicitation', 'sale', 'jurisdiction', 'qualification', 'distribution', 'possession', 'May', 'number', 'September', 'summary', 'approval', 'website', 'filing', 'copies', 'charge', 'fewer', 'representatives', 'purposes', 'provision', 'expression', 'means', 'terms', 'June', 'Republic', 'way', 'investisseurs', 'actin', '4:20']",2023-10-06,2023-10-20,finanznachrichten.de
31642,EuroNext,Bing API,https://markets.businessinsider.com/news/stocks/eqs-news-abivax-announces-the-pricing-of-its-initial-public-offering-on-the-nasdaq-global-market-160-1032724320,EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market,EQS-News: ABIVAX    / Key word (s): IPO Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 20.10.2023 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement.,EQS-News: ABIVAX / Key word(s): IPOAbivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market20.10.2023 / 15:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market PARIS  France  October 20  2023 ‚Äì 3:00 p.m. (CEST) ‚Äì Abivax SA (Euronext Paris: FR0012333284 ‚Äì ABVX) (‚ÄúAbivax‚Äù or the ‚ÄúCompany‚Äù)  a clinical-stage biotechnology company focused on developing therapeutics that harness the body‚Äôs natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases  announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20 325 500 new ordinary shares (the ‚ÄúNew Shares‚Äù)  consisting of a public offering of 18 699 460 ordinary shares in the form of American Depositary Shares (‚ÄúADSs‚Äù)  each representing the right to receive one ordinary share  in the United States (the ‚ÄúU.S. Offering‚Äù) and a concurrent offering of 1 626 040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the ‚ÄúEuropean Private Placement‚Äù and together with the U.S. Offering  the ‚ÄúGlobal Offering‚Äù). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of ‚Ç¨10.9864 per ordinary share based on an exchange rate of ‚Ç¨1.00 = $1.0559 as published by the European Central Bank on October 19  2023. The aggregate gross proceeds are expected to be approximately $235.8 million  equivalent to approximately ‚Ç¨223.3 million  before deduction of underwriting commissions and estimated expenses payable by the Company. The Global Offering is expected to close on October 24  2023  subject to the satisfaction of customary closing conditions. All securities to be sold in the Global Offering will be offered by the Company. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October 20  2023 under the ticker symbol ‚ÄúABVX‚Äù. The Company‚Äôs ordinary shares are listed on the regulated market of Euronext Paris (‚ÄúEuronext Paris‚Äù) under the symbol ‚ÄúABVX‚Äù. The ordinary shares underlying the ADSs sold in the Global Offering will be subject to an application for admission to trading on Euronext Paris (Compartment B) on the same trading line as the existing shares under the same ISIN code FR0012333284 and are expected to be admitted to trading on October 24  2023. Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering. LifeSci Capital is acting as lead manager for the proposed U.S. Offering. Bryan  Garnier & Co is acting as European lead manager for the proposed European Private Placement (collectively  the ‚ÄúUnderwriters‚Äù). Namsen Capital is acting as Abivax‚Äôs capital markets advisor. Pricing of the Global Offering and Discount The offering price was set at $11.60 per ADS. The offering price per ADS corresponds to the offering price of ‚Ç¨10.9864 per ordinary share based on the October 19  2023 exchange rate of ‚Ç¨1.00 = $1.0559. The public offering price per ordinary share in euros (‚Ç¨10.9864) is equal to the volume weighted-average price of the Company‚Äôs ordinary shares on Euronext Paris over the last three (3) trading days preceding the start of the offering (i.e.  16th  17th and 18th of October 2023)  less a discount of 9.4%  and is determined by the Company in compliance with the 15th resolution of the Company‚Äôs combined general shareholders‚Äô meeting held on June 5  2023. Type of Offering The New Shares will be issued through a capital increase without shareholders‚Äô preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier) and under the provisions of Article L.225-136 of the French Commercial Code (Code de commerce) and pursuant to the fifteenth and nineteenth resolutions of the Company‚Äôs combined general shareholders‚Äô meeting held on June 5  2023. Option to Purchase Additional Shares The Company has granted the Underwriters an option to purchase (the ‚ÄúOption‚Äù)  for a 30-day period (until November 20  2023)  up to 3 048 825 additional ADSs and/or ordinary shares  which represents 15% of the aggregate amount of New Shares to be issued in the Global Offering  at the same offering price. Stabilization In connection with the Global Offering  the Underwriters may over-allot the securities or effect transactions with a view to supporting  stabilizing  or maintaining the market price of the securities at a level higher than which might otherwise prevail in the open market. However  there is no assurance that the stabilizing manager will take any stabilization action and  if begun  may be ended at any time without prior notice. Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the Nasdaq Global Market and/or Euronext Paris. Dilution Based on the issuance of 20 325 500 New Shares in the Global Offering (including ordinary shares in the form of ADSs)  the number of ordinary shares held by the existing shareholders after the Global Offering would be 67.7% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering. If the Underwriters exercise their option to purchase 3 048 825 additional ADSs and/or ordinary shares in full  the number of ordinary shares held by the existing shareholders after the Global Offering would be 64.5% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering. Estimated Proceeds from the Global Offering - Reasons of the offering - Use of proceeds The gross proceeds of the sale of 20 325 500 New Shares  including ordinary shares in the form of ADSs  in the Global Offering is expected to be approximately $235.8 million (‚Ç¨223.3 million)  assuming no exercise of the Underwriters‚Äô Option. The Company estimates that the net proceeds of the Global Offering will be approximately $212.2 million (‚Ç¨201.1 million)  after deducting approximately $16.5 million (‚Ç¨15.6 million) in underwriting commissions and approximately $7.0 million (‚Ç¨6.6 million) in estimated offering expenses. The Company expects to use the net proceeds from the Global Offering as follows (assuming an exchange rate of ‚Ç¨1.00 = $1.0559  the exchange rate on October 19  2023): approximately ‚Ç¨160.0 million ($168.9 million) to fund the development of obefazimod for UC;approximately ‚Ç¨14.0 million ($14.8 million) to fund the development of obefazimod for CD; andthe remainder for working capital and for other general corporate purposes  including in the continued research to identify new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments under the Kreos / Claret Financing (as defined below)  and assuming that the Company will repay the Heights Financing (as defined below) through the issuance of new shares instead of making cash payments). The Company believes that the anticipated net proceeds from the Global Offering  together with its current cash and cash equivalents  will allow it to finance its operations through (i) the announcement of its top-line data from its Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of its top-line data from its Phase 2a induction trial for CD. The Company believes that based on its current clinical plan and its anticipated net proceeds from the Global Offering  together with (a) its existing cash and cash equivalents of ‚Ç¨114.4 million as of June 30  2023  (b) the net proceeds of the August 2023 drawdown of the first tranches of the financing agreements entered into with entities affiliated with Kreos Capital (‚ÄúKC‚Äù) and Claret European Growth Capital (the ‚ÄúKreos / Claret Financing‚Äù) and entities affiliated with Heights Capital Management (the ‚ÄúHeights Financing‚Äù)  collectively amounting to ‚Ç¨27.2 million (net of repayments of all outstanding amounts that remained due under the prior two financing agreements entered into with KC and the OCEANE bonds)  (c) the anticipated net proceeds from the drawdown of the second tranche of the Kreos / Claret Financing  amounting to ‚Ç¨25 million (which is a portion of the total available drawdown of ‚Ç¨65 million from the Kreos / Claret Financing and the Heights Financing) and (d) the expected Research Tax Credit (CIR) reimbursements would enable the Company to fund its operations through the fourth quarter of 2025. Under these assumptions and based on its current clinical plan  the Company would have sufficient funds to finance its operations through (i) the announcement of its top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of its top-line data from the Phase 2a induction trial for CD. If the Company further draws down on the third tranche of the Kreos / Claret Financing  amounting to ‚Ç¨25 million and the second tranche of the Heights Financing amounting to ‚Ç¨40 million  the Company expects to have sufficient funds to finance its operations through the first quarter of 2026. Under these assumptions and based on its current clinical plan  it would have sufficient funds to finance its operations through the announcement of its top-line data from the Phase 3 ABTECT maintenance trial for UC. Underwriting The Global Offering is subject to an underwriting agreement entered into on October 19  2023. The underwriting agreement does not constitute a ‚Äúgarantie de bonne fin‚Äù within the meaning of Article L. 225-145 of the French Commercial Code (Code de commerce). Documentation The securities referred to in this press release will be offered only by means of a prospectus. When available  copies of the final prospectus relating to and describing the terms of the proposed Global Offering may be obtained from: Morgan Stanley & Co. LLC  Attention: Prospectus Department  180 Varick Street  2nd Floor  New York  NY 10014 or by email at prospectus@morganstanley.com; or Leerink Partners LLC  Attention: Syndicate Department  53 State Street  40th Floor  Boston  MA 02109  by telephone at (800) 808-7525  ext. 6105  or by email at syndicate@leerink.com. Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on Euronext Paris pursuant to a listing prospectus subject to an approval from the French Autorit√© des march√©s financiers (‚ÄúAMF‚Äù) and comprising (i) the 2023 Universal Registration Document (Document d‚ÄôEnregistrement Universel 2023) filed with the AMF on May 4  2023 under number D.23-0394  as amended by a first amendment filed with the AMF on September 29  2023 under number D.23-0394-A01  as completed by a second amendment to such 2023 Universal Registration Document  which will be filed with the AMF  and (ii) a Securities Note (Note d‚Äôop√©ration)  including a summary of the prospectus. Copies of the 2023 Universal Registration Document are available free of charge at the Company‚Äôs head office located at 7-11 boulevard Haussmann  75009 Paris  France  on the Company‚Äôs website (www.abivax.com) and on the website of the AMF (www.amf-france.org/). Risk Factors Investors should carefully consider the risks factors likely to affect the Company‚Äôs business as described in Chapter 3 ‚ÄúRisk Factors‚Äù of the 2023 Universal Registration Document  in Chapter 5 of its first amendment and in Chapter 3 of its second amendment and in the risk factors section of the Company‚Äôs registration statement on Form F-1 before marking an investment decision. If any of these risks are realized  the Company‚Äôs business  financial condition  operating results and prospects could be materially and adversely affected. In addition  other risks  not identified or considered significant by the Company  could have the same adverse effect and investors could lose all or part of their investment. *** About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body‚Äôs natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S.  Abivax‚Äôs lead drug candidate  obefazimod (ABX464)  is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.Contacts: Abivax CommunicationsRegina Jehleregina.jehle@abivax.com+33 6 24 60 69 63 Abivax Investor RelationsPatrick Malloypatrick.malloy@abivax.com+1 847 987 4878 *** Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Global Offering  including: the completion of the Global Offering  use of proceeds from the Global Offering  as well as statements regarding Abivax‚Äôs clinical development plans  business and regulatory strategy  and anticipated future performance. Although the Company believes its expectations are based on reasonable assumptions  these forward-looking statements are subject to numerous risks and uncertainties  which could cause actual results to differ materially from those expressed in  or implied or projected by  the forward-looking statements. These risks and uncertainties include among other things  the uncertainties inherent in research and development  including related to progression of  and results from  its ongoing and planned clinical trials  including clinical trials for obefazimod  review and approvals by regulatory authorities  such as the FDA or the EMA  of its drug candidates and the Company‚Äôs continued ability to raise capital to fund its development  including as part of the proposed Global Offering  the Company‚Äôs ability to obtain  maintain  protect and enforce its intellectual property rights  as well as those discussed or identified in the Company‚Äôs registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission and the Company‚Äôs public filings with the AMF  in particular in the 2023 Universal Registration Document  as amended  for additional information in relation to such factors  risks and uncertainties. Other than as required by applicable law  the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in the Company in any country. This press release has been prepared in both French and English. In the event of any differences between the two versions of the press release  the French language version shall supersede. Disclaimers This press release does not constitute an offer to sell nor a solicitation of an offer to buy  nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer  solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The distribution of this document may  in certain jurisdictions  be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions. A French listing prospectus comprising (i) the 2023 Universal Registration Document (Document d‚ÄôEnregistrement Universel 2023) filed with the AMF on May 4  2023 under number D.23-0394  as amended by a first amendment filed with the AMF on September 29  2023 under number D.23-0394-A01  as completed by a second amendment to such 2023 Universal Registration Document  which will be filed with the AMF  and (ii) a Securities Note (Note d‚Äôop√©ration)  including a summary of the prospectus  will be submitted to the approval by the AMF and will be published on the AMF‚Äôs website at www.amf-france.org/. Following the filing of the second amendment to the 2023 Universal Registration Document with the AMF  copies of Company‚Äôs 2023 Universal Registration Document  as amended  will be available free of charge at the Company‚Äôs head office located at 7-11 boulevard Haussmann  75009 Paris  France. European Economic Area In relation to each Member State of the European Economic Area (each  a ‚ÄúRelevant State‚Äù)  no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than: to any legal entity which is a qualified investor as defined under Article 2(e) of the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation)  subject to obtaining the prior consent of the representatives for any such offer; or in any other circumstances falling within Article 1(4) of the Prospectus Regulation  provided that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. For the purposes of this provision  the expression an ‚Äúoffer to the public‚Äù in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities  and the expression ‚ÄúProspectus Regulation‚Äù means Regulation (EU) 2017/1129 of June 14  2017  as amended. France The securities have not been and will not be offered or sold to the public in the Republic of France  and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute  directly or indirectly  an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier)). The securities may only be offered or sold in France pursuant to Article L. 411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier) to qualified investors (investisseurs qualifi√©s) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account  and in accordance with Articles L. 411-1  L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code (Code mon√©taire et financier). This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.20.10.2023 CET/CEST Dissemination of a Corporate News  transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements  Financial/Corporate News and Press Releases.Archive at www.eqs-news.com,neutral,0.02,0.97,0.01,neutral,0.03,0.93,0.04,True,English,"['Initial Public Offering', 'Nasdaq Global Market', 'EQS-News', 'Abivax', 'pricing', 'last three (3) trading days', 'combined general shareholders‚Äô meeting', 'Nasdaq Global Market PARIS', 'natural regulatory mechanisms', 'chronic inflammatory diseases', 'European Private Placement', 'European Central Bank', 'customary closing conditions', 'preferential subscription rights', 'same ISIN code', 'Code mon√©taire', 'Code de commerce', 'same trading line', 'aggregate gross proceeds', 'volume weighted-average price', 'U.S. Offering', 'French Commercial Code', 'American Depositary Shares', 'capital markets advisor', 'joint global coordinators', 'Initial Public Offering', 'European lead manager', 'corresponding offering price', 'same offering price', 'public offering price', 'one ordinary share', 'clinical-stage biotechnology company', 'The Global Offering', '20,325,500 new ordinary shares', 'The New Shares', 'October 19, 2023 exchange rate', 'market price', 'Financial Code', 'regulated market', 'open market', 'joint bookrunners', 'French Monetary', 'aggregate amount', '18,699,460 ordinary shares', '1,626,040 ordinary shares', 'concurrent offering', 'Euronext Paris', 'stabilizing manager', 'existing shares', 'Additional Shares', 'capital increase', 'LifeSci Capital', 'Namsen Capital', 'Key word', 'immune response', 'United States', 'underwriting commissions', 'Compartment B', 'Morgan Stanley', 'Leerink Partners', '15th resolution', 'Article L.', 'nineteenth resolutions', '30-day period', 'prior notice', 'applicable rules', 'stabilization action', 'The ADSs', 'ticker symbol', '3,048,825 additional ADSs', 'Abivax SA', 'EQS-News', 'IPO', 'pricing', '15:00 CET', 'CEST', 'issuer', 'content', 'announcement', 'France', 'ABVX', 'therapeutics', 'body', 'patients', 'way', 'form', 'jurisdictions', 'investors', 'deduction', 'expenses', 'satisfaction', 'securities', 'listing', 'application', 'Bryan', 'Garnier', 'Underwriters', 'Discount', 'euros', 'start', 'less', 'compliance', 'June', 'Type', 'offerings', 'financier', 'provisions', 'fifteenth', 'Option', 'November', 'connection', 'transactions', 'view', 'level', 'assurance', 'time', 'allotment', 'accordance', 'regulations', '3:00']",2023-10-20,2023-10-20,markets.businessinsider.com
31643,EuroNext,Bing API,https://finance.yahoo.com/news/abivax-announces-pricing-initial-public-131500673.html,Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market,"PARIS  FRANCE / ACCESSWIRE / / Abivax SA (Euronext Paris:FR0012333284:ABVX) ("" Abivax "" or the "" Company "")  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms","PARIS  FRANCE / ACCESSWIRE / October 20  2023 / Abivax SA (Euronext Paris:FR0012333284:ABVX) ("" Abivax "" or the "" Company "")  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases  announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20 325 500 new ordinary shares (the "" New Shares "")  consisting of a public offering of 18 699 460 ordinary shares in the form of American Depositary Shares ("" ADSs "")  each representing the right to receive one ordinary share  in the United States (the "" U.S. Offering "") and a concurrent offering of 1 626 040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the "" European Private Placement "" and together with the U.S. Offering  the "" Global Offering ""). The offering price was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of ‚Ç¨10.9864 per ordinary share based on an exchange rate of ‚Ç¨1.00 = $1.0559 as published by the European Central Bank on October 19  2023. The aggregate gross proceeds are expected to be approximately $235.8 million  equivalent to approximately ‚Ç¨223.3 million  before deduction of underwriting commissions and estimated expenses payable by the Company. The Global Offering is expected to close on October 24  2023  subject to the satisfaction of customary closing conditions.All securities to be sold in the Global Offering will be offered by the Company. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October 20  2023 under the ticker symbol ""ABVX"". The Company's ordinary shares are listed on the regulated market of Euronext Paris ("" Euronext Paris "") under the symbol ""ABVX"".Story continuesThe ordinary shares underlying the ADSs sold in the Global Offering will be subject to an application for admission to trading on Euronext Paris (Compartment B) on the same trading line as the existing shares under the same ISIN code FR0012333284 and are expected to be admitted to trading on October 24  2023.Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering. LifeSci Capital is acting as lead manager for the proposed U.S. Offering. Bryan  Garnier & Co is acting as European lead manager for the proposed European Private Placement (collectively  the "" Underwriters "").Namsen Capital is acting as Abivax's capital markets advisor.Pricing of the Global Offering and DiscountThe offering price was set at $11.60 per ADS. The offering price per ADS corresponds to the offering price of ‚Ç¨10.9864 per ordinary share based on the October 19  2023 exchange rate of ‚Ç¨1.00 = $1.0559.The public offering price per ordinary share in euros (‚Ç¨10.9864) is equal to the volume weighted-average price of the Company's ordinary shares on Euronext Paris over the last three (3) trading days preceding the start of the offering (i.e.  16th  17th and 18th of October 2023)  less a discount of 9.4%  and is determined by the Company in compliance with the 15th resolution of the Company's combined general shareholders' meeting held on June 5  2023.Type of OfferingThe New Shares will be issued through a capital increase without shareholders' preferential subscription rights by way of a public offering excluding offerings referred to in Article L. 411-2 1¬∞ of the French Monetary and Financial Code ( Code mon√©taire et financier ) and under the provisions of Article L.225-136 of the French Commercial Code ( Code de commerce ) and pursuant to the fifteenth and nineteenth resolutions of the Company's combined general shareholders' meeting held on June 5  2023.Option to Purchase Additional SharesThe Company has granted the Underwriters an option to purchase (the "" Option "")  for a 30-day period (until November 20  2023)  up to 3 048 825 additional ADSs and/or ordinary shares  which represents 15% of the aggregate amount of New Shares to be issued in the Global Offering  at the same offering price.StabilizationIn connection with the Global Offering  the Underwriters may over-allot the securities or effect transactions with a view to supporting  stabilizing  or maintaining the market price of the securities at a level higher than which might otherwise prevail in the open market. However  there is no assurance that the stabilizing manager will take any stabilization action and  if begun  may be ended at any time without prior notice. Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the Nasdaq Global Market and/or Euronext Paris.DilutionBased on the issuance of 20 325 500 New Shares in the Global Offering (including ordinary shares in the form of ADSs)  the number of ordinary shares held by the existing shareholders after the Global Offering would be 67.7% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering. If the Underwriters exercise their option to purchase 3 048 825 additional ADSs and/or ordinary shares in full  the number of ordinary shares held by the existing shareholders after the Global Offering would be 64.5% of the total number of ordinary shares (including ordinary shares in the form of ADSs) outstanding after the Global Offering.Estimated Proceeds from the Global Offering - Reasons of the offering - Use of proceedsThe gross proceeds of the sale of 20 325 500 New Shares  including ordinary shares in the form of ADSs  in the Global Offering is expected to be approximately $235.8 million (‚Ç¨223.3 million)  assuming no exercise of the Underwriters' Option.The Company estimates that the net proceeds of the Global Offering will be approximately $212.2 million (‚Ç¨201.1 million)  after deducting approximately $16.5 million (‚Ç¨15.6 million) in underwriting commissions and approximately $7.0 million (‚Ç¨6.6 million) in estimated offering expenses.The Company expects to use the net proceeds from the Global Offering as follows (assuming an exchange rate of ‚Ç¨1.00 = $1.0559  the exchange rate on October 19  2023):approximately ‚Ç¨160.0 million ($168.9 million) to fund the development of obefazimod for UC;approximately ‚Ç¨14.0 million ($14.8 million) to fund the development of obefazimod for CD; andthe remainder for working capital and for other general corporate purposes  including in the continued research to identify new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments under the Kreos / Claret Financing (as defined below)  and assuming that the Company will repay the Heights Financing (as defined below) through the issuance of new shares instead of making cash payments).The Company believes that the anticipated net proceeds from the Global Offering  together with its current cash and cash equivalents  will allow it to finance its operations through (i) the announcement of its top-line data from its Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of its top-line data from its Phase 2a induction trial for CD.The Company believes that based on its current clinical plan and its anticipated net proceeds from the Global Offering  together with (a) its existing cash and cash equivalents of ‚Ç¨114.4 million as of June 30  2023  (b) the net proceeds of the August 2023 drawdown of the first tranches of the financing agreements entered into with entities affiliated with Kreos Capital ("" KC "") and Claret European Growth Capital (the "" Kreos / Claret Financing "") and entities affiliated with Heights Capital Management (the "" Heights Financing "")  collectively amounting to ‚Ç¨27.2 million (net of repayments of all outstanding amounts that remained due under the prior two financing agreements entered into with KC and the OCEANE bonds)  (c) the anticipated net proceeds from the drawdown of the second tranche of the Kreos / Claret Financing  amounting to ‚Ç¨25 million (which is a portion of the total available drawdown of ‚Ç¨65 million from the Kreos / Claret Financing and the Heights Financing) and (d) the expected Research Tax Credit (CIR) reimbursements would enable the Company to fund its operations through the fourth quarter of 2025. Under these assumptions and based on its current clinical plan  the Company would have sufficient funds to finance its operations through (i) the announcement of its top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC and (ii) the announcement of its top-line data from the Phase 2a induction trial for CD.If the Company further draws down on the third tranche of the Kreos / Claret Financing  amounting to ‚Ç¨25 million and the second tranche of the Heights Financing amounting to ‚Ç¨40 million  the Company expects to have sufficient funds to finance its operations through the first quarter of 2026. Under these assumptions and based on its current clinical plan  it would have sufficient funds to finance its operations through the announcement of its top-line data from the Phase 3 ABTECT maintenance trial for UC.UnderwritingThe Global Offering is subject to an underwriting agreement entered into on October 19  2023. The underwriting agreement does not constitute a "" garantie de bonne fin "" within the meaning of Article L. 225-145 of the French Commercial Code ( Code de commerce ).DocumentationThe securities referred to in this press release will be offered only by means of a prospectus. When available  copies of the final prospectus relating to and describing the terms of the proposed Global Offering may be obtained from: Morgan Stanley & Co. LLC  Attention: Prospectus Department  180 Varick Street  2nd Floor  New York  NY 10014 or by email at prospectus@morganstanley.com ; or Leerink Partners LLC  Attention: Syndicate Department  53 State Street  40th Floor  Boston  MA 02109  by telephone at (800) 808-7525  ext. 6105  or by email at syndicate@leerink.com .Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on Euronext Paris pursuant to a listing prospectus subject to an approval from the French Autorit√© des march√©s financiers ("" AMF "") and comprising (i) the 2023 Universal Registration Document ( Document d'Enregistrement Universel 2023 ) filed with the AMF on May 4  2023 under number D.23-0394  as amended by a first amendment filed with the AMF on September 29  2023 under number D.23-0394-A01  as completed by a second amendment to such 2023 Universal Registration Document  which will be filed with the AMF  and (ii) a Securities Note ( Note d'op√©ration )  including a summary of the prospectus. Copies of the 2023 Universal Registration Document are available free of charge at the Company's head office located at 7-11 boulevard Haussmann  75009 Paris  France  on the Company's website ( www.abivax.com ) and on the website of the AMF ( www.amf-france.org/ ).Risk FactorsInvestors should carefully consider the risks factors likely to affect the Company's business as described in Chapter 3 ""Risk Factors"" of the 2023 Universal Registration Document  in Chapter 5 of its first amendment and in Chapter 3 of its second amendment and in the risk factors section of the Company's registration statement on Form F-1 before marking an investment decision. If any of these risks are realized  the Company's business  financial condition  operating results and prospects could be materially and adversely affected. In addition  other risks  not identified or considered significant by the Company  could have the same adverse effect and investors could lose all or part of their investment.About AbivaxAbivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S.  Abivax's lead drug candidate  obefazimod (ABX464)  is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.Contacts:Abivax CommunicationsRegina Jehleregina.jehle@abivax.com+33 6 24 60 69 63 Abivax Investor RelationsPatrick Malloypatrick.malloy@abivax.com+1 847 987 4878Forward-Looking StatementsThis press release contains certain forward-looking statements with respect to the Global Offering  including: the completion of the Global Offering  use of proceeds from the Global Offering  as well as statements regarding Abivax's clinical development plans  business and regulatory strategy  and anticipated future performance. Although the Company believes its expectations are based on reasonable assumptions  these forward-looking statements are subject to numerous risks and uncertainties  which could cause actual results to differ materially from those expressed in  or implied or projected by  the forward-looking statements. These risks and uncertainties include among other things  the uncertainties inherent in research and development  including related to progression of  and results from  its ongoing and planned clinical trials  including clinical trials for obefazimod  review and approvals by regulatory authorities  such as the FDA or the EMA  of its drug candidates and the Company's continued ability to raise capital to fund its development  including as part of the proposed Global Offering  the Company's ability to obtain  maintain  protect and enforce its intellectual property rights  as well as those discussed or identified in the Company's registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission and the Company's public filings with the AMF  in particular in the 2023 Universal Registration Document  as amended  for additional information in relation to such factors  risks and uncertainties.Other than as required by applicable law  the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in the Company in any country. This press release has been prepared in both French and English. In the event of any differences between the two versions of the press release  the French language version shall supersede.DisclaimersThis press release does not constitute an offer to sell nor a solicitation of an offer to buy  nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer  solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The distribution of this document may  in certain jurisdictions  be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.A French listing prospectus comprising (i) the 2023 Universal Registration Document ( Document d'Enregistrement Universel 2023 ) filed with the AMF on May 4  2023 under number D.23-0394  as amended by a first amendment filed with the AMF on September 29  2023 under number D.23-0394-A01  as completed by a second amendment to such 2023 Universal Registration Document  which will be filed with the AMF  and (ii) a Securities Note ( Note d'op√©ration )  including a summary of the prospectus  will be submitted to the approval by the AMF and will be published on the AMF's website at www.amf-france.org/ . Following the filing of the second amendment to the 2023 Universal Registration Document with the AMF  copies of Company's 2023 Universal Registration Document  as amended  will be available free of charge at the Company's head office located at 7-11 boulevard Haussmann  75009 Paris  France.European Economic AreaIn relation to each Member State of the European Economic Area (each  a "" Relevant State "")  no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than:to any legal entity which is a qualified investor as defined under Article 2(e) of the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation)  subject to obtaining the prior consent of the representatives for any such offer; or in any other circumstances falling within Article 1(4) of the Prospectus Regulation provided that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.For the purposes of this provision  the expression an ""offer to the public"" in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities  and the expression "" Prospectus Regulation "" means Regulation (EU) 2017/1129 of June 14  2017  as amended.FranceThe securities have not been and will not be offered or sold to the public in the Republic of France  and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute  directly or indirectly  an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1¬∞ of the French Monetary and Financial Code ( Code mon√©taire et financier )).The securities may only be offered or sold in France pursuant to Article L. 411-2 1¬∞ of the French Monetary and Financial Code ( Code mon√©taire et financier ) to qualified investors ( investisseurs qualifi√©s ) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account  and in accordance with Articles L. 411-1  L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code ( Code mon√©taire et financier ).This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.SOURCE: ABIVAXView source version on accesswire.com:https://www.accesswire.com/794963/abivax-announces-the-pricing-of-its-initial-public-offering-on-the-nasdaq-global-market",neutral,0.02,0.97,0.01,neutral,0.04,0.91,0.04,True,English,"['Initial Public Offering', 'Nasdaq Global Market', 'Abivax', 'Pricing', ""shareholders' preferential subscription rights"", 'last three (3) trading days', ""combined general shareholders' meeting"", 'natural regulatory mechanisms', 'chronic inflammatory diseases', 'European Private Placement', 'European Central Bank', 'customary closing conditions', 'same trading line', 'aggregate gross proceeds', 'volume weighted-average price', 'same ISIN code', 'Code mon√©taire', 'U.S. Offering', 'capital markets advisor', 'American Depositary Shares', 'French Commercial Code', 'Nasdaq Global Market', 'joint global coordinators', 'European lead manager', 'initial public offering', 'corresponding offering price', 'same offering price', 'one ordinary share', 'clinical-stage biotechnology company', 'public offering price', 'The Global Offering', 'The New Shares', '20,325,500 new ordinary shares', 'October 19, 2023 exchange rate', 'existing shareholders', 'market price', '20,325,500 New Shares', 'regulated market', 'joint bookrunners', 'French Monetary', 'aggregate amount', 'open market', 'Financial Code', '18,699,460 ordinary shares', '1,626,040 ordinary shares', 'stabilizing manager', 'concurrent offering', 'capital increase', 'LifeSci Capital', 'Namsen Capital', 'existing shares', 'Additional Shares', 'immune response', 'United States', 'underwriting commissions', 'Compartment B', 'Morgan Stanley', 'Leerink Partners', '15th resolution', 'Article L.', 'nineteenth resolutions', '30-day period', 'effect transactions', 'prior notice', 'applicable rules', 'Euronext Paris', 'stabilization action', 'The ADSs', 'ticker symbol', 'The Company', 'total number', '3,048,825 additional ADSs', 'Abivax SA', 'FRANCE', 'ACCESSWIRE', 'therapeutics', 'body', 'patients', 'pricing', 'way', 'form', 'jurisdictions', 'investors', 'deduction', 'expenses', 'satisfaction', 'securities', 'listing', 'ABVX', 'Story', 'application', 'Bryan', 'Garnier', 'Underwriters', 'Discount', 'ADS.', 'euros', 'start', 'less', 'compliance', 'June', 'Type', 'offerings', 'financier', 'provisions', 'commerce', 'fifteenth', 'Option', 'November', 'connection', 'view', 'level', 'assurance', 'time', 'allotment', 'accordance', 'regulations', 'Dilution', 'issuance']",2023-10-20,2023-10-20,finance.yahoo.com
31644,EuroNext,Bing API,https://www.thetradenews.com/leaders-in-trading-2023-meet-the-nominees-for-outstanding-derivatives-exchange/,Leaders in Trading 2023: Meet the nominees for‚Ä¶ Outstanding Derivatives Exchange,Learn more about the four firms shortlisted for¬†The TRADE‚Äôs 2023 Editors‚Äô¬†Choice Award for Outstanding Derivatives Exchange: including¬†Cboe European Derivatives Exchange (CEDX)  CME Group  Eurex and Euronext.,Next up in our Leaders in Trading 2023 Editors‚Äô Choice Awards write up series  we bring you the shortlisted candidates for Outstanding Derivatives Exchange  showcasing exceptional performance in the derivatives exchange space.Over the last year  these derivatives exchange groups have helped innovative the marketplace with a wide range of expansions in their respective product suites  increased access to new and existing derivatives  as well as various partnerships which have steered increased growth in this trading segment.Among the key players in this competitive landscape  The TRADE has selected Cboe Europe Derivatives (CEDX)  CME Group  Eurex and Euronext for the 2023 shortlist  following various individual achievements by these venues over the past year.Cboe Europe Derivatives (CEDX)CEDX  Cboe Global Markets‚Äô two-year-old pan-European equity derivatives exchange  has continued to build momentum since its inception in 2021  with over 55 000 index derivatives contracts traded since its launch. Open interest peaked at over 2 000 in March earlier this year. This has led to the derivatives exchange making another appearance in this award category following last year‚Äôs nomination. In November last year  CEDX revealed plans to expand its product suite to include single stock options on leading European companies. The first phase of these new products have been confirmed to be available for trading from 6 November 2023  including options on over 130 companies from 12 European companies  and will be cleared by Cboe Clear Europe N.V. Several firms have recently confirmed their support of CEDX‚Äôs expansion into equity options  including: ABN AMRO Clearing  All Options  Barak Market Making B.V  Goldman Sachs  Morgan Stanley  Susquehanna International Securities. Interactive Brokers also confirmed it will connect to CEDX to trade the range of products offered by the exchange  including single stock products.Elsewhere  CEDX and ION announced a new collaboration in August. As part of the agreement  ION provides direct access to CEDX via its cleared derivatives all-in-one automated trade workflow solution  XTP Execution  which offers Tier one banks and brokers integrated order management  connectivity and order execution. The direct trading connectivity means users of the ION solution will gain access to CEDX‚Äôs futures and options markets for single country and pan-European equity indices.CME GroupAlongside its peers  CME Group is shortlisted for the 2023 Editors‚Äô Choice Outstanding Derivatives Exchange. At the end of last year  CME Group and cryptocurrency benchmark indices provider CF Benchmarks launched three new decentralised finance (DeFi) reference rates and real-time indices  beginning 19 December 2022. The reference rates and real-time indices are calculated and published by CF Benchmarks on a daily basis. Elsewhere  in July  CME Group and The Depository Trust & Clearing Corporation (DTCC) enhanced their existing cross-margining arrangement to increase capital efficiencies for clearing members which trade and clear both US treasury securities and CME Group interest rate futures. The new expansion will allow eligible clearing members to gain increased margin efficiencies between US Treasury securities and CME Group interest rate futures  with changes expected to launch in January 2024. Since announcing the expansion  CME Group has received approvals from both the Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC) for their enhanced cross-margining arrangement.CME Group also announced a restructuring of its foreign exchange businesses in August  seeking to expand trading opportunities and increase efficiency for its clients across futures  cash and OTC markets. CME Group combined its FX derivatives markets and its EBS cash markets business  with the combination set to be leveraged in a bid to increase efficiency  improve client service and enhance product development.EurexEurex is once again recognised in this award category after a nomination at Leaders in Trading 2023. Towards the end of last year  Eurex expanded its interest rate segment with the launch of three-month Euro STR futures referencing ‚Ç¨STR. Eurex stated the launch is an important milestone in both the establishment of the ‚Ç¨STR as the new benchmark risk-free rate  and in expanding the exchange‚Äôs EUR-denominated fixed income product offering. Eurex Frankfurt also partnered with Trading Technologies (TT) in February to offer the Eurex EnLight selective request-for-quote (RFQ) solution directly through the TT platform. According to the two firms  the partnership provides institutions of TT‚Äôs global distribution network the opportunity to streamline their RFQ and larger scale  complex trade execution activity on a single screen.Eurex became the first exchange in Europe to offer Bitcoin index futures in April  with the new contract developed by Eurex in partnership with global index provider FTSE Russel and institutional-grade digital asset data provider Digital Asset Research (DAR). According to Eurex  institutional investors had been waiting for a contract based on a robust underlying index from an established index partner  which is supported by an AA-rated clearing house in Europe. The new futures are traded in EUR and USD  providing trusted access to cryptocurrencies in a regulated market through Eurex. The derivatives venue was also chosen by State Street and BNY Mellon to centrally clear European transactions in May and September  respectively. In the same month  Goldman Sachs became the latest sell-side institution to join Eurex‚Äôs listed FX futures business as a trading and clearing member which Eurex described as a ‚Äúmajor milestone‚Äù in its ambition to become a listed FX liquidity hub in Europe.EuronextRounding up our prestigious list of outstanding derivatives exchanges is Euronext. Euronext operates the second largest equity derivatives market in Europe in terms of number of contracts traded. The product scope covers derivatives on Euronext‚Äôs main local benchmarks and also a wide range of pan-European equity futures and options. Towards the end of 2022  Euronext made additional maturities up to ten years available on the total return future on the CAC 40 Index  addressing investor demands for more long-term capital efficiency. The listed solution allows clients to trade total return swaps with volumes continuously increasing. On 5 January 2023 the contract hit a milestone with one million lots traded  followed by two consecutive monthly volume records  with 79 792 contracts traded in January 2023 and then 84 449 lots traded in February. At the end of H1 this year  the TRF had traded almost 300 000 lots traded  representing ‚Ç¨25bn of value  as much as in the full year 2022.Euronext has also made advancements in the building of its fully-integrated clearing house  Euronext Clearing. All derivatives  including those on Euronext‚Äôs Italian markets  will be part of the same liquidity pool providing increased efficiencies to clients. This liquidity pool  together with the ability of Euronext to be more innovative  will scale up the derivatives franchise and make the segment more attractive to investors  the exchange told The TRADE. Elsewhere  in Q1  Euronext launched its new web-based Euronext Trader GUI to provide members with improved access to the derivatives market. Euronext Trader was developed in-house with technology acquired along with Borsa Italiana. Over ‚Ç¨11.5bn of nominal value has been traded through Euronext Trader on the Amsterdam  Paris and Brussels marketplaces so far this year (as of 6 October 2023)  with 416k contracts traded  including 125k index futures and 291k equity options.,neutral,0.26,0.72,0.01,neutral,0.07,0.92,0.01,True,English,"['Outstanding Derivatives Exchange', 'Leaders', 'Trading', 'nominees', 'larger scale, complex trade execution activity', 'Barak Market Making B.V', 'EUR-denominated fixed income product offering', 'institutional-grade digital asset data provider', 'Cboe Clear Europe N.V', 'one automated trade workflow solution', 'two-year-old pan-European equity derivatives exchange', '2023 Editors‚Äô Choice Outstanding Derivatives Exchange', 'CME Group interest rate futures', 'cryptocurrency benchmark indices provider', 'new benchmark risk-free rate', 'three new decentralised finance', 'Eurex EnLight selective request', 'EBS cash markets business', 'three-month Euro STR futures', 'Commodity Futures Trading Commission', '2023 Editors‚Äô Choice Awards', 'Digital Asset Research', 'interest rate segment', 'pan-European equity indices', 'Tier one banks', 'global index provider', 'Cboe Europe Derivatives', 'Cboe Global Markets', 'Bitcoin index futures', 'respective product suites', '55,000 index derivatives contracts', 'global distribution network', 'FX derivatives markets', 'derivatives exchange space', 'derivatives exchange groups', 'foreign exchange businesses', 'various individual achievements', 'ABN AMRO Clearing', 'Susquehanna International Securities', 'integrated order management', 'The Depository Trust', 'US treasury securities', 'DeFi) reference rates', 'eligible clearing members', 'single stock options', 'leading European companies', 'single stock products', 'existing cross-margining arrangement', 'The TRADE', 'direct trading connectivity', 'order execution', 'Open interest', 'Exchange Commission', 'existing derivatives', 'equity options', 'XTP Execution', 'product development', 'options markets', 'OTC markets', 'real-time indices', 'first exchange', 'various partnerships', 'trading segment', '12 European companies', 'single country', 'Clearing Corporation', 'single screen', 'new products', 'new collaboration', 'new contract', 'RFQ) solution', 'exceptional performance', 'last year', 'key players', 'competitive landscape', 'past year', 'award category', 'first phase', 'Several firms', 'All Options', 'Goldman Sachs', 'Morgan Stanley', 'CF Benchmarks', 'daily basis', 'capital efficiencies', 'margin efficiencies', 'trading opportunities', 'client service', 'important milestone', 'Trading Technologies', 'two firms', 'FTSE Russel', 'direct access', 'new expansion', 'wide range', 'Interactive Brokers', 'Eurex Frankfurt', '130 companies', '‚Ç¨STR.', 'Leaders', 'series', 'candidates', 'marketplace', 'expansions', 'growth', 'CEDX', 'Euronext', '2023 shortlist', 'venues', 'momentum', 'inception', 'launch', 'March', 'appearance', 'nomination', 'November', 'plans', 'support', 'August', 'agreement', 'users', 'peers', 'end', '19 December', 'July', 'DTCC', 'changes', 'January', 'approvals', 'CFTC', 'restructuring', 'efficiency', 'clients', 'combination', 'bid', 'establishment', 'TT', 'February', 'quote', 'platform', 'institutions', 'opportunity', 'April', 'DAR']",2023-10-20,2023-10-20,thetradenews.com
31645,EuroNext,Bing API,https://www.finanznachrichten.de/nachrichten-2023-10/60421152-abivax-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris-200.htm,Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris,"PARIS  FRANCE / ACCESSWIRE / October 20  2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (""Abivax"" or the ""Company"")  a clinical-stage biotechnology company focused on developing therapeutics t","PARIS  FRANCE / ACCESSWIRE / October 20  2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) (""Abivax"" or the ""Company"")  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases  announced today that trading of its ordinary shares on the regulated market of Euronext in Paris (""Euronext Paris"") will be temporarily halted  at the Company's request  from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the initial public offering of the Company's American Depositary Shares (""ADSs"") on the Nasdaq Global Market (the ""Global Offering"")  in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company's ADSs on the Nasdaq Global Market.This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today  October 20  2023  at approximately 4:30 p.m. (CEST)  which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market under the ticker symbol ""ABVX.""***About AbivaxAbivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S.  Abivax's lead drug candidate  obefazimod (ABX464)  is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.Contacts:Abivax CommunicationsRegina Jehleregina.jehle@abivax.com+33 6 24 60 69 63 Abivax Investor RelationsPatrick Malloypatrick.malloy@abivax.com+1 847 987 4878***Forward-Looking StatementsThis press release contains certain forward-looking statements with respect to the proposed Global Offering  including: the timing and completion of the trading halt on Euronext Paris. Although the Company believes its expectations are based on reasonable assumptions  these forward-looking statements are subject to numerous risks and uncertainties  which could cause actual results to differ materially from those expressed in  or implied or projected by  the forward-looking statements.Other than as required by applicable law  the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in the Company in any country. This press release has been prepared in both French and English. In the event of any differences between the two versions of the press release  the French language version shall supersede.DisclaimersThis press release does not constitute an offer to sell nor a solicitation of an offer to buy  nor shall there be any sale of ordinary shares or ADSs in any state or jurisdiction in which such an offer  solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The distribution of this document may  in certain jurisdictions  be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.A French listing prospectus comprising (i) the 2023 Universal Registration Document (Document d'Enregistrement Universel 2023) filed with the French Autorit√© des march√©s financiers (""AMF"") on May 4  2023  under number D.23-0394  as amended by a first amendment filed with the AMF on September 29  2023 under number D.23-0394-A01  as completed by a second amendment to such 2023 Universal Registration Document  which will be filed with the AMF  and (ii) a Securities Note (Note d'op√©ration)  including a summary of the prospectus  will be submitted to the approval by the AMF and will be published on the AMF's website at www.amf-france.org. Following the filing of the second amendment to the 2023 Universal Registration Document with the AMF  copies of Company's 2023 Universal Registration Document  as amended  will be available free of charge at the Company's head office located at 7-11 boulevard Haussmann  75009 Paris  France.European Economic AreaIn relation to each Member State of the European Economic Area (each  a ""Relevant State"")  no offer to the public of ordinary shares and ADSs may be made in that Relevant State other than:to any legal entity which is a qualified investor as defined under Article 2(e) of the Prospectus Regulation; to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation)  subject to obtaining the prior consent of the representatives for any such offer; or in any other circumstances falling within Article 1(4) of the Prospectus Regulation provided that no such offer of the securities shall require the Company or any of its representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.For the purposes of this provision  the expression an ""offer to the public"" in relation to the securities in any Relevant State means the communication in any form and by any means presenting sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities  and the expression ""Prospectus Regulation"" means Regulation (EU) 2017/1129 of June 14  2017  as amended.FranceThe securities have not been and will not be offered or sold to the public in the Republic of France  and no offering of this prospectus or any marketing materials relating to securities may be made available or distributed in any way that would constitute  directly or indirectly  an offer to the public in the Republic of France (except for public offerings defined in Article L.411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier)).The securities may only be offered or sold in France pursuant to article L. 411-2 1¬∞ of the French Monetary and Financial Code (Code mon√©taire et financier) to qualified investors (investisseurs qualifi√©s) (as such term is defined in Article 2(e) of the Prospectus Regulation) acting for their own account  and in accordance with articles L. 411-1  L. 411-2 and D. 411-2 to D.411-4 of the French Monetary and Financial Code (Code mon√©taire et financier).This announcement is not an advertisement and not a prospectus within the meaning of the Prospectus Regulation.SOURCE: ABIVAXView source version on accesswire.com:https://www.accesswire.com/794921/abivax-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris",neutral,0.01,0.98,0.01,negative,0.02,0.33,0.66,True,English,"['Temporary Trading Halt', 'Ordinary Shares', 'Euronext Paris', 'Abivax', 'French Autorit√© des march√©s financiers', 'French language version', 'chronic inflammatory diseases', 'lead drug candidate', 'Phase 3 clinical trials', 'active ulcerative colitis', '7-11 boulevard Haussmann', 'European Economic Area', 'potential local restrictions', 'natural regulatory mechanisms', 'French listing prospectus', 'American Depositary Shares', 'Nasdaq Global Market', '2023 Universal Registration Document', 'earliest time ADSs', 'initial public offering', 'clinical-stage biotechnology company', 'Abivax Investor Relations', 'U.S.', 'Global Offering', 'local legislations', 'qualified investor', 'regulated market', 'immune response', 'ordinary shares', 'new communication', 'ticker symbol', 'press release', 'reasonable assumptions', 'numerous risks', 'actual results', 'applicable law', 'two versions', 'Enregistrement Universel', 'first amendment', 'second amendment', 'op√©ration', 'amf-france.org', 'head office', 'legal entity', 'Prospectus Regulation', 'prior consent', 'other circumstances', 'Forward-Looking Statements', 'securities laws', 'Member State', 'Relevant State', 'Regina Jehle', 'Patrick Malloy', 'forward-looking information', 'legal persons', 'Abivax SA', 'Abivax Communications', 'trading halt', 'Euronext Paris', 'Securities Note', '150 natural', 'investors', '75009 Paris', 'ACCESSWIRE', 'October', 'ABVX', 'therapeutics', 'body', 'patients', 'request', 'opening', '9:00 a', 'CEST', 'place', 'context', 'order', 'confirmation', 'allocations', 'commencement', 'suspension', 'obefazimod', 'treatment', 'Contacts', 'respect', 'timing', 'completion', 'expectations', 'uncertainties', 'obligation', 'solicitation', 'country', 'English', 'event', 'differences', 'Disclaimers', 'sale', 'jurisdiction', 'qualification', 'distribution', 'possession', 'May', 'number', 'September', 'summary', 'approval', 'website', 'filing', 'copies', 'charge', 'Article', 'fewer', 'representatives', '4:30']",2023-10-06,2023-10-20,finanznachrichten.de
